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The majority of women with ovarian cancer (OC) have advanced disease at diagnosis
and -year survival rates of less than %. Women with stage I disease have signi icantly
better -year survival rates of over %. Recent large studies using CA and transvaginal
ultrasound have failed to improve mortality in a screened population. There is therefore a
pressing need for new diagnostic biomarkers in OC.
The primary aim of my project, as a irst step in developing a diagnostic circulating
tumour DNA (ctDNA) biomarker for high grade serous ovarian cancer (HGSOC), was to in-
vestigate low-cost high-throughput next generation sequencing assays in plasma samples
collected from women with newly diagnosed OC. The secondary aim was to apply these
methods to other non-invasive samples including cervical liquid based cytology samples
that might contribute to earlier diagnosis or screening for women with OC.
ctDNA was detected in - % of women with newly diagnosed OC from the UKOPS
(n= ) and CTCR-OV (n= ) cohorts using targeted sequencing. Using the trimmed
median absolute deviation (t-MAD) score, a quantitative measure of genome wide copy
number aberration generated fromshallowwhole genomesequencing (sWGS)data, ctDNA
was detected in – % of the women with newly diagnosed disease.
To improve sensitivity of ctDNA detection I developed an optimised method for tar-
geted sequencing that has the potential to lower the limit of detection of ctDNA in HGSOC
by fold. I have also shown that the size pro ile of HGSOC ctDNA fragments is different
to that of wildtype DNA fragments and shown that selecting for DNA fragments between
– bp can increase rates of ctDNA detection in HGSOC. ctDNA detection increased to
– % of women with newly diagnosed OC using the size selected t-MAD score.
I have evaluated the utility of cervical sampling for earlier diagnosis of OC by testing
and optimising DNA extraction, library preparation and sequencingmethods. I have detec-
ted tumour DNA in routine cervical cytology samples collected fromwomen subsequently
diagnosed with cervical and endometrial cancers.
In summary I have developedmethods for ctDNA detection in womenwith newly dia-
gnosed HGSOC that can be applied and re ined in larger prospective studies of women un-
dergoing follow-up for treated HGSOC, women with symptoms suggestive of OC and wo-
men at high risk of OC.
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UKCTOCS UK Collaborative Trial of Ovarian Cancer Screening.
UKOPS UK Ovarian Cancer Population Study.
VAF variant allele fraction.
WBC white blood cell.
Abstract
The majority of women with OC have advanced disease at diagnosis and -year survival
rates of less than %. Womenwith stage I disease have signi icantly better -year survival
rates of over %. Recent large studies using CA and transvaginal ultrasound have
failed to improve mortality in a screened population. There is therefore a pressing need
for new diagnostic biomarkers in OC.
The primary aim of my project, as a irst step in developing a diagnostic ctDNA bio-
marker for HGSOC, was to investigate low-cost high-throughput next generation sequen-
cing assays in plasma samples collected from women with newly diagnosed OC. The sec-
ondary aim was to apply these methods to other non-invasive samples including cervical
liquid based cytology samples that might contribute to earlier diagnosis or screening for
women with OC.
ctDNA was detected in - % of women with newly diagnosed OC from the UKOPS
(n= ) and CTCR-OV (n= ) cohorts using targeted sequencing. Using the t-MAD score,
a quantitative measure of genome wide copy number aberration generated from sWGS
data, ctDNA was detected in – % of the women with newly diagnosed disease.
To improve sensitivity of ctDNA detection I developed an optimised method for tar-
geted sequencing that has the potential to lower the limit of detection of ctDNA in HGSOC
by fold. I have also shown that the size pro ile of HGSOC ctDNA fragments is different
to that of wildtype DNA fragments and shown that selecting for DNA fragments between
– bp can increase rates of ctDNA detection in HGSOC. ctDNA detection increased to
– % of women with newly diagnosed OC using the size selected t-MAD score.
I have evaluated the utility of cervical sampling for earlier diagnosis of OC by testing
and optimising DNA extraction, library preparation and sequencingmethods. I have detec-
ted tumour DNA in routine cervical cytology samples collected fromwomen subsequently
diagnosed with cervical and endometrial cancers.
In summary I have developedmethods for ctDNA detection in womenwith newly dia-
gnosed HGSOC that can be applied and re ined in larger prospective studies of women un-
dergoing follow-up for treated HGSOC, women with symptoms suggestive of OC and wo-
men at high risk of OC.
Introduction
. Ovarian cancer
Ovarian cancer (OC) is the ifth most common cancer in women in the UK with approx-
imately , new cases diagnosed each year (CRUK ). Approximately % of wo-
men already have stage III/IV disease at the time of diagnosis (CRUK ). Presentation
with advanced disease ismore common (> %) inwomenwith high grade serous ovarian
cancer (HGSOC) and these cases account for the majority of mortality from OC. Although
initially – %ofwomen respondwell to chemotherapy ultimatelymost develop chemo-
therapy resistance leading to treatment failure. -year survival rates for women with ad-
vanced disease at the time of diagnosis are less than %, howeverwomenwith early stage
disease at the time of diagnosis have -year survival rates of over %, including signi ic-
antly improved survival forwomenwithHGSOC (CRUK ). Since the early smortal-
ity rates from OC have only slightly improved (CRUK ) with survival in the UK lagging
behind the rest of Europe (Coleman et al. ). There is therefore a pressing need to de-
velop methods that might enable earlier diagnosis of and potentially screening for OC.
HGSOC originates from the fallopian tube epithelium, speci ically arising from intrae-
pithelial tubal carcinoma, preferentially at the imbrial end of the fallopian tube. High rates
of co-existent serous ovarian carcinoma and serous tubal intraepithelial carcinoma (STIC)
(Kindelberger et al. ; Przybycin et al. ) and primary serous peritoneal carcinoma
and intrapepithelial tubal carcinoma (Carlson et al. ) have been identi ied. Identical
TP mutations have been identi ied in STIC and paired HGSOC samples (Kindelberger et
al. ; Lee et al. ; Kuhn et al. ) suggesting a clonal relationship. Mouse models
of HGSOC have shown that oophrectomy does not prevent the development of HGSOC but
that bilateral salpingectomy is preventative (Perets et al. ; Kim et al. ).
The fallopian tube is in direct communication with the peritoneal cavity. As such
symptoms of OC are generally non-speci ic and include abdominal bloating, loss of ap-
petite, early satiety, abdominal pain, urinary frequency and urgency. One in two women
aged between – present to their GP each year with these symptoms (Lim et al. ).
The unique biology of HGSOC also results in early metastatic spread, particularity to the
omentum. Diagnosis of OC is currently a challenge with only / patients with OC in the
UK presenting through a primary care referral (Elliss-Brookes et al. ). Thus tests with
improved sensitivity and speci icity in women with non-speci ic symptoms are critical to
improving mortality.
The gene TP encodes the tumour suppressor protein p , a transcription factor that
regulates the expression of proteins involved in apoptosis and genomic integrity. TP
mutations are ubiquitous in HGSOC (Ahmed et al. ; Kobel et al. ) and have been
identi ied as early drivers of the disease (Labidi-Galy et al. ). Other pointmutations are
uncommon inHGSOCwhich has been identi ied as a disease characterised by copy number
alterations (Ciriello et al. ) and unlike most other cancer subtypes these are typically
acquired during the irst half of clonal evolution (Gerstung et al. ). The unique genomic
features found in HGSOC present another signi icant challenge to the early detection of
HGSOC.
. CA
CA is a glycoprotein encodedby theMUC gene thatwas originally found to be elevated
(> U/ml) in serum in % of OC cases but only % of healthy and % of benign controls
(Bast et al. ). CA is a well validated biomarker instrumental to the current clinical
management of OC. Current guidelines recommend measuring serum CA in primary
care in all women with symptoms suggestive of OC followed by a transvaginal ultrasound
scan (TVUS) in those with elevated levels (RCOG ; NICE ). The combination of
CA , ultrasound indings (expressed as a score of , or ) and menopausal status (
if premenopausal, if postmenopausal), are used to calculate a Risk of Malignancy Index
(RMI). RMI with a cut-off of was found to have a sensitivity of % and speci icity of
% to discriminate OC cases from benign controls (Jacobs et al. ).
However CA is limited in both sensitivity and speci icity as a diagnostic biomarker.
In both screening and pre-surgical studies it has been shown that > % of women with
stage I disease do not have an elevated CA (Jacobs et al. ; Jacobs et al. ) poten-
tially resulting in delayed ormissed diagnosis. Conversely CA is elevated in a number of
benign gynaecological and non-gynaecological conditions, particularly in premenopausal
women, leading to further potentially unnecessary invasive investigations and associated
anxiety.
. CA based screening
A mortality bene it to OC screening using CA has yet to be elucidated. The prostate,
lung, colorectal and ovarian (PLCO) cancer screening trial of over , women using an-
nual TVUS and CA found no increase in cancers detected at an earlier stage and no im-
provement in mortality (Buys et al. ). This study was limited in that a single threshold
was used for CA , therewas a lack of central protocol formanagement of a positive result
and therewas a long follow upwith %of OC diagnoses occurring after the end of screen-
ing. An increase in detection of early stage cancer was found in the Japanese study of OC
screening of over , women again using annual ultrasound and CA (Kobayashi et
al. ) however, the mortality rates are unknown. An improved survival in women un-
dergoing annual screening with ultrasound was found in The Kentucky screening study of
over , women (Nagell et al. ). This however was not a randomised control trial
(RCT) and indings may be biased by a healthy volunteer effect.
TheUKCollaborativeTrial ofOvarianCancer Screening (UKCTOCS) is the largest screen-
ing study with over , postmenopausal women aged – years recruited from
centres in England, Wales and Northern Ireland. Women were randomised to annual
multimodal screening using CA interpreted using the risk of ovarian cancer algorithm
(ROCA), annual ultrasound or no screening in a : : ratio and followed up for a median
of . years. This study initially reported encouraging data with an increase in sensitivity
and speci icity, . % and . % respectively, for the diagnosis of OC inwomen in themul-
timodal screening arm (Menon et al. ). Primary analysis did not reveal a signi icant
reduction in mortality in the multimodal screening arm (Jacobs et al. ). However, an
encouraging mortality reduction of % was seen in years – compared to % in years
– suggesting that a mortality bene it might be seen after longer follow-up.
. Other biomarkers in ovarian cancer
Signi icant work is currently being undertaken to identify new protein biomarkers that
can potentially be used in combination with CA and RMI to improve triage of OC. One
example is HE , a serum protein biomarker, that has been found to have increased sensit-
ivity for the diagnosis of OC compared to RMI when used in combination withmenopausal
status and CA to calculate a Risk of Ovarian Malignancy Algorithm (ROMA) (Moore et
al. ).
However, despite decades of effort, CA remains the single-best biomarker for OC
with models derived from the most promising markers failing to show improvement over
serum CA alone (Cramer et al. ; Zhu et al. ).
Re ining Ovarian Cancer Test accuracy Scores (ROCkeTS) is a National Institute for
Health Research (NIHR) funded study that has been developed by the University of Birm-
ingham with four phases:
. Systematic review of the literature.
. Interrogationof datasets/samples fromUKOvarianCancerPopulationStudy (UKOPS),
UKCTOCS and International Ovarian Tumour Analysis (IOTA) to re ine model using
tests identi ied in phase .
. Prospective study to collect serum and perform ultrasoundwith IOTA criteria to val-
idate new models.
. Analysis and pathway generation.
Recruitment to the prospective part of the ROCkeTS study commenced in June
and as of March , postmenopausal and premenopausal women had been re-
cruited. This will provide a valuable resource to validate CA and other protein bio-
markers for triage of symptomatic women in secondary care. Interim analysis of current
recruitment to ROCkeTS showed a prevalence of OC of % among postmenopausal women
and . % in premenopausal women (personal communication Sudha Sundar, Univeristy of
Birmingham).
Alternative biomarkers to serum proteins include the detection of tumour-associated
antibodies in serum. Proteins produced by tumour cells can bemutated or over-expressed.
Release of these into the circulation can trigger an autologous immune response generat-
ing autoantibodies. It has been shown that p speci ic autoantibodies can be detected in
– %ofOC cases (Angelopoulou et al. ; Anderson et al. ; Tsai-Turton et al. )
including % of UKCTOCS cases not detected using the multi-modal screening strategy
(Yang et al. ).
. Circulating tumour DNA
An alternative strategy for earlier detection and/or screening is the detection of circulat-
ing tumourDNA (ctDNA). It has been known since that blood contains free circulating
DNA (Mandel et al. ). In it was shown that there are higher levels of free circu-
lating DNA in the blood of patients with cancer (Leon et al. ) and studies have con-
sistently found higher levels of free circulating DNA in the blood of patients with cancer
(mean ng/ml, range – ng/ml) compared to healthy controls (mean . ng/ml,
range – ng/ml) (Jahr et al. ). In it was irst shown that tumour DNA can be
identi ied in the blood of patients with cancer (Stroun et al. ) however, tumour DNA
can make up a tiny fraction of the total cell free DNA (cfDNA). Using next-generation se-
quencing (NGS) techniques it is now possible to amplify small amounts of free circulating
DNA in the blood to identify molecular alterations observed in tumour DNA and identify
these from the large amount of non-tumour cfDNA in the circulation. ctDNA is a highly
speci ic biomarker of cancer and could therefore provide a powerful non-invasive method
for earlier OC diagnosis.
The detection of ctDNA has had an extensive impact in oncology with widespread
use in research studies of advanced and relapsed disease (Wan et al. ). ctDNA has
been shown to be useful for the prediction of clinical response in metastatic breast cancer
(Dawson et al. ), prediction of disease relapse in colorectal cancer (Diehl et al. )
and breast cancer (Garcia-Murillas et al. ) and for the detection of resistance mechan-
isms in colorectal cancer (Diaz et al. ; Kuang et al. ).
There has also been considerable recent interest in using ctDNA for early detection
of cancer (Wan et al. ). There are signi icant challenges in applying this approach to
detection of early disease where levels of ctDNA are expected to be very low and in many
cases below detection thresholds of current methodologies. Strategies applied to increase
the detection of ctDNA in early stage cancers include the detection of patient speci icmuta-
tions (Bettegowda et al. ; Abbosh et al. ), deep sequencing ofmultiple genes (Phal-
len et al. ) and the combination of ctDNA and protein based biomarkers (Cohen et al.
). These powerful methods, able to detect down to an allele fraction (AF) of . – . %,
have been able to detect ctDNA in – % of stage I cancers. Although these studies have
shown feasibility for detection of ctDNA in early stage cancers, results in HGSOC are pre-
liminary. There is not yet any evidence that cancers can be detected earlier, or that thiswill
lead to improved clinical outcomes. These methods are also unlikely to be cost effective.
It is possible that sensitivity also may not be suf icient for the detection of very low tu-
mour volumes. Using linear modelling it has been predicted that a tumour with a volume
of cm will have a variant allele fraction (VAF) of . % and a tumour with a volume of
cm will have a VAF of . % (Abbosh et al. ).
. Circulating tumour DNA in ovarian cancer
Original studies found ctDNA to be present in – % of plasma and serum samples ob-
tained from women with OC (Otsuka et al. ; Swisher et al. ). These studies ex-
amined the frequency of TP mutations in samples but were limited to only a few nucle-
otide substitutions and were relatively insensitive.
A targeted sequencing method (TAm-Seq) developed by the labs uses a two-stage
ampli ication process for ampli ication and deep sequencing of exons of driver genes from
fragmented and/or low abundance input DNA such as plasma cfDNA. Prior knowledge of
the patients tumour speci ic mutation is not required. Control samples are used to assess
background sequencing error rates and each sample is analysed in duplicate to control for
sequencing errors and increase speci icity. The original method using a sequencing depth
of approximately ×was able to detect ctDNA in / ( %) of women with advanced
HGSOC down to AF of % with a speci icity of > % (Forshew et al. ). TAm-Seq is a
cost effective method and may be suitable for clinical application.
Digital PCR has a higher sensitivity for ctDNA detection. Using prior knowledge of
the patients tumour speci ic mutation to design tumour-speci ic assays for TP ctDNA
can be detected in > % of women with HGSOC including women with newly diagnosed
disease (Parkinson et al. ). This method cannot be used in a diagnostic setting as prior
knowledge of the patients tumour speci ic mutation is required. This study does however
provide evidence that ctDNA is present in plasma samples collected before treatment for
HGSOC.
In relapsed HGSOC it has been shown that there is a relationship between tumour
volume measured by D CT volumetric analysis and ctDNA levels. Using digital PCR for
TP / patients with a tumour volume of > cm had detectable ctDNA. Only /
cases with a tumour volume of< cm had detectable ctDNA and one of these can poten-
tially be explained by the presence of large volume ascites. The TP mutant allele fraction
(MAF) was moderately correlated with the tumour volume (correlation coef icient . )
and was higher in cases without ascites (correlation coef icient . ). CA was less well
correlated with tumour volume (correlation coef icient . and . respectively). Inter-
estingly themedian TP MAFper tumour volumewasmuch higher in the relapsedHGSOC
cases ( . % per cm ) compared to newly diagnosed HGSOC cases ( . % per cm )
(Parkinson et al. ).
These studies all focused on the detection of ctDNA in relapsedHGSOC. There is an op-
portunity for earlier detection of HGSOC if appropriatemethodswith high enough sensitiv-
ity can be developed. PersistentTP mutations in fallopian tubal epithelial cells have been
conclusively demonstrated to be the irst pathological change in STIC. STIC is the precursor
or preinvasive lesion to HGSOC (Lee et al. ). p staining of fallopian tube sections to
identify abnormal staining patterns for p protein is established in clinical practice to
identify STIC lesions. A recent publication using whole exome sequencing for detection
of somatic mutations and copy number aberrations for matched STIC and fallopian tube
cancers has con irmed the presence of TP mutations in STIC lesions. Using evolution-
ary analysis, the authors estimate that the average time between development of STIC and
invasive carcinoma to be years (Labidi-Galy et al. ). There is therefore evidence to
suggest that preinvasive lesions to HGSOC do harbour TP mutations and that there is a
signi icant window of opportunity for earlier detection of OC.
. Cervical sampling in ovarian cancer
Routine cervical screeningwas introduced as amethodof detecting pre-malignant changes
in ectocervical cells that could progress to cervical cancer if not treated. In the con-
ventional Pap smear was replaced by liquid based cytology (LBC) as a means of reducing
the number of inadequate samples obtained. In addition the use of LBC has allowed the
collection of DNA as well as cytological evaluation of cervical samples. This has been util-
ised for human papillomavirus (HPV) triage and test of cure.
Cells and DNA shed from the distal fallopian tube can pass through the uterus and
cervix to the vaginawhere they can be sampled. Occasionally OC is diagnosed following an
abnormal cervical cytology sample in asymptomatic women with otherwise normal clin-
ical investigations. It is estimated that < . % of all routine cervical smear samples are
thought to show glandular abnormalities (NHS )which suggest possible endocervical,
endometrial or ovarian abnormalities. Approximately – % of these are subsequently
diagnosed with pre-invasive or invasive disease (DeSimone et al. ; Boyraz et al. ),
the minority of these being ovarian.
Another approach for increasing the sensitivity of detection of early stage disease is
to collect samples proximal to the suspected location of tumour, in which tumour DNA is
likely to be enriched. Maritschnegg et al. found a % sensitivity for the detection of
OC using lavage of the uterine cavity andWang et al. found a sensitivity of % for the
detection of OC by performing direct sampling of the intrauterine cavity using a Tao brush.
These procedures are not suitable for widespread use in symptomatic women as they are
invasive procedures that can only be performedby trained healthcare professionals. These
procedures are also uncomfortable and expensive.
Studies looking at less invasive methods of sampling at the cervical os have shown
that tumour DNA and somatic mutations can be identi ied in cervical cytology samples
(Kinde et al. ) and vaginal tampons (Erickson et al. ) from women with advanced
OC. More recently it has been shown that % of OCs (n= ) were detected using a com-
bination of somatic mutation detection in genes and aneuploidy detection in cervical
cytology samples (Wang et al. ). This included detection in % of early stage cancers.
Combining cervical cytology andplasma increased the sensitivity to % in womenwith
OC. This suggests that cervical sampling could potentially be used as part of a diagnostic
or triage tool for OC.
. Overview
In summary existing approaches for the detection and screening for early stage OC have
a low sensitivity and little impact on mortality. Tests with improved sensitivity for the
detection of early stage disease as well as tests with a higher speci icity are required in
primary care to ensure that all women are triaged appropriately and in a timely manor
following presentationwith symptoms. To achieve an improvement in both sensitivity and
speci icity it is likely that a combination of tests will be required including both protein
markers and potentially ctDNA.
Earlier detection of HGSOC poses a number of challenges relating to the unique bio-
logy and genomic features of the disease. Methods for the detection of ctDNA in early stage
cancers are now being developed. However, these are currently limited by complex library
preparation methods, complex bioinformatics analysis, the requirement for deep sequen-
cing, and ultimately are not cost-effective for routine use as a diagnostic test. I am going to
investigate alternative opportunities to increase the speci icity and sensitivity of detection
of HGSOC using plasma ctDNA and cervical sampling. The long term aim is to investigate
the combination of multiple biomarkers to improve earlier detection of OC.
. Project aims
. To determine if ctDNA can be detected in plasma samples collected fromwomenwith
newly diagnosed OC.
. To develop methods with increased sensitivity for the detection of ctDNA in women
with newly diagnosed HGSOC.





CTCR-OV (Molecular analysis of response to treatment inovarian cancer) (REC /H / )
is an ongoing single centre observational study at AddenbrookesHospital recruiting all pa-
tients with known or suspected ovarian, fallopian tube or primary peritoneal cancer. To
date over patients have been recruited and plasma, tissue, and ascites samples have
been banked at multiple treatment time points.
. . UKOPS
UK Ovarian Cancer Population Study (UKOPS) is a biobanking study that recruited from
centres across England, Wales, and Northern Ireland between and . Inclusion
criteria were:
. Women with an adnexal mass suspicious of OC about to undergo surgery.
. Women with a con irmed diagnosis of primary invasive or borderline OC.
. Women with a probable diagnosis of primary invasive OC not undergoing surgery.
. Womenwith a possible benign or borderline adnexalmass about to undergo surgery.
. Apparently healthy women recruited from the multimodal arm of UKCTOCS when
they attended for annual screening.
In total this study banked samples from , epithelial OCs ( of which were recruited
pre-operatively), benignorborderlineneoplasms, and , healthy controls. Through
a collaboration with Usha Menon at UCL we have had access to formalin ixed paraf in em-
bedded (FFPE) tissue andmatched plasma samples obtained prior to the diagnosis of epi-
thelial OC.
. . CTCR-OV
I am the principle investigator for CTCR-OV (Genetic biomarkers for gynaecological con-
ditions) (REC /EE/ ). I designed and developed study documents for CTCR-OV ,
a single centre observational study recruiting all women referred to Addenbrookes Hos-
pital or undergoing surgery atAddenbrookesHospital for suspectedOC.Between June
and September women were recruited to CTCR-OV . Plasma, tissue, and cervical
samples were collected from participants at multiple treatment time points. In total I col-
lected cervical cytology samples from women recruited to CTCR-OV . See appendix
. for CTCR-OV study documents.
. . CS
I am the principle investigator for CS (Molecular analysis of cervical smear samples)
(REC /LO/ ) an observational study designed to collect all routine cervical smear
samples from West Anglia Pathology Service Cervical Cytology Laboratory showing non-
cervical glandular abnormalities. The study has been developed to assess ifmolecular ana-
lysis of routine cervical smear samples is a sensitive enoughmethod foruse in thediagnosis
of OC. See appendix . for CS study documents. In total cervical cytology samples
were received and analysed between December and March .
. Sample collections
. . FFPE samples
FFPEblockswereobtained fromthepathology archives atAddenbrookesHospital for samples
collected through CTCR-OV , and from the pathology archives at UCL for samples collec-
ted through UKOPS. FFPE blocks were reviewed by the study pathologist and the block
most suitable for DNA extraction (largest area of highest cellularity tumour) was selected.
Based on the tumour area and cellularity between – μm sections on plain glass slides
were cut by Addenbrookes Tissue Bank or CRUK CI histopathology core. Tumour regions
weremarkedby the studypathologist on an adjacent hematoxylin and eosin (H&E) section.
. . Blood samples
Banked plasma samples were retrieved from the Cambridge Cancer Centre Blood Pro-
cessing Laboratory (CCCBPL) from patients recruited to CTCR-OV . Patients recruited
to the referral cohort of CTCR-OV had ml blood collected in an ethylenediaminetet-
raacetic acid (EDTA) tube for plasma and buffy coat isolation, . ml blood collected in an
EDTA tube for whole blood collection and ml blood collected in a serum tube. Patients
recruited to the surgery cohort of CTCR-OV had the schedule of blood collection outlined
in table . .
EDTA tubes for plasma isolationwere kept at room temperature and processedwithin
one hour of collection or kept at ∘C and processedwithin six hours of collection. Samples
collected in EDTA tubes were centrifuged at g for minutes, . ml aliquots of plasma
were subsequently centrifuged at , rpm for minutes. The supernatant was trans-
ferred to sterile . ml screw cap tubes and stored at − ∘C before DNA extraction. Fol-
lowing the initial centrifugation step the buffy coat layer was removed and transferred to
sterile . ml screw cap tube and stored at − ∘C. Serum tubes are left to stand at room
temperature to allow the blood to clot. Samples are subsequently centrifuged at , rpm
for minutes. . ml aliquots are then transferred to sterile . ml screw cap tubes and
stored at - ∘C. Whole blood is stored in ml aliquots in sterile . ml screw cap tubes at
− ∘C.
Time point Samples Collected
Start of Operation 9.0 ml EDTA for plasma and buffy coat
2.5 ml EDTA for whole blood
7.0 ml serum
End of Operation 9.0 ml EDTA for plasma
2 hours post-operative 9.0 ml EDTA for plasma
Day 1 post-operative 9.0 ml EDTA for plasma
7.0 ml serum
Day 2 post-operative and daily whilst inpatient 9.0 ml EDTA for plasma
Table . : Schedule of blood collection for surgery cohort of CTCR-OV
. . Cervical samples
Patients recruited to both the referral and surgery cohort of CTCR-OV had a cervical
mucous aspirate (CMA) and cervical cytology sample collected at the initial sampling time
point. CMAs were collected using a cervical mucous sampling device and transferred to a
cryovial for storage at − ∘C. Cervical cytology samples were collected by routine liquid
based cytology method using a brush and transferred to ml PreservCyt fixative solu-
tion. Samples were stored at room temperature and processed for DNA extraction within
weeks of collection.
. Cell culture
Frozen cell pellets for Hela, OVCAR and SKOV were thawed. ml of the relevant media
was added to each cell pellet and the sample was centrifuged at , rpm for minutes
at room temperature. The media was aspirated to leave the cell pellet which was resus-
pended in ml media and incubated at ∘C with % CO . Samples were cultured to %
con luence and then split bywashingwithwarm phosphate buffered saline (PBS), trypsin-
ising with . % trypsin, neutralising with an equal volume of media, centrifugation at
, rpm for minutes, aspirating themedia and resuspending in the appropriate volume
of media for the number of cells present and size of lask being using for replating. Cells
were cultured by this processing until suf icient cells were present for subsequent experi-
ments. Cells were counted using Vi-Cell according to manufacturers instructions.
. Extraction of DNA
. . Extraction of DNA from FFPE
DNA was extracted from FFPE sections using scrape macro dissection followed by the QI-
AampDNAMicroKit (Qiagen). Firstly tumour areasmarked by the pathologistweremacro
dissected by scraping with a scalpel into a . ml micro-centrifuge tube containing ml xy-
lene to removed the paraf in. Samples were mixed by vortexing for seconds and cent-
rifuged for minutes at full speed. The supernatant was removed and ml % ethanol
added to remove the remaining xylene. The sample wasmixed by vortexing for seconds
and centrifuged for minutes at full speed. The supernatant was removed and the pellet
dried for minutes at ∘C. The pellet was resuspended in μl ATL buffer, mixed by
vortexing and spun down brie ly. The sample was incubated at ∘C for minutes to re-
pair the cross-linking damage caused by the formalin. The sample was brie ly centrifuged
and μl Proteinase K added when the sample reached room temperature. The sample
was mixed by vortexing, centrifuged brie ly and incubated at ∘C for – hours mixing
at rpm. The samplewas incubated at ∘C for hour to reverse the formaldehyde DNA
modi ication. The sample was centrifuged brie ly, μl RNase A ( mg/ml) added and in-
cubated at room temperature for minutes. μl AL buffer and μl % ethanol
were added, mixed by vortexing for seconds and brie ly centrifuged. The sample was
transferred to aQIAampMinElute column and centrifuged for minute at , g. The low
throughwas discarded and the column placed in a clean collection tube. μl AW buffer
was added and centrifuged for minute at , g. The low through was discarded and
the column placed in a clean collection tube. μl AW buffer was added and centrifuged
for minute at , g. The low through was discarded and the column placed in a clean
collection tube and centrifuged for minutes at full speed. The QIAmp Min Elute column
was placed in a . ml micro-centrifuge tube and μl ATE buffer added to the membrane,
incubated at room temperature for minutes and centrifuged for minute at full speed. A
further μl ATE buffer was added to the membrane, incubated at room temperature for
minutes and centrifuged for minute at full speed. The sample was stored at− ∘C.
. . Extraction of DNA from cervical cytology
DNA was extracted from cervical cytology samples within weeks of collection using the
QIAamp DNA Micro Kit (Qiagen). Samples were transferred to a ml falcon tube and
centrifuged at full speed for minutes. The fixative was aspirated and the cell pellet re-
suspended in ml % ethanol. The protocol for DNA extraction from FFPE samples was
then followed (see section . . , page ).
. . Extraction of DNA from cervical mucous
DNA was extracted from CMA samples using the QIAamp DNA Micro Kit (Qiagen). μl
ATL buffer and μl Proteinase K were added to the sample and transferred to a . ml
micro-centrifuge tube. The sample was incubated at ∘C for hours. μl of RNase A was
added at room temperature and incubated for minutes. μl AL buffer and μl %
ethanol were added to the sample, mixed by vortexing and brie ly centrifuged. The sample
was transferred to a QIAamp MinElute column and centrifuged for minute at full speed.
The low through was discarded and the column placed in a clean collection tube. μl
AW buffer was added and centrifuged for minute at full speed. The low through was
discarded and the column placed in a clean collection tube. μl AW buffer was added
and centrifuged for minute at full speed. The low throughwas discarded and the column
placed in a clean collection tube and centrifuged for minutes at full speed. The QIAamp
MinElute column was placed in a . ml micro-centrifuge tube and μl ATE buffer added,
incubated at room temperature for minutes and centrifuged for minute at full speed.
A further μl ATE buffer was added, incubated at room temperature for minutes and
centrifuged for minute at full speed. The sample was stored at− ∘C.
. . Extraction of DNA from cultured cells
DNA was extracted from cultured cells using the DNeasy Blood & Tissue kit. Cells were
centrifuged for minutes at g. The pellet was resuspended in μl PBS and μl
Proteinase K added. μl AL buffer and μl % ethanol were added, mixed by vor-
texing and incubated at ∘C for minutes. The sample was placed in a DNeasy Mini spin
column placed in a ml collection tube and centrifuged at , g for minute. The low
through was discarded and the column placed in a new collection tube. μl AW buffer
was added and centrifuged for minute at , g. The low throughwas discarded and the
column placed in a new collection tube. μl AW buffer was added and centrifuged for
minute at , g. The spin column was placed in a clean . ml micro-centrifuge tube
and μl AE buffer applied to the membrane. The column was incubated at room tem-
perature for minute and the centrifuged for minute at , g. The sample was stored
at− ∘C.
. . Extraction of DNA from plasma
Circulating nucleic acids were extracted from between . – ml of plasma with either the
QIAvac plus vacuum manifold and the QIAamp Circulating Nucleic Acid kit (Qiagen) or
the QIAsymphony (Qiagen).
For theQIAvac extraction sampleswasadjusted to inal volumeusingPBS. ProteinaseK
and ACL buffer containing . μg of carrier RNA were added to the sample and mixed by
vortexing for seconds (Table . ). The sample was brie ly centrifuged and ACB buffer
added (Table . ). The sample was mixed by pulse vortexing for seconds. The sample
was incubated on ice for minutes. The lysate was applied to the QIAamp Mini column. A
vacuumwas applied to draw lysate through the column. μl ACW bufferwas applied to
the column and the pump used to draw the sample through the column. μl ACW buf-
fer was applied to the column and the pump used to draw the sample through the column.
μl % ethanol was applied to the column and the pump used to draw the sample
through the column. The column was placed in a clean ml collection tube and centri-
fuged at full speed for minutes. The column was placed in a new ml collection tube
and incubated at ∘C with the lid open for minutes to dry the membrane. The column
was placed in a clean . ml micro-centrifuge tube, μl AVE buffer applied to the mem-
brane and incubated at room temperature for minutes. The column was centrifuged for
minute at , g. The eluate was reapplied to the membrane, incubated at room tem-
perature for minutes and centrifuged at , g for minute. The sample was stored at
− ∘C.
The QIAsymphony extractions were performed by the Cancer Molecular Diagnostics









1 100 0.8 1.8
2 200 1.6 3.6
3 300 2.4 5.4
Table . : Volume of reagents added depending on initial starting volume of sample.
. . Quanti ication of DNA
DNAwas quanti ied using the Qubit dsDNABR assay kit or HS assay kit. The Qubit working
solution was prepared by diluting the relevant dsDNA reagent : in the relevant dsDNA
buffer. Appropriate standards were prepared using μl of working solution and μl
standard. Sampleswere prepared using μlworking solution and μl sample. Standards
and samples were mixed by vortexing for – seconds. The standards and samples were
read using the Qubit Fluorometer.
. Library preparation
. . TAm-Seq
The TAm-Seq library preparation method has previously been published (Forshew et al.
).
For FFPE and buffy coat samples TAm-Seq was performed using μl of DNA at a con-
centration of ng/μl or from μl of DNA for low concentration samples. Owing to the low
concentrations of plasma and serum samples TAm-Seq was performed using μl of DNA.
All samples are run in duplicate.
Firstly a pre-ampli ication step was performed by combining μl of sample with μl
of pre-ampli icationmastermix (see below). The primermix is speci ic to the primer panel
for speci ic experiments (see appendices . , . , . for primer panel details).
Pre-ampli ication master mix μl
10× FastStart High Fidelity Reaction Buffer with MgCl2 (Roche) 1.00
25 m MgCl2 (Roche) 1.08
DMSO (Roche) 0.50
10 m PCR Grade Nucleotide Mix (Roche) 0.20
5 U/μl FastStart High Fidelity Enzyme Blend (Roche) 0.10
Primer mix (made by combining 1 μl of each primer (100 μ stock concentration)) 0.48
H2O 1.64
The following pre-ampli ication protocol was then run.
∘C 10 min
∘C 15 sec 15 cycles
∘C 4 min
μl of each pre-ampli ied sample was added to μl of ExoSAP-IT and incubated at
∘C for minutes followed by ∘C for minutes.
To dilute the pre-ampli ication products μl PCR certi ied water was added to each
sample. μl of the diluted pre-ampli ication productwas combinedwith μl of pre-sample
master mix solution (see below).
Pre-Sample Master Mix μl
10× FastStart High Fidelity Reaction Buffer without MgCl2 (Roche) 0.50
25 m MgCl2 (Roche) 0.90
DMSO (Roche) 0.25
10 m Grade Nucleotide Mix (Roche) 0.10
5 U/μl FastStart High Fidelity Enzyme Blend (Roche) 0.05
20× Access Array Loading Reagent (Fluidigm) 0.25
H2O 1.95
A × Access Array IFC was primed, μl of × primer solution added to each of
the primer inlets and μl of sample plus master mix added to each of the sample inlets.
The Access Array was loaded using the IFC Controller AX and then placed in the Fluidigm
Thermal Cycler and the AA × Standard v protocol run. After the thermal cycling
had inished μl × Access Array Harvest Reagent was added to each of the sample inlets.
Samples were harvested using the IFC Controller AXwith approximately μl of harvested
PCR product retrieved per sample. μl of PCR productwas diluted in μl of PCR certi ied
water. μl of diluted harvested PCR product was added to μl of pre-sample master mix
(see below) and μl of the relevant Access Array Barcode Library for the Illumina Genome
Analyser ( μ ).
Pre-Sample Master Mix μl
10× FastStart High Fidelity Reaction Buffer without MgCl2 (Roche) 1.00
25 m MgCl2 (Roche) 1.80
DMSO (Roche) 0.50
10 m PCR Grade Nucleotide Mix (Roche) 0.20
5 U/μl FastStart High Fidelity Enzyme Blend (Roche) 0.10
H2O 3.40
The following PCR protocol was run.
∘C 10 min
∘C 15 sec
∘C 30 sec 15 cycles
∘C 1 min
∘C 3 min
μl of each PCR product was pooled to create the library ( μl total). The library
was puri ied by adding . μl (ratio of : . ) AMPure XP magnetic beads. The bead mix
solution was mixed by vortexing and placed on a magnet for – minutes to separate the
beads from the solution. The supernatant was aspirated and discarded. The beads were
washed twice using μl of %ethanol. Thebeadswere left to air dry for – minutes.
μl PCR certi ied water was added to the beads and mixed by vortexing. The bead mix
solution was placed on the magnet for – minutes. The clear solution was collected and
stored at− ∘C. The librarywas quanti ied either using the Bioanalyzer Agilent DNA
kit or Tapestation Agilent D ScreenTape System according to manufacturers protocol.
Librarieswere diluted to n , pooled and submitted to the genomics core for sequencing
using Illumina MiSeq, HiSeq or HiSeq .
. . Whole genome library preparation
Whole genome libraries were prepared using Rubicon ThruPlex DNA-Seq kit. A single rep-
licate for each sample was run using this protocol.
For FFPE samples DNA was irst sheared using the Covaris LE . ng of DNA in
μl was placed in a microTUBE- AFA bead strip V well and spun down. The settings
used are listed below. The sameprotocolwas used for shearingDNA fromcervical cytology
samples but the treatment time was extended to seconds.
Target BP, peak (bp) 200–250
Peak Incident Power (W) 180
Duty Factor (%) 30
Cycles per Burst 50
Treatment time (sec) 120
Temperature (∘C) 20
Water level 4
Y Dither (mm) 5
X-Y Dither Speed (mm/ sec) 20
X Dither (mm) 0
X-Y Dwell (sec) 0
μl of sheared DNA or μl of plasma or serum DNA was then combined with μl of
template preparation buffer and μl of template preparation enzyme. The samples were
incubated at ∘C for minutes followed by ∘C for minutes. μl of library synthesis
buffer and μl of library synthesis enzyme were added to each sample and incubated at
∘C for minutes. μl of library ampli ication buffer, μl of library ampli ication en-
zyme and μl of nuclease freewaterwas added to each samplewith μl of the appropriate
indexing reagent. The library ampli ication reaction was performed with the number of
PCR cycles varying depending on the DNA input according to manufacturers protocol.





∘C 20 sec 4 cycles
∘C 40 sec
∘C 20 sec n cycles
∘C 50 sec
∘C hold
Libraries were puri ied using AMPure XP magnetic beads ( : ratio). The bead mix
solution was mixed by vortexing for minutes and incubated at room temperature for
minutes. The samplewasplacedon amagnet for minutes to separate the beads from the
solution. The supernatant was aspirated and discarded. The beads were washed twice us-
ing μl of %ethanol. Thebeadswere left to air dry for minutes. μl of librarydilu-
tion bufferwas added to the beads,mixedby vortexing for minutes and incubated at room
temperature for minutes. The beadmix solutionwas placed on themagnet for minutes.
The supernatant was collected and stored at − ∘C. The libraries were quanti ied using
the KAPPA library quanti ication kit or the Tapestation Agilent D ScreenTape System
according to manufacturers protocol. Libraries were diluted to n , pooled and sub-
mitted to the genomics core for sequencing using Illumina HiSeq generating bp
paired-end reads.
. . Digital PCR
Firstly the assay mix was prepared.
20× assay mix
F primer (100 μ ) 4.50 μl
R primer (100 μ ) 4.50 μl
Probe (100 μ ) 1.25 μl
H2O 14.75 μl
Depending on the number of samples to be run either the K chip or the . chip
was used. Two replicates were performed for all samples following this protocol.
For the K chip irstly the chip was primed. Next the PCR master mix was prepared.
Master Mix for 37K chip (volume per inlet) μl
20× PCR Master Mix 3.0
20× GE Sampling Loading Reagent 0.6
20× Gene speci ic assay 1 0.3
20× gene speci ic assay 2 or nuclease free water if using 1 probe 0.3
The master mix was mixed by vortexing and . μl aliquoted into PCR strips for the
number of reactions required. μl × GE sample loading reagent was prepared by dilu-
tion μl × GE sample loading reagent in μl nuclease free water. . μl of DNA was
aliquoted for each reaction into PCR strips. The DNA was denatured at ∘C for minute
and then transferred to ice for minute. The sampleswerebrie ly centrifuged. . μl sample
was transferred to the PCR strips containing the master mix. The samples were mixed by
vortexing and brie ly centrifuged. Once primed the chip was removed from the IFC Con-
troller and μl × GE sample loading reagent added to all hydration inlets. . μl sample
master-mix was added to each sample inlet. Bubbles were removed from all inlets before
loading. The chip was placed in the IFC Controller MX and the load ( ×) script run. Once
complete the chip was removed from the controller and sticky tape used to remove any
dust/debris from the chip surface. The chip was placed in the Biomark and the PCR pro-
tocol run (Figure . ).
Master Mix for 12.765 chip (volume per inlet) μl
20× PCR Master Mix 5.0
20× GE Sampling Loading Reagent 0.5
20× Gene speci ic assay 1 1.0
Nuclease free water 0.5
For the . chip the master mix was prepared irst. The master mix was mixed by
vortexing and μl aliquoted into PCR strips for the number of reactions required. The chip
was primed using the IFC Controller MX. . μl of DNA was then added to a PCR strip and
heat denatured at ∘C for minute. The samples were then transferred to ice for at least
minute and then brie ly centrifuged. μl of the heat denatured sample was transferred
to the PCR strips containing the master mix. The samples were mixed by vortexing and
brie ly centrifuged. Once primed the chip was removed from the IFC Controller and . μl
water to the H wells. . μl sample master-mix was added to each sample inlet. Bubbles
were removed from all inlets and the samples loaded using the IFC Controller MX. Once
complete the chip was removed and sticky tape used to remove any dust/debris from the
chip surface. The chip was placed in the Biomark and the PCR protocol run (Figure . ).
Figure . : Digital PCR protocol.
. . Whole genome single stranded library preparation
Single stranded libraries were prepared using the DNA SMART ChIP-Seq Kit. A single rep-
licate of each sample was run using this protocol. Up to ng DNA in a volume of μl was
aliquoted into PCR tubes. The sample was incubated in a preheated hot lid thermal cycler
at ∘C for minutes to convert dsDNA to ssDNA. The samples were removed and imme-
diately placed on ice for at least minutes. The tubes were brie ly centrifuged. Next . μl
DNA SMART buffer and . μl shrimp alkaline phosphatase were added to each sample.
The samples were mixed by vortexing and brie ly centrifuged. The samples were placed
in a preheated thermal cycler at ∘C for minutes followed by ∘C for minutes to de-
phosphorylate the ′ end of the ssDNA in preparation for T-tailing. Next μl of DNA SMART
T-Tailing mix and μl Terminal Deoxyynucleotidyl Transferase was added to each sample.
The samples weremixed by vortexing and brie ly centrifuged. The samples were placed in
a preheated thermal cycler and heated to ∘C for minutes then ∘C for minutes to
add poly(T) tail to the ssDNA to provide a site for the DNA SMART Pold(dA) primer. μl
of DNA SMART Poly(dA) Primer was added to each sample, mixed by vortexing and brie ly
centrifuged. The samples were incubated in a preheated, hot lid thermal cycler at ∘C for
minute for theDNA SMARTPoly(dA) primer to anneal to the ssDNA template. The sample
was immediately placed on ice for at least minutes and then centrifuged brie ly. μl
DNA SMART buffer, μl DNA SMART oligonucleotide mix and μl SMARTScribe Reverse
Transcriptase were added to each sample, mixed by vortexing and centrifuged brie ly. The
samples were placed in a preheated thermal cycler at ∘C for minutes then ∘C for
minutes. μl SeqAmp PCR buffer and μl SeqAmpDNA polymerase was added to each
sample with μl of each of the relevant forward and reverse primers. The samples were
mixed by vortexing and brie ly centrifuged. The following PCR protocol was run with the




∘C 15 sec n cycles
∘C 30 sec
∘C hold
The samples were then puri ied using AMPure XP magnetic beads at a ratio of :
sample:beads. The library was quanti ied either using the Bioanalyzer Agilent DNA
kit or Tapestation Agilent D ScreenTape System according to the manufacturers pro-
tocol. Libraries were diluted to n , pooled and submitted to the genomics core for se-
quencing using Illumina MiSeq or HiSeq .
. . TAm-Seq V
DNA was diluted to copies/μl based on digital PCR quanti ication of both ends of TP
using CXP AandAmplicon primers andprobes (see section . . , page ). PCRmas-
ter mix was prepared using the following reagents per well. The total number of replicate
wells varied for each sample depending on the expectedMAF and amount ofmaterial avail-
able. Aminimumof replicatewellswere performed for each samplewithmore replicate
wells included if suf icientmaterial was available and theMAFwas expected to be very low
(eg. < . %). Reactions were performed in a well plate. Two primer pools were run in
parallel.
TAm-Seq V2 master mix μl
5× Q5 buffer 1.00
dNTPs (10 m ) 0.10
HS-Q5 0.05
Primers (1 μ ) 2.40
H2O 0.45
DNA 1.00
The following PCR cycling conditions were then run.
∘C 30 sec
∘C 10 sec
∘C 15 sec 30 cycles
∘C 5 sec
∘C 2 min
Primers were tagged with a well-speci ic barcode to enable pooling of μl from up to
wells (pool and ) per sample ( μl total). Puri ication was performed using Pippin
% Agarose – bp B cassette (HTC ) selecting for – bp following manu-
facturers instructions. Master mix for barcoding was then prepared.
TAm-Seq V2 barcoding master mix μl
5× Q5 buffer 2.00




DNA (direct from Pippin) 1.00
The following PCR protocol was run.
∘C 30 sec
∘C 10 sec
∘C 30 sec 15 cycles
∘C 8 sec
∘C 2 min
μl of PCRproductwas added to μl ofwater and μl of AMPure XPmagnetic beads.
The bead mix solution was mixed by vortexing and placed on a magnet for – minutes
to separate the beads from the solution. The supernatant was aspirated and discarded.
The beads were washed twice with μl of % ethanol and then left to air dry for up
to minutes. μl PCR certi ied water was added to the beads and mixed by vortexing.
The bead mix solution was placed on the magnet for – minutes. The supernatant was
collected and stored at− ∘C. The libraries were quanti ied using the Tapestation Agilent
D ScreenTape Systemaccording to themanufacturers protocol. Librarieswere diluted
to n , pooled and submitted to the genomics core for sequencing using Illumina MiSeq
or HiSeq .
. In vitro size selection
In-vitro size selection of DNA was performed using the PippinHT (Sage Bioscience). For
each sample between – ng DNA in μl H O was combined with μl of the relevant
marker solution. The protocol was selected depending on the loading cassette used and
the size selection parameters required. The cassette was prepared as per manufacturers
guidelines. Samples were eluted in μl Tris-TAPS buffer and collected.
. p peptide microarray
The p peptide microarray was developed in the Wandall laboratory (Pedersen et al.
). Brie ly, a peptide array covering thewhole of p with -mer peptides and amino
acid overlaps was designed. Serum samples were incubated on the microarray with con-
jugated goat anti-human IgG. Slides were scanned and the mean value of relative luores-
cence intensity recorded. Values higher than standard deviations over the mean were
considered positive.
. Bioinformatics analysis
. . Analysis of TAm-Seq
TheTAm-Seq analysis pipeline has previously been published (Forshewet al. ). Brie ly,
reads are demultiplexed and aligned to the human reference genome (GRCh ). Aligned
reads are separated into the constituent amplicons and an alignment pileup generated.
Frequencies of non-reference alleles are calculated using a base quality and a mapping
quality cut off. The normal and Poisson distribution of non-reference alleles is modelled
and the probability of obtaining the observed non-reference alleles determined. Mutations
that pass a probability cut off of . are kept for further analysis, ranked by observed
frequency and corrected for median frequency across all samples for each locus. Known
SNPs are discarded. A mutation is called if it ranks highly in non-reference frequency in
both replicates. The IntegrativeGenomicsViewer (IGV) (Thorvaldsdottir et al. ) is used
for manual curation of all mutation calls and inspection of samples that had no mutations
called by the analysis pipeline.
When performing speci ic variant calling for a known mutation the frequency of the
non-reference allele can be read out directly from the desired locus. The background noise
at each locus is calculated by determining the frequency of non-reference reads at that
locus in all other samples. A mutation is only called if the frequency is larger than the
maximum background value at that speci ic locus.
. . Analysis of shallow whole genome sequencing data
Sequence data was analysed using an in-house pipeline that carried out the following;
paired end sequence reads were aligned to the human reference genome (GRCh ) using
BWA-mem following the removal of contaminating adapter sequences. PCR and optical
duplicates were marked using MarkDuplicates (Picard Tools) feature and these were ex-
cluded from downstream analysis along with reads of low mapping quality and supple-
mentary alignments. When necessary, reads were down-sampled for comparison pur-
poses. Somatic copy number aberration analysiswas performed inRusing a software suite
for shallow whole genome sequencing (sWGS) analysis named CNAclinic (Chandrananda
) aswell as theQDNAseqpipeline. Sequencing readswere randomly sampled to mil-
lion readsperdataset andallocated into equally sized ( Kbp)non-overlappingbins through-
out the length of the genome. Read counts in each bin were corrected to account for se-
quence GC content and mapability, and bins overlapping ‘blacklisted’ regions prone to
alignment artefacts (derived from the ENCODE project + Genomes database) were
excluded from downstream analysis. Read counts in test samples were normalized by the
counts from an identically processed healthy individual and log transformed to obtained
copy number ratio values per genomic bin. Read counts in healthy controls were normal-
ized by their median genome-wide count. Next, bins were segmented using both Circular
Binary Segmentation and Hidden-Markov Model based algorithms, and an averaged log R
value per bin was calculated. An in-house empirical blacklist of aberrant read count re-
gions was constructed as follows: sWGS datasets from healthy plasma were used to
calculatemedian read counts per Kbp genomic bin as a function of GC content andmap-
pability. A D LOESS surface is applied and the difference between the actual count and
the LOESS itted values were calculated. The median of these residual values across the
controls were calculated per genomic bin. Regions with median residuals greater than
standard deviations were blacklisted. The averaged segmental log R values in each test
sample that overlap this cfDNA blacklist were trimmed and themedian absolute valuewas
calculated. This score is de ined as t-MAD or the trimmedmedian absolute deviation from
log R = .
. . In silico size selection
Paired-end reads were generated by sequencing DNA from both ends of the fragments
present in the library. The original length of the DNA can was inferred using the map-
ping locations of the read ends in the genome. Once alignment was complete, Samtools
software was used to select paired reads that correspond to fragment lengths in a speci ic
range.
. . Quanti ication of the bp periodic oscillation
The amplitude of the bp periodic oscillation observed in the size distribution of cfDNA
samples was determined from the sWGS data as follows: the local maxima and minima in
the range bp to bpwere calculated. The average of their positions across the samples
was calculated: (minima: , , , , , , , andmaxima: , , , , , ,
). To compute the amplitude of the oscillations below bp with bp periodicity we
calculated the sum of the height of the maxima and subtracted the sum of theminima. The
height of the peak is de ined as the number of fragments with that speci ic length divided
by the total number of fragments. To de ine local maxima, we selected the positions y such
that y was the largest value in the interval [y- , y+ ]. The same approach was used to pick
minima.
. . Analysis of TAm-Seq V
For analysis of TAm-Seq V irstly well demultiplexing was performed using an in house
pipeline followed by alignment using BWA-MEM. The coverage per amplicon was calcu-
lated using bedtools requiring % coverage of the region. Mutation calling was then per-
formedby calculating the background frequency of non-reference alleles in a cohort of con-
trol samples. Changes above the background ratewere then determined in the samples us-
ing a beta distribution to determine a probability at each base. Scores were iltered based





. Same variant called on F and R reads
All mutations called in over two wells were reviewed manually.
Detection of plasma circulating tumour
DNA in women with newly diagnosed
ovarian cancer
. Introduction
It has previously been shown that plasma ctDNA can be detected in> %of women with
HGSOC (Parkinson et al. ). Importantly, for the development of ctDNA as a diagnostic
biomarker, this study detected ctDNA in caseswith newly diagnosed disease. However, the
majority of women in this study had relapsed HGSOC, and those few women with newly
diagnosed HGSOC had stage III or IV disease. The median TP MAF was an order of mag-
nitude lower in the newly diagnosed cases compared to the relapsed cases, even after ad-
justing for volume of disease (Parkinson et al. ). Therefore sensitivity of ctDNA detec-
tion in newly diagnosed disease may be challenging.
Developing a method for detection of ctDNA in a diagnostic setting is also challen-
ging. Parkinson et al. used digital PCR which requires prior knowledge of a patients
tumour speci ic mutation, and is therefore not applicable in a diagnostic setting. Targeted
sequencing for TP using TAm-Seq is a low-cost, high-throughput technique that does not
require prior knowledge of a patients tumour speci ic mutation so therefore could be used
in a diagnostic setting. However, using this method the sensitivity for detection of ctDNA
in relapsed HGSOC was lower at % (Forshew et al. ). Since the original publication
the TAm-Seq method has been optimised by increasing the depth of sequencing and in-
cluding primers for shorter overlapping amplicons. Recently the Rosenfeld and Brenton
laboratories have also developed sWGS for the detection of ctDNA in plasma samples (Tsui
et al. ).
In this chapter Iwill discuss ctDNAdetection inplasma samples collected fromwomen
with newly diagnosedOC from theUKOPS cohort (see section . . ) and the CTCR-OV co-
hort (see section . . ) using targeted sequencing and sWGS (Figure . ). This will provide
information about the prevalence of ctDNA in women at the time of diagnosis of OC us-
ing high-throughput, low-cost sequencingmethods that do not require prior knowledge of
the patients tumour speci ic mutation. These are therefore methods that could be directly
translated to routine clinical use as a diagnostic test in the future.
To determine the speci icity of ctDNA detection the OC cohorts were compared to a
group of healthy controls for which plasma was obtained commercially and benign
controls recruited through CTCR-OV at the time of primary surgery for suspected OC
who were subsequently diagnosed with benign disease.
For the UKOPS cohort sWGS data was down-samples to million reads to allow direct
comparison between patients. For the CTCR-OV sWGS data was down-sampled to
million reads.
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Figure . : Schematic illustrating approach for detection of ctDNA in women with newly
diagnosed OC.
For these cohorts the TAm-Seq analysis pipeline was run by JamesMorris. The t-MAD
score is a quantitative score calculated from sWGS data that is used to measure the extent
of copy number aberration across the whole genome. The t-MAD score was developed by
Dineika Chandrananda. See section . . , page for description of t-MAD score calcula-
tion. For the cohorts discussed in this chapter sWGS analysis and calculation of the t-MAD
score was performed by Dineika Chandrananda. DNA from some plasma samples from
the CTCR-OV cohort were extracted by the QIASymphony at CMDL. Radiological assess-
ment and tumour volume measurements were calculated by Ramona Woitek. The cases
for inclusion from the UKOPS cohort were identi ied by Aleksandra Gentry-Maharaj and
Chloe Karpinskyj from UCL. For the UKOPS cohort the histology described is the de initive
histological diagnosis provided by UCL where available.
. Results
. . UKOPS cohort
Fifty-four cases from theUKOPS cohortwith epithelial OCwere identi ied (see section . . ,
page ). These cases all had an elevatedCA , pre-treatment plasma sample available for
ctDNA analysis and access to a FFPE tissue block. Table . summarises the demographic
data for the selected cohort.
FFPE review and sequencing using TAm-Seq primer panel (Appendix . ) was per-
formed for the OC cases (Figure . , step ). caseswereHGSOC and %of these had a
TP mutation identi ied in the FFPE tissue sample (Appendix . ). This detection rate is
lower than expected (Kobel et al. ). The highly fragmented DNA found in these HGSOC
with a non-detected TP mutation may account for this (Figure . ).
PlasmaDNAwas extracted using theQIAvac Plus vacuummanifold and theQIAamp
Circulating Nucleic Acid kit ( ml protocol) and targeted sequencing performed (Figure . ,
step ) using the UKOPS TAm-Seq primer panel (Appendix . ).
Using de novomutation calling ctDNAwas detected in / ( %) of plasma samples
(Appendix . ) including / ( %) of the HGSOC cases. %matched the correspond-
ing tumour speci ic FFPE mutation. Two ( %) plasma mutations did not match the cor-
responding tumour speci ic FFPE mutation and are therefore either false positive calls or
subclonal mutations not identi ied in the FFPE sample.
As the sensitivity of ctDNA detection was low using targeted sequencing of plasma
Total number of women 54
Age at diagnosis, median (IQR) (years) 63 (57–72)
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Table . : Summary of demographic data for UKOPS selected cohort
DNA I investigated whether whole genome ampli ication (Rubicon ThruPlex DNA Seq kit
with PCR cycles) followed by targeted sequencing could increase the sensitivity of detec-
tion (Figure . , step ). Using de novomutation calling ctDNAwas detected in / ( %)
of samples (Appendix . ) with – mutations called in each sample. Thirty-two of these
mutations did not match the corresponding tumour speci ic FFPE mutation. Again it is a
possibility that these are low cellularity clones however, the additional PCR cycles from
whole genome ampli ication would have increased the number of PCR errors increasing
the likelihood that these are false positive calls.
When performing speci ic variant calling for the known tumour speci ic mutation the
ctDNA detection rate increased to % for the targeted sequencing performed directly
from the samples and to % for targeted sequencing performed on the whole genome
library (Appendix . ).
Targeted sequencing of plasma DNAwith de novomutation calling had a low sensitiv-
ity for detection of ctDNA in this cohort and targeted sequencing of whole genome ampli-
ied plasma DNA had a high false positive detection rate. I therefore wanted to investigate
whether quantitative analysis of copy number changes from sWGS data using the t-MAD
score could be used to increase the sensitivity of ctDNA detection (Figure . , step ).
Using sWGS and the t-MAD score with a cut off of the highest t-MAD score calculated
for healthy controls the rate of ctDNA detection for the whole cohort was % and %
for the HGSOC cases (Figure . a).
Importantly the copy number changes seen in the plasma samples did appear to rep-
resent ctDNA in a sample as plasma pro ileswere similar to pro iles seen formatched FFPE
samples (Appendix . ). Secondly the unselected t-MAD score was highly correlated with
the MAF determined by targeted sequencing in the HGSOC cases but not correlated in the
other histological subtypes (Figure . b). This may re lect the fact that HGSOC is predom-
inately driven by copy number changes but other OC subtypes are not.
To summarise ctDNA was detected in % of cases using targeted sequencing and
in % of cases using sWGS. Two cases with a t-MAD score below the maximum healthy
control cut off had a mutation detected by targeted sequencing. The combination of the





































Figure . : Experimental approach to UKOPS cohort, n= . . DNA was extracted from a
representative FFPE block for each cases and sequenced using TAm-Seq primer panel .
Mutations were detected in % of cases. . DNA was extracted from < ml plasma for
of the cases. Targeted sequencing was performed using the UKOPS TAm-Seq primer
panel (Appendix . ). . Targeted sequencing of whole genome ampli ied samples was
performed using the UKOPS TAm-Seq primer panel. Mutations called in steps and were
compared to the patients tumour speci ic FFPEmutations. . sWGSwas performed. Reads
were down-sampled to million to allow comparison. Nine samples were excluded due to
low read count.
Figure . : Bioanalyzer traces for two HGSOC FFPE samples in which a TP mutation was





















































Figure . : a) t-MAD score for all UKOPS cases calculated after down sampling to million
reads by histological subtype. Dashed line indicates the highest t-MAD score calculated
in a cohort of healthy controls. b) Comparison of unselected t-MAD score and MAF
where ctDNA detected by targeted sequencing for HGSOC cases (correlation coef icient
. , p< . ) and cases with other histological subtypes (correlation coef icient − . ,
p= . ).
. . CTCR-OV cohort
The UKOPS cohort consists of samples collected from women with a range of histological
subtypes of OC. HGSOC is themost common subtype of OC and accounts for themajority of
mortality. It is characterised by ubiquitous TP mutations (Kobel et al. ) and complex
genomic rearrangements (Ciriello et al. ). I therefore decided to focus on the detection
of ctDNA in womenwith newly diagnosed HGSOC. Cases from the CTCR-OV cohort were
identi ied (see section . . ). Inclusion criteria were:
. Womenundergoing primary surgery forHGSOCwith a pre-treatment plasma sample
available and CT scan within days of the baseline plasma sample.
. Womenbeing treatedwithneo-adjuvant chemotherapy forHGSOCwithplasmasamples
available before cycle , and of chemotherapy and a CT scan within days of the
baseline plasma sample.
Table . summarises the demographic data for the selected cohort.
Total number of women 156
Age at diagnosis, median (IQR) (years) 67 (58–73)





Treatment (number of women)
Neo-adjuvant chemotherapy 127
Primary surgery 28
Table . : Summary of demographic data for CTCR-OV selected cohort
I performed targeted sequencing for TP and sWGS for baseline plasma samples col-
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Targeted sequencing  
Figure . : Experimental overview for CTCR-OV newly diagnosed cohort, n= .
ctDNA was detected in % of the cohort using de novo mutation calling of targeted
sequencing with TAm-Seq primer panel (Figure . a) with a MAF ranging from . to
. (Figure . c, e). See appendix . for all de novomutation calls. Importantly ctDNA
could be detected in cases with early stage disease (Figure . a). Sensitivity for ctDNA
detection was slightly higher in this cohort compared to the HGSOC cases in the UKOPS
cohort (detection rate %), however remained too low to be useful as a diagnostic bio-
marker for HGSOC. However, speci icity of ctDNA detection using this method is high with
no TP mutations detected in plasma samples collected from women before under-
going primary surgery for suspected OC who were subsequently diagnosed with benign
disease (Figure . a). See appendix . for details about histological diagnosis for the
benign controls.
There was no difference in the rate of ctDNA detection by menopausal status (Fig-
ure . a) and no correlation between age at diagnosis and TP MAF (Figure . b). There
was no difference in the range of pre treatment CA values between women with and
without a TP mutation detected (Figure . c). There was no correlation between CA
and TP MAF in those women with a detectable mutation in plasma (Figure . d). wo-
OV04 Stage CA 125 (U/ml) TP53 mutation status Mutant allele fraction
95 I 30 Not Detected NA
133 I 18 Not Detected NA
254 III 5 Not Detected NA
430 III 26 Not Detected NA
469 III 33 Not Detected NA
547 III 28 Not Detected NA
559 III 9 Detected 0.025
629 IV 25 Detected 0.040
709 III 11 Not Detected NA
776 IV 27 Not Detected NA
805 I 10 Detected 0.023
870 III 8 Detected 0.015
Table . : CTCR-OV cases with with CA < U/ml
men in the cohort had a CA < U/ml (Table . ). Four of these had ctDNA detected by
targeted sequencing.
/ ( %) of the mutations detected in plasma did not match the mutations detected
in the corresponding FFPE sample. One of these mutations had a MAF of . which is
close to the limit of detection using this method and could therefore potentially be a false
positive call. Four of these mutations had a MAF of > . which is above the limit of de-
tection suggesting they could be low cellularity clonal mutations not identi ied in the FFPE
sample as a result of heterogeneity within the tissue.
The rate of plasma ctDNAdetection increased to % ( / ) (Figure . b)when vari-
ant calling for the patients tumour speci ic TP mutationwas performed. The lowestMAF
detected was . (Figure . d, f). See appendix . for all speci ic variant calls.
In this cohort targeted sequencing had a high speci icity and positive predictive value
meaning that it would give very few false positive results if used in a diagnostic setting.
However, due to the low sensitivity > % of cases would be missed if this method was
used in isolation as a diagnostic biomarker. sWGSwas therefore performed for all basleine
plasma samples. The t-MAD score was highly correlated with the TP MAF (correlation
coef icient of . ) (Figure . a) providing con idence in the t-MAD score as a means of
quantifying the levels of ctDNA in a sample.
Using the highest t-MAD score in a cohort of healthy controls as a cut off ctDNAwas
detected in / ( %) of the whole cohort (Figure . b). The rate of ctDNA detection
decreased to %when using the highest t-MAD score in a cohort of benign controls as
a cut off, excluding one outlier (Figure . b). As with targeted sequencing ctDNA could be
detected in HGSOC cases with early stage disease (Figure . b).
Although the sensitivity of ctDNA detection using sWGS was lower than when using
targeted sequencing it is likely that the combination of the two assays will increase the
sensitivity of detection. / ( %) of the cases not detected by targeted sequencing (in-
cluding case with stage I disease) had detectable ctDNA by sWGS using the upper limit of
the healthy controls as a cut off (Figure . c). Even if the upper limit of the benign controls
was used as a cut off, excluding one outlier, the addition of sWGS to targeted sequencing
would have detected an additional three cases (Figure . c).
In relapsedOC theTP MAFmeasuredbydigital PCR is highly correlatedwith volume
of disease measured by -D reconstruction of CT images after exclusion of cases with as-
cites (Parkinson et al. ). Using digital PCR the limit of detection was an MAF of .
and a tumour volume of cm . When developing a diagnostic biomarker it is important
to be able to detect low volume/early stage disease. I therefore investigated the limit of de-
tection using TAm-Seq and sWGS by comparing the TP MAF and t-MAD score to tumour
volume.
Tumour volumewasmeasured for of the newly diagnosed CTCR-OV cohort. The
median tumour volume was . cm (IQR . – . cm ) (Figure . a). ctDNA was
detected in a cases with a tumour volume of . cm using targeted sequencing and in a
case with a tumour volume of . cm using sWGS (Figures . b–c, . d). However, there
was no correlation between TP MAF and tumour volume (correlation coef icient . )
or t-MAD score and tumour volume (correlation coef icient . ) even accounting for the
presence of ascites or pleural effusions at baseline (Figures . b–c, . d). For example a
casewith a tumour volume of , . cm did not have aTP mutation detected in plasma.
Before ctDNA can be used as a diagnostic biomarker it is therefore important to better




















































































































Figure . : Targeted sequencing forTP . a)Number of caseswithTP mutation detected
by de novo mutation calling by stage of disease. b) Number of cases with TP mutation
detected by identi ication of patients tumour speci ic mutation by stage of disease. c) Box-
plot of TP MAF by de novo mutation calling in cases with ctDNA detected by stage of
disease. d) Boxplot of TP MAF by patient speci ic mutation calling in cases with ctDNA





















































































































































































































Figure . : a)Number of cases with TP mutation detected bymenopausal status de ined
as age under years (premenopausal) or age years or over (postmenopausal). b) Cor-
relation between age at diagnosis and TP MAF from targeted sequencing (correlation
coef icient - . , p= . ). c) CA pre diagnosis by TP mutation status. d) Correlation
between pre diagnosis CA and TP MAF from targeted sequencing (correlation coef-




































































































































































































Figure . : a) Correlation between unselected t-MAD score from sWGS data and TP MAF
from targeted sequencing. b) t-MAD score calculated from sWGS data for HGSOC cases
by stage, benign controls and healthy controls. Dashed line indicates the highest t-
MAD score calculated in the cohort of healthy controls. Dotted line indicates the highest t-
MAD score calculated in the cohort of benign controls excluding one outlier. c) t-MAD score
calculated from sWGS data for HGSOC caseswith undetected TP mutation by targeted
sequencing by stage, benign controls and healthy controls. Dashed line indicates the
highest t-MAD score calculated in the cohort of healthy controls. Dotted line indicates the
highest t-MAD score calculated in the cohort of benign controls excluding one outlier. d)
Comparison of t-MAD score with total tumour volumemeasured by -D CT reconstruction































































































































































Figure . : a) Tumour volume measured by -D CT reconstruction by stage of disease. b)
Correlation of TP MAF from targeted sequencing with total tumour volume including
semi-quantitative assessment of ascites at baseline. ND = ctDNA not detected. b) Correl-
ation of TP MAF from targeted sequencing with total tumour volume including semi-
quantitative assessment of pleural effusion at baseline.
. Discussion
It has previously been shown that ctDNA can be detected in over % of women with
HGSOC (Parkinson et al. ). The majority of women in this study had relapsed disease
I therefore wanted to investigate whether ctDNA could be detected in women with newly
diagnosed HGSOC as a irst step towards developing a diagnostic biomarker. Parkinson
et al. also used digital PCR to detect patient speci ic TP mutations which cannot be
applied in a diagnostic setting. I wanted to investigate low-cost, high throughput assays
that can be directly translated to clinical use in a diagnostic setting.
Targeted sequencing for TP does not require prior knowledge of the patients tu-
mour speci ic mutation. It has previously been shown that ctDNA can be detected by tar-
geted sequencing in % of women with relapsed HGSOC down to a MAF of % (Forshew
et al. ). The compromise with this method is reduced sensitivity compared to digital
PCR, Parkinson et al. were able to detect a minimumMAF of . %.
Since this original publication improvements have beenmade to the TAm-Seqmethod
including optimisation of the primers and increasing the depth of sequencing. In this
chapter I have shown that using this optimised TAm-Seq method I can detect ctDNA with
a minimumMAF of . %. Despite this improvement compared to Forshew et al. I de-
tected ctDNA in only % of newly diagnosed HGSOC cases from the UKOPS cohort and
%of newly diagnosed cases from the CTCR-OV cohort. Importantly ctDNAwas detec-
ted by targeted sequencing in / cases with a CA < U/ml. The majority of women
in the CTCR-OV cohort had an elevated CA before diagnosis re lecting the cohort
selection of womenwith a con irmed HGSOC diagnosis. In future studies it will be import-
ant to compare the performance of ctDNA to CA and investigate the combination of
the two markers for detection of OC in women who do not already have a diagnosis. It is
also important to note that TP mutations are not speci ic to HGSOC and can be found in
other cancer types. However, it could be argued that detection of a TP mutation in an
individual within the general population would be important irrespective of the cancer of
origin and referral would then be tailored depending on symptoms and results of other
triage tests.
In relapsed HGSOC a strong correlation between TP MAF and tumour volume was
observed (Parkinson et al. ). It is therefore possible that the lower rate of ctDNA de-
tection in newly diagnosed HGSOC is due to lower disease volume. However, I found no
correlation between TP MAF and tumour volume in the CTCR-OV newly diagnosed
HGSOC cohort. Parkinson et al. found a lower correlation between ctDNA levels and
tumour volume in women with ascites. I did not ind the presence of ascites or pleural
effusions to correlate with TP MAF.
It is possible that the nature and extent of release of ctDNA from newly diagnosed
tumours is different to relapsed disease. This is supported by Parkinson et al. who
found that the median TP MAF per volume was lower ( . %) in women with newly
diagnoseddisease compared towomenwith relapseddisease ( . %). In newlydiagnosed
non small cell lung cancer (NSCLC) only a moderate correlation between tumour volume
andmean clonal VAFwas found (Abbosh et al. ). However, in lung cancer proliferation
was highly correlated with levels of ctDNA with both a high ki proliferation index and
high FDG-PET avidity independent predictors of ctDNA detection. Although proliferation
is generally high in HGSOC it is possible that cases with undetected ctDNA are cases with
low tumour proliferation. There is no reliable measure of tumour proliferation across un-
diagnosed patients. Ongoing work is looking at cellular proliferation at multiple tumour
sites in FFPE tissue collected at the time of primary surgery for HGSOC.
sWGS is another low cost, high-throughput sequencing assay. HGSOC is a cancer char-
acterised by copy number changes which can be detected by sWGS. The t-MAD score is
a new quantitative measure of copy number changes across the whole genome (unpub-
lished). I found a high correlation between TP MAF and the t-MAD score suggesting that
the t-MAD score is a reliable measure of ctDNA levels. The addition of the t-MAD score to
the TP MAF increased the rate of ctDNA detection to % in the UKOPS HGSOC cohort
and % in the CTCR-OV cohort. sWGS data was down-sampled to million reads in the
UKOPS cohort which may have effected the sensitivity of ctDNA detection.
Other studies looking at women with newly diagnosed OC have identi ied ctDNA in
– % of cases (Bettegowda et al. ; Phallen et al. ). The improved sensitivity in
these studies is a result of parallel analysis of multiple genes and very deep sequencing.
This results in complex library preparationmethods, complex bioinformatics analysis and
high cost rendering thesemethods incompatiblewith clinical use in their current iteration.
The lower rates of detection in the UKOPS and CTCR-OV cohorts are likely to be for
a number a reasons. Firstly limitations of the cohorts themselves. The UKOPS cohort in-
cluded in this thesis is a small number of samples with a range of histological subtypes.
Only of the cases had HGSOC. The CTCR-OV cohort although larger in number and re-
stricted to HGSOC cases remains a small cohort in comparison to other published cohorts.
In particular the number of cases with early stage disease was low, however, this re lects
the current real world clinical situation with very fewwomen having early stage HGSOC at
the time of diagnosis. Limitations also relate to the samples used. Plasma samples from
the UKOPS cohort were< ml in volume so sensitivity of ctDNA detection is limited by the
number of available DNA molecules in the sample. Plasma samples from the CTCR-OV
cohort ranges from – ml in volume which is also lower than that used in recent publica-
tions. Limitations of themethods are also apparent. The panel of primers used for targeted
sequencing was developed with a focus on HGSOC. It is therefore not optimised for detec-
tion of ctDNA is plasma samples collected fromwomenwith other histological subtypes of
OC. Similarly the t-MAD score is only relevant for detecting ctDNA in cancers that exhibit
signi icant copy number rearrangements. This is not the cases for non-HGSOCs.
In an attempt to overcome some of the limitations of ctDNA detection relating to the
methods used I wanted to investigate strategies that could be applied to targeted sequen-
cing and sWGSmethods thatmight improve the sensitivity fordetectionof ctDNA inwomen
with newly diagnosed disease that could be easily translated to a diagnostic setting.

Improving sensitivity and speci icity for
circulating tumour DNA detection
. Introduction
Interest in the use of ctDNA for the detection of early stage cancers has recently increased
(Wan et al. ). Approaches to increase the sensitivity of ctDNA detection in early stage
disease include: the use of patient speci ic assays, the interrogation of multiple genes in
one assay, deep sequencing and the combination of protein biomarkers with ctDNA assays
(Bettegowda et al. ; Phallen et al. ; Abbosh et al. ; Cohen et al. ). These
methods have allowed the detection of ctDNA in – % of stage I cancers. These meth-
ods involve complex library preparation techniques and bioinformatics analysis. There is
little data about how these assays perform in a real world situation and they are offered
by commercial providers with no option to improve the technique to focus on a speci ic
cancer type. They are also costly, so may not be suitable for deployment in the NHS.
One alternative strategy to increase sensitivity for ctDNA detection is to overcome
background sequencing error rates. One way to do this is by limiting the number of input
DNAmolecules in a reaction to ensure that theminimumAF is suf iciently above the level of
background noise which currently de ines the limit of detection. Multiple reactions can be
performed in parallel in order to screen suf icient molecules to observe low AF mutations
(Figure . a). This optimised targeting sequencing method had previously been conceptu-
alised by the lab and the technology iled and granted as a patent by CRT (Rosenfeld et al.
). In this chapter I will discuss the optimisation of this method (referred to as TAm-
Seq V ). Optimisation of this method was performed in conjunction with Wendy Cooper
and the bioinformatics analysis performed by James Morris.
A second strategy for increasing the sensitivity of ctDNA detection is to enrich for cell
free tumour DNA in a sample using selective sequencing. cfDNA fragments are commonly
around bp in length suggesting release fromcells undergoing apoptosis (Jahr et al. ;
Lo et al. ; Chandrananda et al. ; Jiang et al. ). However, circulating fetal DNA
has been shown to be shorter than maternal plasma cfDNA and this difference has been
utilised to improve the sensitivity of non-invasive prenatal testing (Lo et al. ; Yu et al.
; Lun et al. ; Minarik et al. ). In cancer it has also been shown that circulating
tumour DNA fragments can be a different size to non-tumour cfDNA fragments but the res-
ults are con licting (Mouliere et al. ; Umetani et al. ; Giacona et al. ; Underhill
et al. ; Jiang et al. ; Mouliere et al. ).
In this chapter I will discuss the investigation of the features of ctDNA fragments com-
pared to non-tumour cfDNA fragments in plasma (Figure . b). I will discuss the use of
selective sequencing based on these observations as a means of improving sensitivity of
detection of ctDNA inwomenwith newly diagnosed HGSOC. This workwas part of a larger
investigation of the fragmentation features of cfDNA seen in a range of cancer types led by
Florent Mouliere, Dineika Chandrananda and Anna Piskorz. Dineika Chandrananda per-
formed the in-silico size selection, calculation of t-MAD and determined the fragmentation
features presented in this chapter. This manuscript has been accepted for publication in
Science Translation Medicine (Appendix . ).
AF = 20%
















Figure . : Approaches for increasing the sensitivity of ctDNA detection. a) TAm-Seq V . If
original samplewithMAFof %contains copies ofDNA, twoaremutant and wildtype.
If the sample is split into replicates each containing two DNA molecules this would give
two positive wells each with a MAF of % and three negative wells with an MAF of %.
In practice this means that a sample with an MAF of . % which is currently below the
limit of detection could be partitioned into wells each with molecules (if suf icient
moleculeswere available) andwewould expect to detect positivewells eachwith anMAF
of . % which is above the limit of detection. b) Selective sequencing of ctDNA fragments
using size selection.
. Results
. . TAm-Seq V
Optimisation of method
Extensive optimisations were performed to determine the experimental conditions that
provided the most even coverage across all amplicons for the TAm-Seq V method. The
broad approach is summarised in Figure . . Details of the experimental conditions are















Figure 5.3 Figure 5.4 Figure 5.5
Figure 
5.6
Figure . : Experimental conditions investigated to optimise TAm-Seq V method. Further
detail in appendix . .
Investigationof different enzymes, annealing temperatures, extension times andprimer
concentrations found the Q HS enzymewith an annealing temperature of ∘C and exten-
sion time of seconds and the Q HS enzyme with an annealing temperature of ∘C and
extension time of seconds to have the most even coverage across amplicons (Figure . ).
Coverage decreased with increasing amplicon length for all experimental conditions.
Initial optimisations selected for a range of – bp using the PippinHT for puri-
ication of the irst round PCR product as the PCR product was expected to range from
– bp (based on amplicon size and barcode ( bp each end) and CS /CS tag ( bp
each end)). As coverage was poorer for the longer amplicons I hypothesised that these
were being lost during during puri ication of the irst round PCR product. I therefore in-
vestigated whether selecting for different size ranges would improve the coverage of the
longer amplicons. Coverage for the longer amplicons was higher when selecting for frag-
ments between – bp (Figure . ). There is no disadvantage in selecting for longer
fragments as the main aim of this puri ication step is to remove the short primer dimer
fragments. Interestingly two amplicons have signi icantly lower coverage compared to the
other amplicons for all puri ication ranges.
Investigation of different barcoding enzymes and differentmethods for puri ication of
the inal PCR product revealed that the AMPure bead puri ication provided the most even
coverage across amplicons (Figure . ). Although the Roche enzyme performed slightly
better than the Q HS in terms of evenness of coverage the HS Q was selected as it is
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HS 63°C 10 sec
HS 63°C 5 sec
HS 65°C 10 sec
HS 65°C 5 sec
HS 67°C 10 sec
HS 67°C 5 sec
HS long
UII 63°C 500 nM
UII 65°C 100 nM
UII 65°C 500 nM
UII TD 100 nM
UII TD 500 nM
Figure . : Sequencing coverage by irst round PCR product length for different enzymes
(HS=Q HS, UII =Ultra II), annealing temperatures, extension times andprimer concentra-
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Figure . : Sequencing coverage by irst round PCR product length for different size
ranges used for puri ication of irst round PCR product. See appendix . , section . . ,
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Enzyme:Q5 HS, Purification:AMPure beads
Enzyme:Q5 HS, Purification:Pippin prep
Figure . : Sequencing coverage by irst round PCR product length for different barcoding
enzymes and different inal puri ication methods. See appendix . , sections . . and
. . , page cxiii for description of methodology.
Investigation of different primer pooling strategies found strategy (Appendix . )
to provide themost even coverage across all amplicons (Figure . a). An annealing temper-
ature of ∘C and an extension time of seconds provided the most even coverage within
this pooling strategy (Figure . b).




Extension time 5 seconds
Primer concentration 100n
Puri ication 1st round PCR product PippinHT 140–250 bp
Barcoding enzyme Q5 HS
Final puri ication AMPure bead
Primer pooling Strategy 4






























































































































150 160 170 180




























































































































































































150 160 170 180

























Figure . : a) Sequencing coverage per product length for different primer pooling
strategies. See appendix . , section . . , page cxv for description of methodology. b)
Sequencing coverage per product length for different experimental conditions for primer
pooling strategy . TD=touchdown PCR protocol. See appendix . , section . . ,
page cix for description of methodology.
Amplicon Forward Primer Reverse Primer Probe
Amplicon001 GTGGGGAACAAGAAGTGGAGA CTCCCTGCTTCTGTCTCCTAC ATGTCAGTCTGAGTCAGGCC
Amplicon001.2 TCAGTCTGAGTCAGGCCCTTCT AAGTCCAAAAAGGGTCAGTCTACCT TTGAACATGAGTTTTTTATGGC
CXP039A CAGCTCTCGGAACATCTCGAA CAACAGAGGAGGGGGAGAAGT CTCACGCCCACGGAT
Amplicon023 CTAGGATCTGACTGCGGCTC TGGAAGTGTCTCATGCTGGATC GCTGCTGCAAGAGGAAAAGT
Table . : Digital PCR primers and probes for quanti ication of both ends of TP .
Quanti ication of DNA for input into PCR
Due to the principle of TAm-Seq V accurate quanti ication of the number of copies of DNA
input into the reaction is required. RPP is a stable region in most genomes and primers
and probes against RPP are routinely used in the laboratory for quanti ication of total
copies of DNA. In HGSOC RPP is not a stable region. I therefore designed digital PCR
primers and probes for both ends of TP in order to quantify the number of copies of
TP input into the reaction (Table . ). Primers and probes were tested in singleplex
and multiplex using cell line DNA and DNA from healthy control serum samples obtained
commercially (Table . ). Amplicon and Amplicon performedwell in singleplex but
were not as ef icient in multiplex. The same pattern was seen with Amplicon . and
Amplicon . CXP A and Amplicon however, multiplexed well and was therefore
the assay used for quanti ication of DNA for subsequent experiments.
Investigation of sensitivity
To investigate the sensitivity of ctDNA detection using TAm-Seq V DNA from three patient
samples was pooled (Table . ) and diluted using healthy control DNA. Targeted sequen-
cing of the pooled dilutionswas performed using the standard TAm-Seqmethod to provide
a comparison for MAF and sensitivity (Table . ). The lowest MAF detected was . %.
Mutations were not detected in the : dilution where the MAF was expected to be . %
or lower. This is consistent with previous limits of detection observed using this method
(Section . ).
The expected MAF for the mutations at different dilutions was extrapolated from the
TAm-Seq results for the neat sample (Table . ). From this the number of expected positive
wells was determined for each of the three mutations (Table . ).








HeLa(10 ng/μl) 9044 8239 5023 8818 8874
SKOV3(10 ng/μl) 4100 5918 3423 6167 6144
Female control 200 221 180 195 200
Male control 64 69 74 92 64








CIOV1 (10 ng/μl) 4195 1223 3759 4244
CIOV1 (1 ng/μl) 221 154 167 218
CIOV1 (0.1 ng/μl) 31 18 23 26
COV362 (10 ng/μl) 10 1210 3541 3
COV362 (1 ng/μl) 392 259 269 44
COV362 (0.1 ng/μl) 26 15 21 18
H2O 0 0 0 0








CIOV1 (10 ng/μl) 976 1024 788 962
CIOV1 (10 ng/μl) 1028 1024 755 1036
CIOV1 (1 ng/μl) 72 100 46 63
CIOV1 (1 ng/μl) 68 76 52 50
CIOV1 (0.1 ng/μl) 6 5 10 7
CIOV1 (0.1 ng/μl) 5 1 3 8
H2O NA 0 0 NA
H2O NA 0 0 NA









OV04 68 7578534C>G, c.G396C, p.K132N 1182 513 831 5.00
OV04 114 7578406C>T, c.G524A, p.R175H 1126 218 564 7.76
OV04 70 7577538C>T, c.G743A, p.R248Q 2846 1682 2149 11.58
Table . : Three patient serum samples quanti ied by digital PCR and pooled to use in
dilution experiment to asses sensitivity of TAm-Seq V .
Mutation Neat 1:5 1:25 1:100 1:400
7578534C>G 5.32 0.87 ND ND NA
7578406C>T 11.07 2.55 ND ND NA
7577538C>T 10.31 2.41 ND ND NA
Table . : MAF (%) detected in neat pool and diluted pool samples using standard TAm-
Seq. ND=not detected. NA=not run as this was expected to be well below the limit of de-
tection using standard TAm-Seq.
Mutation Neat 1:5 1:25 1:100 1:400
7578534C>G 5.32 1.06 0.21 0.05 0.01
7578406C>T 11.07 2.21 0.44 0.11 0.03
7577538C>T 10.31 2.06 0.41 0.10 0.03
Table . : ExpectedMAF (%) for the threemutations in thepool at different dilutions based
on the standard TAm-Seq neat sample MAF and the dilution factor.
Mutation Neat 1:5 1:25 1:100 1:400
7578534C>G 42 17 4 4 2
7578406C>T 47 28 8 8 4
7577538C>T 47 27 7 8 4
Total wells analysed 48 48 48 192 384
Table . : Number of positive wells expected for eachmutation at different dilutions based
on the total number of wells and the expected MAF.
Mutation Neat 1:5 1:25 1:100 1:400
7578534C>G 34 6 0 0 0
7578406C>T 44 23 3 7 2
7577538C>T 48 20 2 5 2
Total wells analysed 48 48 48 192 384
Table . : Number of positive wells for each mutations at different dilutions.
Mutation calling was performed using the TAm-Seq V method for the pooled dilu-
tions. All mutations called in at least twowells were reviewed. TheMAFwas calculated by
dividing the total number of non-reference alleles across all wells by the total number of
wells multiplied by the number of copies of DNA in each well (Table . ). The observed AF
correlated well with the expected AF (Figure . ). With approximately , input mo-
lecules ( replicates of pools of molecules) the limit of detection was a MAF of ap-
proximately . – . %. No unexpectedmutationswere observed in the : , : , : and
: dilutions in > wells. However, in the undiluted (neat) sample unexpected muta-
tionswere observed each in wells out of the analysed ( T>C (c.A G, p.Y C),
C>T (c.G A, p.C Y) and C>T (c.G A, p.G S)). These could repres-
ent false positive calls or could be true positive mutations that were not identi ied in the
FFPE sample due to tumour heterogeneity. If a threshold of > wells is used to call a true
positive mutation these potential false positive calls are eliminated along with three true
positive calls (Table . ). The coverage at position was low in the control samples
which may explain why this mutation was not observed in the patient pool at the lower
dilutions.
Mutation Neat 1:5 1:25 1:100 1:400
7578534C>G 5.26 0.69 ND ND ND
7578406C>T 8.84 1.84 0.35 0.16 0.02
7577538C>T 7.32 2.06 0.26 0.14 0.01
Table . : Calculated AF (%) for each mutation at different dilutions based on the number
of positivewells, total number ofwells screened, number ofmutant reads and total number
of reads.
To investigate if these unexpectedmutations were true or false positive calls a further
replicates of the undiluted pool were performed. (This experiment was done with the
optimised primer pooling strategy that had not been used for the irst experiments of the
pooled samples). The following mutations were detected:
Position Mutation Number of positive wells
7578534 C>G (c.G396C, p.K132N) 43
7578406 C>T (c.G524A, p.R175H) 48
7577538 C>T(c.G743A, p.R248Q) 48
7577548 C>T (c.G733A, p.G245S) 4
7579325 G>T (c.C362A, p.S121Y) 2
C>T and C>T were expected mutations detected in approximately
the samenumbers ofwells aswith the initial pooling strategy and experimental conditions.
C>G was previously detected in wells in the undiluted sample and not at all in
the : , : and : dilutions due to lowcoverage at this locus in the controls. Using the
new pooling strategy C>G was detected in wells which suggests that mutation
calling acrossTP maynowbemore even. C>Twas previously detected in wells
in the undiluted sample which suggests this may be a true positive mutation. G>T
was not previously called which suggests that this is a false positive call and suggests that












































Figure . : a) Expected AF extrapolated from standard TAm-Seq mutation calling and ob-
served AF for all calls. b) Expected AF extrapolated from standard TAm-Seqmutation call-
ing and observed AF for calls with an AF of < %. Those marked in red were not detected
by TAm-Seq V .
Application to clinical samples
The TAm-Seq V method was then applied to plasma samples collected from three women
with HGSOC where a TP mutation had been detected at close to the limit of detection
using standard TAm-Seq. A mutation was identi ied in > of the replicate wells for each
sample and in each case an identicalmutationwas identi ied at a similar AF using standard
TAm-Seq (Table . ). When using a threshold of wells to de ine a true positive muta-
tion three other alterations were observed in JBLAB- ( C>A, G>A and
A>C). It was encouraging that the same TP mutations were called at a similar
MAF using both the standard TAm-Seq and TAm-Seq V methods. However, the TP MAF
in these samples was within the limit of detection of standard TAm-Seq so not testing the
increased sensitivity of TAm-Seq V .
I therefore wanted to apply the TAm-Seq V method to plasma samples in which a
TP mutation had not been detected using TAm-Seq V .
Sample Mutation Positive wells/
wells analysed
Observed AF (%) AF (%) by
standard Tam-Seq
JBLAB-16676 7577539G>A 10/48 0.83 0.78
JBLAB-16679 7577124C>T 7/95 0.31 0.54
JBLAB-16710 7578413C>A 13/43 0.73 0.64
Table . : TAm-Seq V mutation calling results for three patient plasma samples.
In order to detect mutations at an AF of . – . % replicate wells needed to be
analysed. Each well contains copies of DNA and is run in duplicate for the two different
primer pools. , DNA molecules therefore need to be screened to reach this level of
sensitivity. Digital PCR for both end of TP was performed to quantify DNA from plasma
samples from women with HGSOC (Table . ). Samples had been extracted from . –
ml of plasma and contained between – total DNA molecules. Only one sample
contained suf icient molecules to perform replicate TAm-Seq V reactions.
The median number of DNA copies per ml of plasma was (range – )
(Table . ). A median of ml of plasma is therefore required for extraction in order to
obtain suf icient DNA molecules to screen for the detection of low AF mutations.
Sample Volume of plasma (ml) Total TP53 copies Copies/ml plasma
JBLAB-16679 3.0 41385 13795
JBLAB-14752 3.0 29538 9846
JBLAB-16676 3.0 27308 9103
JBLAB-16710 3.0 22846 7615
JBLAB-15562 3.0 17769 5923
JBLAB-15108 3.0 15000 5000
JBLAB-16616 1.5 14769 9846
JBLAB-15067 3.0 10462 3487
JBLAB-15441 3.0 10077 3359
JBLAB-16628 0.9 9385 10427
JBLAB-15711 3.0 9000 3000
JBLAB-16687 3.1 9000 2903
JBLAB-16632 2.1 6154 2930
JBLAB-16642 1.7 6000 3529
JBLAB-16627 1.5 5385 3590
JBLAB-16614 1.5 5231 3487
JBLAB-16635 0.7 4308 6154
JBLAB-15179 3.0 3769 1256
JBLAB-16648 0.8 3538 4423
JBLAB-16640 1.2 3231 2809
JBLAB-16622 0.9 2923 3248
JBLAB-16629 0.7 2769 3956
JBLAB-16625 0.7 1154 1648
Table . : Plasma samples from women with HGSOC. Total number of TP mutations
based on digital PCR for both ends of TP . Copies of TP per ml plasma.
. . Selective sequencing using DNA fragment sizes
I used xenograft models to test the hypothesis that selective sequencing of ctDNA could
be performed by leveraging differences in DNA fragmentation patterns between tumour
derived and non-tumour derived cfDNA fragments (Figure . ). In this model tumour de-
rived cfDNA fragments align to the human genome and non-tumour derived cfDNA frag-
ments align to the host genome (in this case mouse). Whole genome libraries were pre-
pared from plasma DNA using the Rubicon ThruPlex DNA-kit (Table . ) and submitted
for paired-end sequencing on the Illumina MiSeq.
Figure . : Mouse model with xenografted tumour cells enabled the discrimination of tu-
mour derived cfDNA fragments from non-tumour cfDNA fragments.
Figure . shows the proportion of reads aligning to the human genome (tumour)
and the proportion of reads aligning to themouse genome (non-tumour) against fragment
length. Themedian difference between the proportion of tumour derived and non-tumour
derived cfDNA fragments between – bpwas . %. In thismodel system, tumour de-




Proportion of fragments between 90-150bp:
Tumour: 57.3%
Non-Tumour: 34.9%
Proportion of fragments between 90-150bp:
Tumour: 58.2%
Non-Tumour: 33.3%
Proportion of fragments between 90-150bp:
Tumour: 65.1%
Non-Tumour: 20.7%
































































































Figure . : Xenograft fragmentation pro iles a) Plasma DNA from mouse implanted with
OVCAR cultured cells b) Plasma DNA from mouse implanted with ascites collected from
a women before treatment for HGSOC c) Plasma DNA from mouse implanted with tissue
collected at the time of primary surgery for HGSOC.










a OVCAR3 plasma 55 0.015 0.3 16
a OVCAR3 serum 62 <0.005 a unknown 16
b ascites plasma 270 0.338 1.0 11
b ascites serum 160 0.618 1.0 11
c solid tumour plasma 180 0.490 1.0 11
c solid tumour serum 90 0.678 1.0 11
Table . : Xenograft samples and whole genome library preparation. OVCAR is a HGSOC
cell line implanted into a mouse. Ascites was collected from a women before treatment
for HGSOC and implanted into a mouse. Solid tumour was obtained at the time of primary
surgery for HGSOC and implanted into a mouse.
atoo low to quantify
The next step was to investigate if there is difference in fragment length between
tumour-derived andnon-tumourderived cfDNA inplasma samples frompatientswith can-
cer. It is not easy to distinguish tumour derived cfDNA fragments fromnon-tumour derived
cfDNA fragments within a single sample without the identi ication of multiple mutations
and ultra-deep sequencing. I therefore performed sWGS to compare the fragment sizes of
DNA identi ied in plasma samples from womenwith relapsed HGSOC to healthy con-
trols (Figure . a). The proportion of DNA fragments < bp was higher for the HGSOC
cases compared to the healthy controls (Figure . b). Although this approach cannot
con irm that these shorter fragments are tumour derived cfDNA fragments the fact that
the same pattern is not seen in cfDNA from healthy controls supports the hypothesis that
ctDNA fragments may be shorter than non-tumour derived cfDNA fragments.
Parallel experiments performed by other members of the lab in other cancer types
support the generalisability of these indings and led to the hypothesis that selecting for
DNA fragments between – bp could enrich for tumour derived cfDNA.




































































































































Figure . : a) Fragmentation pro iles for HGSOC cases and healthy controls. b)
Proportion of cfDNA fragments below bp for healthy controls and HGSOC cases.
To investigate this hypothesis I performed targeted sequencing for TP using TAm-
Seq primer panel (Appendix . ) for plasma samples before in-vitro size selection and
after in-vitro size selection (PippinHT %agarose gel selecting for bases – bp) collec-
ted from womenwith relapsedHGSOC.An increase inMAFwasobserved for themajority
of samples (at baseline and after one cycle of chemotherapy) following in-vitro size selec-
tion (Figure . ). Samples with a MAF < % can generally not be used for more in depth
analysis for example whole exome or whole genome sequencing. The dotted area in ig-
ure . a illustrates sampleswith aMAF< %before size selectionwhich increased to> %
following in vitro size selection making them accessible for further wide-scale analysis.
sWGSwas also performed for the samples before and after in-vitro size selection. Im-
portantly we see that following in-vitro size selection the majority of cfDNA fragments lie
























Figure . : a) MAF before and after in-vitro size selection for plasma samples collected
before (red circles) and after (blue triangles) starting chemotherapy for relapsed disease
in women with HGSOC. The dotted area indicates samples with a MAF < % pre size
selection and > % post size selection. b) Comparison of MAF before and after treatment
initiation with (yellow triangles) and without (green circles) in-vitro size selection.
Figure . shows an example of the copy number pro iles generated from sWGS data
for one patient. Figure . a shows the baseline plasma sample with no size selection
where the ctDNA levels are highwith blue illustrating ampli ications, orange deletions and
black copy number neutral regions. In the post treatment plasma sample (Figure . b)
the level of ctDNA is reduced with fewer ampli ications and deletions observed. Follow-
ing in-vitro size selection of the post-treatment sample (Figure . c) ampli ications and
deletions that match those observed in the pre-treatment plasma sample become visible
suggesting an enrichment in ctDNA post size selection. Copy number plots for the remain-




















































































Figure . : Distribution of DNA fragments determined by sWGS for plasma samples col-
lected before and after treatment from women with relapsed HGSOC. The distribution
of cfDNA without size selection is shown in green and the distribution of the same sample
after in-vitro size selection is shown in orange. The vertical lines represent the range of
fragments selected with the PippinHT cassettes, between and bp.













Sample post-treatment - with in vitro size selection













Sample post-treatment - no size selection













Sample pre-treatment - no size selectiona
c
b
Figure . : a) SCNA analysis of sWGS data from a plasma sample collected from a women
with relapsedHGSOCbefore initiation of chemotherapy. Inferred ampli ications are shown
in blue anddeletions in orange. b) SCNAanalysis of a plasma sample from the samewomen
after initiation of chemotherapy. c) SCNA analysis of the sample plasma sample as shown
in b, after in-vitro size selection for DNA fragments between – bp.
sWGS was performed on a further plasma samples collected from women with re-
lapsed HGSOC before and after in-vitro size selection for fragments between – bp.
The t-MAD score was calculated for all plasma samples to quantitatively asses the enrich-
ment in ctDNAafter size selectiononagenome-wide scale. Following in-vitro size selection
a signi icant increase in the t-MAD score was observed for the cohort (Figure . b). The
t-MAD score increased in / ( %) of the plasma samples (Figure . a) with amedian
increase of . fold (Figure . c). The degree of enrichment varied per sample but was
higher for samples with a lower initial t-MAD score and therefore a lower level of original
ctDNA (Figure . c). This provides further evidence that selective sequencing of shorter






















































































Figure . : a) t-MAD score pre and post in-vitro size selection for plasma samples col-
lected fromwomenwith relapsedHGSOC.b) Comparison of t-MAD scorewith andwithout
in-vitro size selection for the whole cohort. c) t-MAD score without size selection and t-
MAD fold enrichment with in-vitro size selection.
To investigate if sWGS and size selection to enrich for ctDNA in a sample allowed for
increased detection of cancer cases receiver operating characteristic (ROC) analysis com-
paring womenwith relapsedHGSOC to healthy controlswas performed (Figure . ).
A signi icant increase in area under the curve (AUC) was seen following in-silico size se-
lection and in-vitro size selection compared to the unselected t-MAD score. A maximum
sensitivity and speci icity of % and % respectively was seen using the t-MAD score
calculated for all samples following in vitro size selection. Again this illustrates the en-
richment of tumour derived cfDNA in a sample following size selection (both in-vitro and
in-silico) and suggests that size selection may improve ctDNA detection rates in women





















with in silico size selection
with in vitro size selection
Figure . : ROC analysis comparing HGSOC cases and healthy controls using t-MAD
(AUC . ), t-MAD following in-silico size selection (AUC . ) and t-MAD following in-
vitro size selection (AUC . ).
To assess if SCNAs with potential clinical value could be detected by sWGS following
in vitro size selection the relative copy number values of genes frequently altered in
HGSOC were compared before and after size selection. A large number of SCNAs were re-
vealed following size selection that were not detected in the same sample without size se-
lection. This included ampli ications in key genes includingNF , TERT andMYC. This could
be useful clinically for patient strati ication to clinical trials and treatment with targeted
therapy.
In addition to the sizeof cfDNA fragmentsdifferent fragmentation features (Figure . a)
were de ined in the plasma samples collected from women with relapsed HGSOC and
the healthy controls. The proportion (P) of DNA fragments observed by sWGS in mul-
tiple size ranges, the ratios of proportions of fragments in these size ranges and the amp-
litude of oscillations in fragment size density with bp periodicity observed below bp
were calculated. The proportion (P) of fragments between – bp and the ratio of the
proportion (P) of fragments between – bp and – bp (P( – )/P( – ))
were best able to discriminate the HGSOC cases from the healthy controls (Figure . b).
Selective sequencing of DNA fragments based on size and fragmentation features is























Figure . : Detection of SCNA in women with relapsed HGSOC across genes fre-
quently mutated in recurrent HGSOC. Patients ranked from left to right by increasing tu-
mour fraction quanti ied by t-MAD. SCNA are labelled as detected for a gene if the relative
copy number in that region was greater than . . Empty squares represent copy num-
ber neutral regions, bottom left triangles in light blue indicate SCNAs that were detected























P(20−150) AUC = 0.885


















P(20−150)/P(163−169) P(20−150/P(180−220) 10 bp amplitude
Figure . : a) Schematic illustrating the selection of different size ranges and features in
the distribution of fragment sizes. For each sample features include the proportion (P) of
DNA fragments observed by sWGS in multiple size ranges (P( – ), P( – ), P( –
), P( – ), P( – )), the ratios of proportions of fragments in these size ranges
(P( - )/P( – ), P( – )/P( – ), P( – )/P( – ) and the amplitude
of oscillations in fragment size density with bp periodicity observed below bp. b)
ROC analysis of fragmentation features comparing HGSOC cases to healthy controls.
. Discussion
Due to the low rates of detection of ctDNA in women with newly diagnosed HGSOC using
targeted sequencing and sWGS I wanted to investigate methods to improve the sensitivity
of detection that could be easily translated for routine clinical use.
In this chapter I havediscussed theoptimisationof theTAm-SeqV methodand shown
that thismethod has the potential to detectmutationswith aminimumMAFof . – . %.
Thismethod is potentiallymore sensitive than other recently publishedmethods that have
been applied to newly diagnosed cancers using patient speci ic assays and multi-region
deep sequencing enabling detection of a minimum MAF of . – . % (Phallen et al. ;
Abbosh et al. ). However, in this chapter I have only provided proof of principle of the
method I have not been able to demonstrate clinical utility due to the limitations outlined
below.
The major limitation of the TAm-Seq V method is that a large number of DNA mo-
lecules need to be input into multiple replicate reactions in order to screen suf icient DNA
molecules for the detection of low AF mutations. Using TAm-Seq V over , DNA mo-
lecules need to be screened in order to detect a minimumMAF of . %. I have found that
plasma samples contain a median of DNA copies per ml (range – ). A me-
dian of ml of plasma is therefore required for extraction in order to obtain suf icient DNA
molecules to screen for the detection of low AF mutations using this method. Currently
our standard practice locally is to extract DNA from ml of plasma. In the future it may
be important to increase the volume of blood collected from patients and optimise extrac-
tions from larger volumes of plasma. Other recently published methods have used ml of
plasma and detected a minimumMAF of . % (Bettegowda et al. ; Abbosh et al. ).
Estimates suggest that being able to detect ctDNA at a MAF of . % would allow de-
tection of tumours with a volume of cm (Abbosh et al. ). Improving this detection
to a MAF of . % using TAm-Seq V could allow detection of tumours with a volume of
< . cm . However, to detect a tumour with a volume of cm would require detection
of a minimum MAF of . % (Abbosh et al. ). This would require screening of over
, DNA molecules and extraction from even larger volumes of plasma which may not
be feasible particularly in future studies looking at a combination of assays and markers
all of which will require increased volumes of blood to be collected.
An alternative approach tomassively parallel TAm-Seq is selective sequencing of DNA
fragments based on cfDNA size and fragmentation features.
cfDNA fragments are commonly found to be around bp in length corresponding
to DNA wrapped around a nucleosome ( bp) and linker DNA associated with histone
H . DNA fragments of this length are thought to be released into the circulating from cells
undergoing apoptosis (Jahr et al. ; Lo et al. ; Chandrananda et al. ; Jiang et al.
). However, it has been shown that tumour derived cfDNA fragments can be a different
size to non-tumour derived cfDNA fragments (Mouliere et al. ; Underhill et al. ;
Jiang et al. ).
In this chapter I have found that tumour-derived cfDNA fragments can be shorter than
non-tumour derived cfDNA fragments. The origin of these shorter fragments is still un-
known but is likely to be a result of the mechanism of compaction and release into the cir-
culation. One possibility is that shorter fragments could be released as a result of tumour
proliferation (Abbosh et al. ).
I have shown that selective sequencing for shorter fragments can enrich for ctDNA in
a sample measured by targeted sequencing and sWGS. This approach is similar to that ap-
plied to non-invasive prenatal testing to improve the sensitivity of detection of fetal cfDNA
(Lo et al. ; Yu et al. ; Lun et al. ; Minarik et al. ).
A limitation of this analysis is that only samples from relapsed HGSOC were included.
It is possible that the size of cfDNA fragments present at the time of newly diagnosed dis-
ease will differ due to difference in the biological features of newly diagnosed compared
to relapsed disease. It is also possible that the volume of disease or stage of disease may
effect the pattern of cfDNA fragments observed meaning that there may not be one size
range that can be applied to enrich for tumour-derived cfDNA in all cases. This will be a
particular issue if using in-vitro size selection due to the inevitable loss of material.
I have compared in-vitro size selectionwith in-silico size selection. In-vitro size selec-
tion adds marginally to the cost and time required for whole genome library preparation
but does not effect the bioinformatics analysis. Although this approach led to a signi icant
enrichment in tumour-derived cfDNA, material is inevitably lost during the size selection
process. This could result in the loss of tumour derived cfDNA fragments important for
downstream analysis. In comparison in-silico size selection does not add and additional
step and does not add to the cost of library preparation but does add an additional step to
thebioinformatics analysis. The enrichment observed following in-silico size selectionwas
disappointingly not a large as following in-vitro size selection but there is no irreversible
loss of material meaning that all cfDNA fragments can be interrogated for analysis.
The use of selective sequencing may result in more samples being available for whole
exome or whole genome analysis which is currently limited to those with a MAF above –
% (Murtaza et al. ; Belic et al. ). Selective sequencing may be useful to identify
clinically actionable mutations thereby allowing entry into clinical trials and the applic-
ation of targeted therapies. It is also possible that a selective sequencing approach may
improve the rate of ctDNA detection in women with newly diagnosed HGSOC. However, it
is also possible that size selectionmay result in some actionablemutations beingmissed as
a result of being present on cfDNA fragments outside of the fragment size range of interest.
Other limitations of this approach are that only double stranded DNA has been se-
quencedwhichmay result in biased information about DNA fragmentation sizes. The DNA
extraction and sequencing methods may also provide additional biases to DNA fragments
observed. Finally this investigation was limited to plasma. Different fragmentation pat-
terns may be seen in other sample types including urine and serum.

Improved sensitivity for detection of
circulating tumour DNA in newly
diagnosed ovarian cancer
. Introduction
Due to the signi icant enrichment in ctDNA seen in the relapsedHGSOC caseswith selective
sequencing using DNA fragment size information I wanted to apply this to the cohorts of
women with newly diagnosed OC.
In this chapter I will describe the effect of in-silico size selection for DNA fragments
on the t-MAD score in the UKOPS and CTCR-OV cohorts. I will discuss the effect of in-
silico size selection for two different size ranges: – bp and – bp. For the UKOPS
cohort all reads were downsampled to million to allow direct comparisons between all
samples. For the CTCR-OV cohort all reads were downsampled to million reads again
to allow direct comparisons between samples. Samples with read counts lower than this
were excluded. I will also describe the effect of in-vitro size selection in the CTCR-OV
cohort.
I will also discuss the effect of in-silico size selection on IchorCNA, a tool that has re-
cently been developed by the Broad Institute for quantifying ctDNA from sWGS data (Adal-
steinssonet al. ) and is therefore a similarmetric to the t-MADscore. IchorCNAoutputs
a tumour fraction. I will discuss the tumour fraction output for two different sets of para-
meters. The irst is recommended for samples with higher ctDNA fractions and I will refer
to this as ’IchorCNA default’. The second assumes a lower ctDNA fraction and I will refer
to this as ’IchorCNA customised’.
In this chapter in-silico size selection and calculation of the t-MAD and IchorCNA val-
ues has been performed by Dineika Chandrananda.
. Results
. . UKOPS cohort
In the UKOPS cohort the size selected t-MAD score was highly correlated with the TP
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Figure . : a) Comparison of t-MAD score following in-silico size selection for DNA frag-
ments between – bp and TP MAF for HGSOC cases (correlation coef icient . ,
p< . ) and non-HGSOC cases (correlation coef icient − . , p= . ), . b) Comparison
of t-MAD score following in-silico size selection for DNA fragments between – bp and
TP MAF for HGSOC cases (correlation coef icient . , p= . ) and non-HGSOC cases
(correlation coef icient− . , p= . ).
Following in-silico size selection copy number ampli ications and losses are revealed
in the plasma samples that match those seen in the tumour samples (Appendix . ). This
suggests that size selection is enriching for ctDNA and that the changes in t-MAD score
following size selection are not an artefact of in-silico size selection .
The change in t-MAD score following size selectionwas variable across all cases in the
UKOPS cohort (Figure . ). One example where we see a large increase in t-MAD score is
TUKO (Appendix . ). There are very few copy number changes in the unselected
plasma sample however following size selection we see gains in chromosomes , and
that are also present in the matched tumour sample. This is re lected by a % increase


















































































































































Figure . : Unselected t-MAD score and size selected t-MAD score (logarithmic scale) for
UKOPS plasma samples. Panel on the left showsHGSOC cases and panel on the right shows
all other histological subtypes.
The median change in t-MAD was % (IQR – %) and % (IQR – %) for the
whole cohortwhen selecting forDNA fragments between – bpand – bp respect-
ively. For the HGSOC cases the median change in t-MAD was higher at % (IQR – %)
and % (IQR – %) when selecting for DNA fragments between – bp and –
bp respectively (Figure . a).
In relapsedHGSOCwe sawa greater increase in t-MADscore for those caseswith a low
unselected t-MAD score (see section . . , page ) . This is not the case in the UKOPS co-
hort where we see no correlation between the unselected t-MAD score and the percentage
change in t-MAD score following size selection (Figure . b, c).
Before size selection % of the whole cohort and % of the HGSOC cases had a t-
MAD score above the highest t-MAD score calculated for healthy controls (Section . . ,
page ). Following size selection the ctDNA detection rate increased to % for thewhole
cohort but did not change for the HGSOC cases (Figure . ).
After seeing an improvement in ctDNA detection in women with newly diagnosed OC
using the size selected t-MAD score I wanted to investigate whether IchorCNA could im-
prove detection rates further.
The tumour fraction calculated by IchorCNAwasmoderately correlatedwithMAF cal-
culated by targeted sequencing in the UKOPS cohort (Figure . ).
Depending on the IchorCNA tumour fraction cut off used ctDNAdetection ranged from
– % for the whole cohort and – % for the HGSOC cases (Table . , Figure . ).
IchorCNA using the customised settings and the upper limit of the healthy controls as a
cut off had the highest rate of detection. This was higher than the rate of detection using
targeted sequencing, t-MAD score, or size selected t-MAD score.
IchorCNA settings Cohort Cut off Detection (%)
default all 10% 44
default hgsoc 10% 44
default all 5% 70
default hgsoc 5% 67
default all 3% 83
default hgsoc 3% 83
default all healthy control 61
default hgsoc healthy control 61
customised all healthy control 88
customised hgsoc healthy control 83
Table . : ctDNA detection rate for the whole UKOPS cohort and HGSOC cases alone us-
ing different cut off values for detection. %, % and % correlate to the tumour frac-
tion. Healthy control is the highest IchorCNA tumour fraction value calculated using the
matched parameters from healthy controls.
In-silico size selection was then performed before calculating the IchorCNA tumour
fraction to investigate if this would further improve detection rates. As with the unselec-
ted IchorCNA the rate of detectionwas better using the customised settings andwas higher
in the HGSOC cases than the cohort as awhole (Table . ). However, therewas no improve-
ment in the rate of detection using the size selected IchorCNA compared to the unselected
IchorCNA.
Size Selection (bp) IchorCNA Settings Cohort Detection (%)
20–150 default all 45
20–150 default hgsoc 44
20–150 customised all 73
20–150 customised hgsoc 83
90–150 default all 46
90–150 default hgsoc 44
90–150 customised all 69
90–150 customised hgsoc 72
Table . : Detection using highest IchorCNA tumour fraction calculated using matched
parameters in cohort of healthy controls as a cut off.
ROC analysis con irmed that the customised unselected IchorCNA tumour fraction
was best at discriminating the OC cases from healthy controls for the whole cohort (Fig-
ure . a) with a sensitivity of % for a speci icity of % (AUC . ) and HGSOC cases
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Figure . : a) Percentage change in t-MAD score following in-silico size selection for DNA
fragments between – bp and – bp by histological subtype. b) Comparison of
unselected t-MAD score with percentage change in t-MAD score following in-silico size
selection for DNA fragments between – bp for HGSOC cases (correlation coef icient
. , p= . ) and non-HGSOC cases (correlation coef icient . , p= . ). c) Comparison
of unselected t-MAD score with percentage change in t-MAD score following in-silico size
selection for DNA fragments between – bp for HGSOC cases (correlation coef icient













































Figure . : Size selected t-MAD score for all UKOPS cases calculated after down sampling
to million reads by histological subtype. Dashed line indicates the highest size selected
t-MAD score calculated in a cohort of healthy controls. Top panel shows in-silico size



































































Figure . : a) Comparison betweenMAFmeasured by targeted sequencing and unselected
IchorCNA tumour fraction using default settings (correlation coef icient . ). b) Compar-
ison between MAF measured by targeted sequencing and unselected IchorCNA tumour








































Figure . : a) IchorCNA tumour fraction calculated using default settings for all UKOPS
cases by histological subtype. Dashed line indicates the highest tumour fraction calcu-
lated by default settings in a cohort of healthy controls. b) IchorCNA tumour fraction
calculated using customised settings to allow for low levels of ctDNA for all UKOPS cases
by histological subtype. Dashed line indicates the highest tumour fraction calculated by
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size selected IchorCNA customised (20−150) size selected IchorCNA default (90−150)
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Figure . : a)ROCanalysis comparingwhole cohort to healthy controls. b)ROCanalysis
comparing HGSOC cases to healthy controls. c) AUC for all methods for whole cohort
(plot a) and HGSOC cases (plot b).
. . CTCR-OV cohort
To investigate whether the size selected t-MAD score or the customised IchorCNA tumour
fraction performed as well in a larger cohort of HGSOC cases I applied these methods to
the newly diagnosed CTCR-OV cohort.
Firstly I wanted to investigate the effect of in-vitro size selection on the t-MAD score.
In-vitro size selection (PippinHT % cassette selecting for fragments – bp) was per-
formed for cases with a starting MAF between . – %. AF’s in this range are within
the limits of detection of both targeted sequencing and sWGS but are low enough that an
enrichment in ctDNA with size selection could potentially be observed. Whole genome
library preparation was performed for the unselected and size selected sample using the
Rubicon ThruPlex DNA-Seq kit. In / ( %) of the samples an increase in t-MAD score
was seen following in-vitro size selection of the samples (Figure . ). The median change
in t-MAD between the unselected sample and size selected sample was % (IQR % to
%) suggesting a signi icant enrichment in ctDNA in these samples.
As in-vitro size selection requires use of furthermaterial from the sample I performed
size selection of thewhole genome library for of the cases (PippinHT %cassette select-
ing for fragments – bp). The median change in t-MAD score calculated from sWGS
of the the unselected sample and sWGS of the size selected library was % (IQR − % to
%). Whereas size selection of the input DNA led to a signi icant enrichment this was not
so far achieved with size selection of the sequencing library (Figure . a).
Another way of preserving material is to perform in-silico size selection of sWGS data
from an unselected sample. I have previously shown that in-silico size selection can in-
crease ctDNA detection both by targeted sequences and sWGS (see section . . ). In the
CTCR-OV newly diagnosed cohort the median increase in t-MAD following in-silico size
selection was % (IQR – %). Although this suggests an increase in ctDNA in these
samples the enrichment is not as signi icant as that seen following in-vitro size selection
(Figure . b). There is therefore a trade off between a greater increase in the amount of
ctDNA accessible in a sample using in-vitro size selection and retaining material for other
applications whilst still observing amoderate increase in the amount of ctDNA in a sample
using in-silico size selection. In-silico size selection of libraries produced from in-vitro size













































































































































































Figure . : a) t-MAD score for unselected samples, in-vitro size selected samples (ss
sample) and in-vitro size selected libraries (ss library). b) t-MAD score for samples
calculated following sWGS of unselected sample, in-vitro size selection for DNA fragments
between – bp and in-silico size selection of DNA fragments between – bp.
In thewhole newly diagnosed CTCR-OV cohort an increase in t-MAD scorewas seen
in / ( %) and in / ( %) of cases following in-silico size selection for DNA
fragments – bp and – bp respectively. This increase was seen in all stages of
disease (Figure . ). Interestingly the highest median increase in t-MAD score was seen
in the cases with early stage disease following in-silico size selection for DNA fragments
between – bp (Table . ). Importantly size selection did not lead to an increase in
t-MAD score for the cohort of healthy controls and size selection for DNA fragments
between – bp did not lead to an increase in t-MAD score for the cohort of benign
controls. It is therefore possible that size selection for DNA fragments between – bp
might be optimal both in terms of increased rates of detection in early stage disease but
also in better discrimination between HGSOC cases and benign controls.
Stage Size range Median Q1 Q3
healthy 20–150 11 − 26
healthy 90–150 11 − 26
benign 20–150 24 − 54
benign 90–150 36 4 78
I 20–150 124 78 150
I 90–150 96 57 133
II 20–150 176 119 193
II 90–150 130 72 169
III 20–150 85 27 137
III 90–150 95 29 153
IV 2–150 77 14 116
IV 90–150 63 14 128
Table . : Median and IQR percentage change in t-MAD following in-silico size selection
for DNA fragments between – bp and – bp.
The rate of detection of ctDNA using the unselected t-MAD score in the CTCR-OV
cohort was % using the upper limit of the healthy controls as a cut off and % using
the upper limit of the benign controls as a cut off (see section . . , page ). Using the
size selected t-MAD score this increased to %when using the upper limit of the healthy
controls as a cut off and % when using the upper limit of the benign controls as a cut
off (Figure . a,b). Using in-silico size selection for DNA fragments between – bp
included detection of ctDNA in % of the early stage cases using the healthy control cut
off and % of the early stage cases using the benign control cut off (Figure . a).
Depending on the stage of disease and cut off used between – % of cases that
were negative for ctDNA by targeted sequencing for TP were positive for ctDNA using
the size selected t-MAD score (Figure . c). In particular % of the stage TP negative
cases and % of the stage II TP negative cases were detected using the size selected
t-MAD score ( – ).
The smallest tumour volume detected using the unselected t-MAD score using both
the upper limit of the healthy and the upper limit of the benign controls as a cut offwas .
cm (see section . . , page ). The size selected t-MAD score performed better detecting
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Figure . : t-MAD score calculated from unselected sWGS data and following in-silico size
selection for DNA fragments between – bp and – bp by stage of disease.
ROC analysis con irmed that the size selected t-MAD score performed better than the
unselected t-MAD score in discriminating HGSOC cases from both healthy and benign con-
trols (Figure . ). A maximum sensitivity of % for a speci icity of % was observed
when comparing the cases to the healthy controls and a maximum sensitivity of % for a
speci icity of % when comparing the cases to the benign controls. Importantly a good
sensitivity of % for a speci icity of % was observed when comparing the stage I/II
HGSOC cases (with the caveat that this is a low number of samples) to the healthy controls
and a sensitivity of % for a speci icity of % when comparing to the benign controls
(Figure . c, d). The ability to discriminate early stage disease from benign controls with
a good sensitivity and speci icity needs con irming in larger studies but is promising for
the development of a diagnostic biomarker.
In relapsed HGSOC we found that the addition of fragmentation features increased
our ability to discriminate between HGSOC cases from healthy controls (in press, Science
Translational Medicine). I therefore wanted to investigate whether the same was true
in newly diagnosed disease. The proportion (P) of DNA fragments observed by sWGS in
multiple size ranges, the ratios of proportions of fragments in these size ranges, the pro-
portion of fragments greater than a certain size and the amplitude of oscillations in frag-
ment size density with bp periodicity observed below bp were calculated for the
healthy controls, benign controls and HGSOC cases (Figure . a). There were no differ-
ences between the fragmentation features across different stages of disease and there was
no feature that was able to clearly discriminate between newly diagnosed HGSOC cases
and healthy and/or benign controls (Figure . ).
ROC analysis con irmed that the fragmentation features alone were not a good dis-
criminator of newly diagnosed HGSOC cases from controls (Figure . ). The proportion
of fragments between – bp (P – ) was best able to discriminate the HGSOC
cases from the healthy controls however the sensitivity was low at % for a speci icity
of %. The ratio of the proportion of fragments between – bp to the proportion
of fragments between – bp (P – :P – ) was best able to discriminate the
HGSOC cases from the benign controls however, again the sensitivity was low at % for a
speci icity of %.
As the IchorCNA tumour fraction had performedwell in the UKOPS cohort I applied it
to the newly diagnosed CTCR-OV cohort. High correlation was seen between the TP
MAFand the IchorCNA tumour fraction (Figure . a, b). Therewasno correlationbetween
the IchorCNA tumour fraction and tumour volume (Figure . c, d). Depending on the
parameters and cut off used ctDNA detection using IchorCNA tumour fraction ranged from
– % for the whole cohort (Table . , Figures . e, f). Using the unselected IchorCNA
tumour fraction did not improve the rates of ctDNA detection over the size selected t-MAD
score.
Unlike in the UKOPS cohort (see section . . , page ) the number of cases with a
ctDNA fraction above %, % and % increased following in-silico size selection for DNA
fragments between – bp and – bp using both the default and customised Ichor-
CNA settings (Figure . ). ROC analysis showed that the size selected IchorCNA tumour
fraction ( – bp and – bp) performed marginally better at distinguishing HGSOC
cases from healthy controls (Figure . a) than size selected t-MAD but did not help the
discrimination between HGSOC cases and benign controls (Figure . b).







default healthy control 37
customised healthy control 57
default benign control 16
customised benign control 12
Table . : ctDNA detection rate for the newly diagnosed CTCR-OV cohort using Ichor-
CNA tumour fraction with different cut off values for detection. %, % and % correl-
ate to the tumour fraction. Healthy control is the highest IchorCNA tumour fraction value
calculated using the matched parameters from healthy controls. Benign control is the
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Figure . : a) t-MAD score calculated following in-silico size selection for DNA fragments
between – bp from sWGS data for HGSOC cases by stage, benign controls and
healthy controls. Dashed line indicates the highest t-MAD score calculated in the cohort
of healthy controls. Dotted line indicates the highest t-MAD score calculated in the cohort
of benign controls excluding one outlier. b) t-MAD score calculated following in-silico size
selection for DNA fragments between – bp from sWGS data for HGSOC cases by
stage, benign controls and healthy controls. Dashed line indicates the highest t-MAD
score calculated in the cohort of healthy controls. Dotted line indicates the highest t-MAD
score calculated in the cohort of benign controls. t-MADscorewasnot calculated for outlier
due to low coverage. c) Percentage of ctDNA negative cases by targeted sequencing for
TP that are detected using size selected t-MAD score using either highest value in the
healthy controls or highest value in the benign controls as a cut off. (Stage I n= , stage II
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Figure . : Comparison of size selected t-MAD score for detected cases with total tumour
volume measured by -D CT reconstruction. a) – bp, cut off upper limit healthy con-
trols. b) – bp, cut off upper limit benign controls. c) – bp, cut off upper limit
healthy controls. d) – bp, cut off upper limit benign controls.
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a b
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Figure . : ROC analysis of unselected t-MAD score, t-MAD score following in-silico size
selection for DNA fragments between – bp and t-MAD score following in-silico size
selection for DNA fragments between – bp. a) Comparing HGSOC cases to healthy
controls. b) Comparing HGSOC cases to benign controls. c) Comparing stage I/II HGSOC




















































































































































































































Figure . : Theproportion (P) ofDNA fragments observedby sWGS inmultiple size ranges
(P – , P – , P – , P – , P – , P – , P – ), the ratios of pro-
portions of fragments in these size ranges (P – :P – , P – :P – ), thepro-
portion of fragments greater than a certain size (P> , P> ) and the amplitude of oscil-
lations in fragment size density with bp periodicity observed below bp for healthy










































































Figure . : ROC analysis of the proportion (P) of DNA fragments observed by sWGS in
multiple size ranges (P – , P – , P – , P – , P – , P – , P –
), the ratios of proportions of fragments in these size ranges(P – :P – , P –
:P – ), the proportion of fragments greater than a certain size (P> , P> ) and
the amplitude of oscillations in fragment size density with bp periodicity observed be-




























































































































































































































































































































































































































Figure . : a) Comparison between unselected IchorCNA tumour fraction calculated with
default settings and TP MAF (correlation coef icient . ). b Comparison between unse-
lected IchorCNA tumour fraction calculated with customised settings and TP MAF (cor-
relation coef icient . ). c) Comparison between unselected IchorCNA tumour fraction
calculated with default settings and tumour volume. d) Comparison between unselected
IchorCNA tumour fraction calculatedwith customised settings and tumour volume. e)Un-
selected IchorCNA tumour fraction calculated using default settings by stage of disease.






























































































































Figure . : IchorCNA tumour fraction calculated following in-silico size selection by stage
of disease. a) – bp using default settings. b) – bp using customised settings. c)
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Figure . : a)ROC analysis comparing HGSOC cases and healthy controls with t-MAD, size
selected t-MAD and IchorCNA values. b) ROC analysis comparing HGSOC cases and benign
controls with t-MAD, size selected t-MAD and IchorCNA values.
. Discussion
I have previously shown that ctDNA can be detected in – % of women with newly dia-
gnosed HGSOC using targeted sequencing for TP and sWGS (Section . ).
Other studieshave identi ied ctDNA in – %of casesof newlydiagnosedOC (Bettegowda
et al. ; Phallen et al. ). These studies used complex library preparation methods,
complex bioinformatics analysis and are therefore costly and not applicable to clinical use
currently. These studies also compared results in cases to healthy controls and have not
looked at discriminating OC cases from benign controls.
In this chapter I have discussed the effect of in-vitro and in-silico size selection on
the t-MAD score. I have also discussed IchorCNA, a tool that has recently been developed
by the Broad Institute for quantifying the tumour content of cfDNA from sWGS data (Adal-
steinsson et al. ). I have also discussed the effect of in-silico size selection on the Ichor-
CNA tumour fraction. Thesemethods only addmarginally to the cost and turn around time
of analysiswhichmeans they aremethods that can potentially be translated to routine clin-
ical practice is found to increase rates of ctDNA detection.
However, it is not currently clear if any of these methods will be clinically useful for
increases rates of ctDNA detection in women with newly diagnosed disease and therefore
whether they will be useful in a diagnostic setting. The main reason for this is the incon-
sistent indings across the two cohorts.
In the UKOPS cohort the effect of in-silico size selection was variable even within the
HGSOCcases. In thenon-HGSOCcaseswhich arenot drivenby copynumber changes sWGS,
evenwith size selection, is not the optimalmethod for detection of ctDNA. The size selected
t-MAD score is therefore on its own not a useful metric for triage of symptomatic women
with suspected ovarian cancer. Even in some of the HGSOC cases size selection resulted
in a reduction in t-MAD score. If size selection were applied to all samples, either in-vitro
or in-silico, for the detection of ctDNA this may result in some cases that would have been
detected becoming non-detected leading to a false negative test. One solution to this is
to calculate the t-MAD score and then apply in-silico size selection to those non-detected
cases in an attempt to increase the rates of detection.
The IchorCNAmethod alsoperformedbetter in theHGSOC cases compared to thenon-
HGSOC cases in the UKOPS cohort. This is not unexpected as IchorCNA, as with t-MAD,
relies on detecting copy number changes in plasma. IchorCNA predicts segments of SCNA
and estimates of tumour fraction, taking into account subclonality and tumour ploidy. The
lower limit of detection using this method is a tumour fraction of . (Adalsteinsson et
al. ). The t-MAD score is a quantitative measure of global copy number change. The
UKOPS cohort the IchorCNA tumour fraction using the customised settings was best able
to discriminate HGSOC cases from healthy controls (sensitivity %). However, using the
customised IchorCNA reduced the highest tumour fraction in the healthy controls from
% to %. There is therefore a possibility that the higher detection of cases is a result of
over- itting to this set of healthy samples.
In a subset of the CTCR-OV cohort I compared in-vitro size selection to in-silico size
selection. As with relapsed disease in-vitro size selection resulted in a greater increase in
t-MAD score compared to in-silico size selection. The liitations of in-vitro size selection
were discussed in Section . (page ). In the whole CTCR-OV cohort the size selec-
ted t-MAD score was best able to discriminate HGSOC cases from healthy controls with a
sensitivity of %. This sensitivity although approaching that found in previous studies
of newly diagnosed OC (Bettegowda et al. ; Phallen et al. ) remains too low to be
clinical useful.
Previous studies although having good rates of detection of ctDNA in women with
newlydiagnoseddiseasehaveonlybeenable todetect – %of stage I cancers (Bettegowda
et al. ; Phallen et al. ). Using the size selected t-MADscore I detected %ofHGSOC
cases with stage I/II disease. Selecting for fragments between – bp detected more
early stage cases than when selecting for fragments between – bp. This suggests
that early stage disease could have a higher proportion of very short fragments whichmay
be related to the tumour proliferation (Abbosh et al. ). The limitations of this analysis
are the very small number of early stage OC cases included in this analysis and these ind-
ings will require validation in much larger cohorts. If it is the case that early stage cancers
have a greater proportion of shorter cfDNA fragments implementation of size selection for
detection of ctDNA as a diagnostic tool will be challenging. Practically at the time of per-
forming this analysis the stage of disease will be unknown therefore knowing what size
range to select for in the absence of this information may be challenging.
In this chapter I have also discussed the cfDNA fragmentation features found in newly
diagnoseddisease. The sensitivity for all features individually to discriminateHGSOC cases
from healthy controls was < %. In relapsed HGSOC the combination of size selected t-
MAD, proportion of fragments between – bp, proportion of fragments between –
bp, proportion of fragments between – bp and the bp amplitude enabled the
best discrimination between HGSOC cases and controls (in press, Science Translational
Medicine). It is therefore possible that the sensitivity for detection of newly diagnosed
disease could be improvedusing a combination of features. It is likely that a combination of
assays, potentially including fragmentation features of cfDNAwill be required to optimised
detection of OC in symptomatic women in primary care.
In contrast to other studies I have also comparedHGSOC cases to benign controls (wo-
menwhounderwent primary surgery for suspected ovarian cancer andwere subsequently
diagnosed with benign disease). Using the size selected t-MAD score I was able to detect
% of stage I/II disease from a cohort of benign controls. This sensitivity is higher than
that seen in other studies of early stage disease compared to healthy controls (Bettegowda
et al. ; Phallen et al. ). An important limitation is the small number of womenwith
early stage disease included in the the newly diagnosed CTCR-OV cohort.
These results provide promising insights into methods that may allow a clinically-
meaningful sensitivity of ctDNA detection in women been investigated for suspected OC,
including early stage disease. These methods now need to be validated in larger cohorts
of symptomatic women to investigate the clinical utility for diagnosis of OC compared to
CA .

Investigating cervical sampling to increase
detection of ovarian cancer
. Introduction
Haematologicalmetastatic spread inOC is uncommon. Detectionof ctDNA inplasmasamples
may therefore not be the most sensitive approach for disease detection, particularly in
early stage/low volume disease. Direct metastatic spread within the peritoneal cavity is
very common inOCdue to thedirect communicationbetween thedistal endof the fallopian
tube (site of origin of HGSOC) and the peritoneal cavity. It is therefore possible that cells
and DNA shed from the distal fallopian tube can also pass down the fallopian tube, through
the uterus to the external cervical os, and be sampled in the upper vagina.
Studies have shown that tumour DNA and somatic mutations can be identi ied in cer-
vical cytology samples (Kinde et al. ) and vaginal tampons (Erickson et al. ) from
women with advanced OC. More recently it has been shown that % of OCs (n= ) were
detected using cervical cytology samples (Wang et al. ) including detection of % of
early stage cancers. Combining cervical cytology and plasma increased the sensitivity of
detection to %. This suggests that cervical sampling could potentially be used as part of
a diagnostic or triage tool for OC.
In this chapter I will discuss the optimisation of DNA extraction, library preparation,
and sequencing of cervical cytology samples. I will discuss targeted sequencing of DNA
obtained from cervical cytology samples collected through theNHS cervical screening pro-
gramme through a collaboration with theWest Anglia Pathology Service Cervical Cytology
Laboratory. I will also discuss targeted sequencing and sWGS of DNA obtained from cer-
vical cytology samples collected at Addenbrookes Hospital from women with newly dia-
gnosed HGSOC (Figure . ).
In this chapter the TAm-Seq analysis pipeline was performed by JamesMorris and the
t-MAD scores calculated by Dineika Chandrananda.
* Optimisation of DNA extraction, library 
preparation and sequencing 
* Targeted sequencing and sWGS of cervical 
cytology samples from women with newly 
diagnosed HGSOC  
* Targeted sequencing of routine cervical 
cytology samples with non-cervical glandu-
lar abnormalities
ThinPrep
Figure . : Overviewof approach for investigating cervical sampling for use in thedetection
of OC.
. Results
. . Investigation of quality of cervical cytology DNA for sequencing
Routine cervical samples are collected with a brush and stored in ml of PreservCyt
(methanol based) ixative before cytological evaluation. The cellularity of cervical cyto-
logy samples is variable with a median of . million cells per ml (IQR . - . million
cells/ml) (Figure . c) based on measurements of volume of ixative remaining after cyto-
logical evaluation and cell count (Figure . a, b, d) in samples from the NHS cervical
screening programme. DNA yield following extraction was also variable and was not cor-
related with the total number of cells in the sample (Figure . e). The targeted sequencing
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Figure . : a) Volume of ixative remaining following cytological evaluation for routine
cervical cytology samples. b) Total number of cells in remaining volume of ixative. c)
Number of cells per ml in original sample. d) Comparison between remaining volume and
total number of cells (correlation coef icient . ). e)Comparisonbetweennumber of cells


































































































































Figure . : Sequencing coverage per amplicon (ordered by panel order from left to right
see Appendix . ) for cervical cytology samples and four FFPE samples for comparison.
The red line indicates a coverage of ×.
As cervical cytology samples are stored in ixative it is possible that this may have an
impact of the quantity and quality of DNA obtained from samples. By introducing cultured
cells into PreservCyt and extractingDNA at different time points I found a large variation in
total DNAyield thatwas not affected by ixation time (Figure . a). TheDNA fragmentation
pattern (Figure . ) and the sequencing coverage also did not appear to vary with ixation
time (Figure . ). Hela cells (no TP mutation) and OVCAR cells (substitution mutation
in TP c.G A, p.R Q) were mixed in an equal ratio. As such the expected MAF was
%. The calculated AF by de novo mutation calling remained approximately % for all
replicates across all time points (Figure . b). This was reassuring that time in ixation did
not appear to impact the quantity and quality of DNA.
I then wanted to investigate the sensitivity of mutation detection in cervical cytology
samples. Cultured cells (OVCAR and SKOV (deletion in TP c.C del, p.P fs)) were
mixed in different proportions with Hela cells in PreservCyt. DNA was extracted after
weeks and TAm-Seq using primer panel performed (Appendix . ). The observedMAF
was similar to the expectedMAFwith a lower limit of detection of . % for the deletion and
. % for the substitution mutation (Figure . c). This is consistent with the lower limit of
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Figure . : a) DNA concentration following extraction of cell lines in ixative at hours,
hours, week and weeks. b) MAF of cervical smear samples by TAm-Seq. Expected
MAF was % as cells mixed in a ratio of ∶ OVCAR :Hela. c) Expected MAF based on





























































Figure . : Sequencing coverageper ampliconusingprimerpanel (orderedbypanel order
from left to right see Appendix . ) for three replicate smear samples and DNA extraction
at hours, hours, week and weeks. The red line indicates a coverage of ×.
Figure . : Bioanalyzer traces showing fragmentation patterns of cell lines in ixative with
DNA extracted at different time points in triplicate.
. . Application of targeted sequencing to routinely collected cer-
vical cytology samples
Targeted sequencing using TAm-Seq primer panel (Appendix . ) was applied to DNA
extracted from cervical cytology samples collected through the NHS cervical screen-
ing programme (Appendix . ). Code samples are samples classi ied as ”?glandular
neoplasia of endocervical type” which would have resulted in further investigation for a
possible cervical cancer. Code samples are samples classi ied as ”glandular neoplasia
(non-cervical)” which would have been investigated for possible endometrial cancer and
potentially for OC.
Mutationsweredetected in / ( %)of the code samples subsequentlydiagnosed
with a cancer and / ( %) of the code samples subsequently diagnosed with a cancer
(Appendix . ). Mutations were also detected in of the code samples subsequently
diagnosed with a pre-invasive cervical lesion.
Using these samples I have shown that somatic mutations can be detected in cervical
cytology samples collected from women with cervical and endometrial cancers. A limita-
tion of this study is the sparse clinical data. However, this was necessary in order to have
ethical approval for access to these samples. Mutations were detected in some samples
with no clinical information, these could have a cancer diagnosis, and in some samples that
were annotated as having normal large loop excision of the transformation zone (LLETZ)
or pipelle samples, this does not preclude a subsequent cancer diagnosis. Unfortunately
none of the cervical cytology samples available through the NHS cervical screening pro-
gramme had been collected from women diagnosed with OC.
. . Cervical samples in high-grade serous ovarian cancer
I therefore looked at cervical cytology samples collected from women with newly dia-
gnosed HGSOC. De novo calling of targeted sequencing using TAm-Seq primer panel
(Appendix . ) did not identify a TP mutation in any of the samples. When perform-
ing speci ic variant calling for the known TP mutation identi ied in the matched FFPE
sample the rate of detection increased to / ( %) (Appendix . ).
As sWGS and the t-MAD score had been useful in detecting ctDNA in plasma samples
I therefore performed sWGS using the Rubicon ThruPlex DNA-Seq kit ( ng DNA input,
cycles of PCR) for the cervical cytology samples. For comparison I performed the same
library preparation and sequencing for cervical cytology samples obtained from three wo-
men subsequently diagnosedwith benign disease. Therewas no difference in t-MAD score
between the HGSOC cases and the benign controls (Figures . a, c).
Cervical cytology samples were developed to detect pre-malignant changes in ecto-
cervical cells that could progress to cervical cancer if not treated. This sampling technique
is not optimised to collect cells shed from the distal fallopian tube. This could explain the
low sensitivity for detection of tumour DNA using de novo calling of targeted sequencing
and sWGS in the cervical cytology samples from HGSOC cases. It is likely that collecting
samples from a more focused location at the cervical os or from within the cervical canal
may increase the collection of relevant cells that have been shed from the distal fallopian
tube. This would also reduce the number of cells collected from the ectocervix or vagina
which will contribute to the background DNA.
I thereforeperformed targeted sequencingofDNA fromcervicalmucous aspirate (CMA)
samples obtained from of thewomenwith newly diagnosedHGSOC. ATP mutationwas
detected in / ( %) of the CMA samples, however only of these matched the mutation
identi ied in thematched FFPE sample. The rate of detection increased to / ( %)when
performing speci ic variant calling for the know TP mutation identi ied in the matched
FFPE sample (Appendix . ).
The t-MAD score was higher in the two cases with a detected TP mutation by de
novo calling. There was however no difference in t-MAD score for CMA samples from the
HGSOC cases without a TP mutation detected and the benign controls (Figures . a, d).
The t-MAD score was lower in the CMA sample compared to the match cervical cytology
samples other than in the two cases with a detected TP mutation in the CMA sample
(Figures . b).
It is possible that the limited sensitivity of standard TAm-Seq and the t-MAD score
without size selection may explain the undetected tumour DNA in these samples. As the
total DNA yield from cervical samples is – , times greater than plasma samples I
investigated the TAm-Seq V method ( wells per sample) for the detection ofmutations
in cervical cytology and CMA samples. The tumour speci ic TP mutation was identi ied
in only two of the HGSOC cervical cytology samples (Appendix . ). In one sample the
tumour speci ic TP mutation was detected in wells (there were other mutations also
called in wells) and in the other sample the tumour speci ic TP mutation was detected
in wells (there was other mutation called in wells, called in wells and called in
wells). The tumour speci ic TP mutation was not called in any of the CMA samples.
Unexpected TP mutations were called in between – wells in a number of the cer-
vical cytology and CMA samples collected from the HGSOC cases as well as in samples col-
lected fromwomenwith benign disease (Appendix . ). Figure . shows the unexpected
mutations with the trinucleotide context.
It therefore appears that cervical cytology samples and CMA samples are not optimal
for the detection of tumour cells from the ovary/fallopian tube and currently are not suf-






























































Figure . : a) t-MAD calculated from sWGS data from CMA samples and cervical smear
samples collected from women with HGSOC and benign gynaecological conditions. b) t-
MAD score for matched cervical smear and CMA samples from women with HGSOC. c)




















































































Figure . : All mutations (excluding true positive mutations) called in cervical smear and
CMA samples in wells or more with TAm-Seq V with trinucleotide context. As sequen-
cing was paired-end the strand that themutation is on cannot be con irmed. Therefore for
easemutationsweremerged eg. all reference bases C and Gmerged and classi ied as C and
all reference bases A and T merged and classi ied as T.
. Discussion
In this chapter I have shown that DNA can be extracted from cervical cytology samples and
sequencedusing targeted sequencing and sWGSmethods. I have shown thatmutations can
be detected using targeted sequencing in cervical cytology samples collected through the
NHS cervical screening programme fromwomen diagnosedwith cervical and endometrial
cancer. However, further conclusions cannot be drawn from this study due to the small
number of included samples and the lack of clinical data. The targeted sequencing panel
and the use of sWGS had been optimised to detect HGSOC which may account for the low
rates of detection in the available samples.
Previous studies have shown that somatic mutations can be detected in cervical cyto-
logy samples collected fromwomen with OC (Kinde et al. ; Wang et al. ). Unfortu-
nately none of the cervical cytology samples available through the NHS cervical screening
programme had been collected fromwomen diagnosed with OC. In the future a large scale
study including all routinely collected cervical cytology samples classi ied as showing non-
cervical glandular abnormalities from across the country could enable more meaningful
conclusions to be drawn about whether cervical cytology samples are useful for the detec-
tion of OC.
Through CTCR-OV I collected cervical cytology samples from women with suspec-
ted or con irmed OC. Although cervical cytology samples were collected in total only
of these were collected before treatment for HGSOC (others were collected before inter-
val debulking surgery (IDS) or before primary surgery from women not diagnosed with
HGSOC). De novo calling of targeted sequencing and sWGS did not detect tumour DNA in
any of the samples collected before treatment from women with HGSOC. The minimum
MAF detected using targeted sequencing in plasma samples was . % resulting in a low
rate of ctDNA detection (Section . ). A similarly low rate of detection for ctDNA was seen
in plasma samples using sWGS. It is therefore possible that targeted sequencing and sWGS
are not sensitive enough for the detection of tumour DNA in cervical cytology samples. In
comparison themethods used by Kinde et al. andWang et al. were able to detect
a minimumMAF of . % and . % respectively. The sensitivity of the methods used is a
limitation of this study particularly since tumour DNAwas detected in % of the cervical
cytology sampleswhen performing speci ic variant calling for theTP mutation identi ied
in FFPE, therefore suggesting it is present but not detected using de novo calling.
A factor effecting sensitivity is the amount of non-tumour DNA in a sample. Cervical
cytology samples were designed to detect pre-malignant changes in ectocervical cells. The
majority of cells in cervical cytology samples are therefore from the ectocervix, endocervix
and vagina. Samples are also likely to contain in lammatory cell, red blood cells andmicro-
organisms. These will all therefore contribute DNA to the sample causing a reduction in
the signal to noise ratio leading to non-detection of tumour DNA in a sample. As such this
method is not optimal for collecting cells/DNA shed from the distal fallopian tube.
Wang et al. increased the sensitivity of detection from % using cervical cyto-
logy to % by performing direct sampling of the intrauterine cavity using a Tao brush.
A procedure such as the Tao brush will not be useful as a triage tool in primary care as it
is an invasive procedure that can only be performed by a trained healthcare professional.
I therefore wanted to investigate other collection methods that may increase the rate of
tumour DNA detection but can potentially in the future be performed in primary care.
Aprevious study investigated thepresenceofTP mutations in cervicalmucous samples
obtained from hysterectomy samples (Lamzabi et al. ). Mutations were identi ied in
/ malignant cases. Mutations were also identi ied in two cases with STIC lesions. CMA
samples can be collected at the time of speculum examination and as such could be collec-
ted in primary care. I therefore investigated CMA samples collected at the time of primary
surgery for HGSOC. TP mutations were detected in two CMA samples collected before
treatment from women with HGSOC. This suggests that detection rates can potentially be
increased by more focused sampling from the cervical os. The limitation of this collection
method is that not all women, particularly post-menopausal women, produce a suf icient
quantity of cervical mucous to enable a sample to be collected. although cervical cyto-
logy samples were collected through CTCR-OV only CMA samples could be collected.
Another way of improving the sensitivity of detection is to apply alternative methods
for the detection of ctDNA. Size selection is not applicable in this setting as it is cellular not
cell-free DNA that is being investigated. TAm-Seq V was therefore applied to the cervical
cytology and CMA samples.
Using TAm-Seq V the tumour speci ic TP mutation was identi ied in two of the
HGSOC cervical cytology samples. A large number of unexpectedmutations were detected
in up to wells in samples fromHGSOC cases and benign controls. Themajority of the un-
expectedmutations called in both the cervical smear samples and CMA samples were C>T
mutations with a CpG context. CpG sites have a higher mutation rate than other sites, as
the C in this context is usually methylated and therefore hypermutable resulting in spon-
taneous deamination of methyl-C to T. This inding is therefore not unexpected and it is
possible that in the future the analysis of TAm-Seq V calling could incorporate a weight
dependent on the type of mutation to aid in the determination of true positive and false
positive calls. However, currently the TAm-Seq V method results are too ’noisy’ with too
many false positive mutations called to be a useful analysis method.
It is dif icult to commenton thenumberof unexpectedmutations in the smear samples
compared to the CMA samples as there weremore smear samples included in the analysis.
Cervical smear samples are collected and stored in a methanol based ixative. Although
methanol based ixatives have been shown to have lower deleterious effects onDNAquant-
ity and quality compared to formalin based ixation for tissue (Piskorz et al. ) this has
not been studied in cervical samples. It is therefore possible that some of the unexpected
mutations seen in the cervical smear samples are a result of methanol ixation inducing
chemical modi ications and degrading the DNA. Ideally a future cervical sampling device
for use in the diagnosis of OC would be collected and stored fresh as is with the current
trend for tissue collection for molecular analysis.
In the future if cervical sampling is to be further explored to aid in the triage of symp-
tomatic women from primary care either a more sensitive method for detection of tumour
DNA will be required or an alternative sampling method more focused on collecting cells
and DNA shed from the distal fallopian tube.




Standard irst line therapy for HGSOC is a combination of surgery and chemotherapy (usu-
ally carboplatin and paclitaxel). % of women do not respond to irst line therapy and
have a poor outcome. The development of blood based biomarkers to measure and pre-
dict response to treatment would be particularly bene icially for identifying those women
who are not responding to standard of care treatment enabling early entry into clinical
trials that may improve long term outcome.
It has previously been shown that a decrease of > % in levels of ctDNA measured
by digital PCR for TP after one cycle of chemotherapy for treatment of relapsedHGSOC is
a signi icant predictor of -month time to progression (TTP). CA decrease in the same
cohort was not a signi icant predictor (Parkinson et al. ). It is not yet known whether
the same is true in newly diagnosed HGSOC treated with neo-adjuvant chemotherapy.
In this chapter I will compare ctDNA levels at baseline, measured by targeted sequen-
cing and sWGS with end of treatment response. I will also compare the change in ctDNA
levels after one and two cycles of chemotherapy.
In this chapter radiological assessment andRECIST . measurementswereperformed
by Helen Addley, the TAm-Seq analysis pipeline was run by James Morris and the t-MAD
scores and fragmentation features calculated by Dineika Chandrananda.
. Results
. . CTCR-OV cohort
End of treatment response measured by RECIST . was determined for of the newly
diagnosed CTCR-OV cohort (Table . ) and compared to ctDNA levels at baseline. % of
the cohort did not respond to standard irst line therapy. More than %of the responders
had a detectable TP mutation at baseline however, only % of the cases with stable
disease (SD) and % of the cases with progressive disease (PD) had a detectable TP
mutation at baseline (Figure . a). There was no difference in TP MAF, unselected t-
MAD, or size selected t-MAD score at baseline in clinical responders compared to non-
responders (Figure . b-e). There was also no difference in ctDNA fragmentation features
at baseline in clinical responders compared to non-responders (Figure . ).
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Figure . : a) Number of women with a detectable TP mutation at baseline by end of
treatment response determined by RECIST . . b) TP MAF for detected cases at baseline
by end of treatment response determined by RECIST . . c) Unselected t-MAD score at
baseline by end of treatment response determined by RECIST . . d) Size selected t-MAD
score ( – bp) at baseline by end of treatment response determined by RECIST . . e)
Size selected t-MAD score ( – bp) at baseline by end of treatment response determ-
ined by RECIST . .






Table . : Percentage of responders and non-responders with > % reduction in MAF
after (C -C ) and (C -C ) cycles of chemotherapy.
The TP MAF dropped after cycle of chemotherapy for the majority of cases (Fig-
ure . a). There was an inverse relationship between the median decrease in TP MAF
after one cycle of chemotherapy and stage of disease however after two cycles of chemo-
therapy themediandecrease inTP MAFwas similar for all stages of disease (Figure . b).
The median decrease in TP MAF was higher for clinical responders compared to non-
responders after both one and two cycles of chemotherapy (Figure . c) however, there
was one case with a partial response (PR) that had an increase in TP MAF after one
cycle of chemotherapy. The only cases with an increase in TP MAF after two cycles of
chemotherapy had SD. None of the cases with PD had an increase in TP MAF after two or
three cycles of chemotherapy. A % reduction in TP MAF was not predictive of end of
treatment response in a neo-adjuvant setting particularly after two cycles of chemotherapy
(Table . ).
The change in t-MAD score (unselected and size selected) after one and two cycles
of chemotherapy did not correlate with stage of disease (Figure . a, c, e). Neither was
it predictive as an increase in t-MAD score after one and two cycles of chemotherapy was
seen in both responders and non-responders (Figure . b, d, f).
cfDNA fragmentation features provide information about the mechanism of release
of cfDNA. I was therefore interested in whether the DNA fragmentation features changed
after one and two cycle of chemotherapy. The proportion of the different fragmentation
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End of Treatment Response
Figure . : The proportion (P) of DNA fragments observed by sWGS inmultiple size ranges
(P – , P – , P – , P – , P – , P – , P – ), the ratios of pro-
portions of fragments in these size ranges (P – :P – , P – :P – ), thepro-
portion of fragments greater than a certain size (P> , P> ) and the amplitude of os-
cillations in fragment size densitywith bp periodicity observed below bp at baseline
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Figure . : a) TP MAF at baseline, pre cycle and pre cycle of neo-adjuvant chemother-
apy. b) Percentage change in MAF between baseline and pre cycle and baseline and pre
cycle by stage of disease. c) Percentage change in MAF between baseline and pre cycle
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Figure . : Percentage change in t-MAD between baseline and pre cycle and baseline and
pre cycle for: a) unselected t-MAD by stage, b) unselected t-MAD by end of treatment
response, c) size selected t-MAD ( – ) by stage, d) size selected t-MAD ( – ) by end
of treatment response, e) size selected t-MAD ( – ) by stage, f) size selected t-MAD























































































































































































































Figure . : The proportion (P) of DNA fragments observed by sWGS inmultiple size ranges
(P – , P – , P – , P – , P – , P – , P – ), the ratios of pro-
portions of fragments in these size ranges (P – :P – , P – :P – ), thepro-
portion of fragments greater than a certain size (P> , P> ) and the amplitude of os-
cillations in fragment size densitywith bp periodicity observed below bp at baseline
at baseline, pre cycle and pre cycle .
. Discussion
It has previously been shown that ctDNAcanoutperformCA inmetastatic breast cancer
(Dawson et al. ) and CA in recurrent OC (Parkinson et al. ) as a prognostic and
predictive biomarker. In recurrent HGSOC baseline TP MAF was a signi icant predictor
of TTPwith womenwith a higher baseline TP MAF having a shorter time to progression.
I wanted to investigate whether ctDNA was a prognostic or predictive marker in newly
diagnosed HGSOC. There have been no previous studies investigating the change in ctDNA
with irst line treatment for HGSOC and as the natural progression of the disease is not
fully understood it cannot be assumed that newly diagnosed disease responds in the same
way as recurrent disease. In fact anecdotal evidence suggests that recurrent HGSOC has a
different appearance at surgery to newly diagnosed disease.
In womenwith newly diagnosed HGSOC I found no relationship between the baseline
TP MAF or t-MAD score and end of treatment response suggesting that baseline ctDNA
is not prognostic in newly diagnosed disease. This conclusionmay be effect by the low rate
of ctDNA detection at baseline within the CTCR-OV cohort. Interestingly I did ind that
a higher proportion of responders ( %) had a detectable TP mutation at baseline com-
pared to non-responders ( %). It is possible that if ctDNA release is related to tumour
proliferation then highly proliferative tumours that have a better response to chemother-
apy have ctDNA detectable at baseline. However, this hypothesis is yet to be investigated
as currently there are no reliable measure of tumour proliferation across undiagnosed pa-
tients.
In relapsed HGSOC a reduction of> % in TP MAFwas predictive of TTP. This was
not the case in newly diagnosed disease. One limitation of this analysis is that % of the
cohort didnot havedetectable ctDNAat baseline so this analysiswas limited to cases and
only of these were non-responders. This analysis was undertaken using speci ic variant
calling for the tumour speci ic TP mutation identi ied in the baseline plasma sample and
therefore not limited to the lower limit of detection of aMAF of . % thatwas the casewith
de novo mutation calling.
After cycle of chemotherapy % of the responders and % of the non-responders
had > % reduction in TP MAF. After two cycles of chemotherapy this had increased to
% of the responders and % of the non-responders. It is possible in newly diagnosed
disease an initial response is seen even in the non-responders as the chemotherapy kills
the sensitive cells. It may be that stable or progressive disease is a result of overgrowth of
resistant clones and that this will not be detected after just two cycles of chemotherapy. If
this is the case it would have been useful to look at the TP MAF in an end of treatment
plasma sample as it is possible it would have increased by this stage mirroring the non-
response. It would have also be interesting to compare the baseline ctDNA levels and the
change in ctDNA levels to time to progression in the clinical responders as it is possible that
this may be predictive. Unfortunately this clinical data was not available for this cohort.
The fragmentation features of cfDNA re lect themechanismof compaction and release
into the circulation. The change in fragmentation features after the start of treatment could
therefore be used to distinguish ctDNA from cells killed by treatment compared to those
resistant to treatment thereby elucidating the mechanistic effect of treatment on tumour
cells. However, I did not identify any change in fragmentation features after one or two
cycles of neo-adjuvant chemotherapy. It is however possible that again this is too short a
time frame to identify sensitive and resistant cells and it would again be interesting to see
if any changes were seen at the end of irst line treatment (following the completion of
cycles of chemotherapy). This may also be a result of the generally low levels of tumour-
derived cfDNA in the samples meaning that the fragmentation features re lect the non-
tumour derived cfDNA fragments which are not expected to change with chemotherapy.
Although this analysis was performed on a relatively small cohort it appears that, in
contrast to recurrent HGSOC, ctDNA is neither predictive or prognostic in newly diagnosed
HGSOC.




In the future clinical trials investigating therapies for the treatment of HGSOC are likely
to involve the collection of blood for the analysis of ctDNA. Further understanding of how
ctDNA behaves during standard treatment is therefore necessary to investigate the effects
of new treatments. In this chapter I will therefore discuss the change in ctDNA around
the time of ascites drainage and surgery to provide further insights into the dynamics of
ctDNA.
Trials are likely to be large multi-centre trials. Blood processing at a central location
will reduce biases seen in equipment and processing technique. Cell stabilisation tubes
(such as STRECK BCT) provide stable ctDNA for up to hours. In this chapter I will dis-
cuss the effect of postage of these tubes on sWGS analysis. This work is part of a larger
body of work investigating blood processing and cell stabilisation tubes with amanuscript
accepted for publication in the Journal of Molecular Diagnostics (Appendix . ).
Finally investigation of ctDNA changes longitudinally is currently limited as it is only
recently that studies have started to collect plasma and not serum. For example UKCTOCS
collected serum for investigation of protein based biomarkers. Serum is not as useful as
plasma for ctDNA analysis due to the high amount of backgroundDNA resulting fromwhite
blood cell (WBC) lysis. I was therefore interested in whether ctDNA levels could be en-
riched in serum samples using a similar size selectionmethod to that discussed in plasma.
In this chapter I will discuss the investigation of the size of cfDNA fragments in serum com-
pared to plasma.
In this chapter the TAm-Seq analysis pipeline was run by James Morris. The t-MAD
score and fragmentation features were calculated by Dineika Chandrananda.
. Results
. . Dynamics of circulating tumour DNA
It has previously been shown that drainage of ascites can result in a decrease in ctDNA
measured by TP MAF (Parkinson et al. ). However, in this example ctDNA levels
were quanti ied at baseline (day ) (MAF= . %), litres of ascites was drained on day
and then ctDNA levels were quanti ied on day (during which time the patient did not
receive any treatment) at which point the TP MAF had dropped to . %.
To investigatehowquickly ctDNA levels changeafter ascitesdrainage I collectedplasma
samples before ascites drainage and immediately after the drain was removed for pa-
tients (Table . ). The volume of ascites drained ranged from to . litres. I quanti ied
ctDNA levels using MAF calculated from targeted sequencing (TAm-Seq with primer panel
- appendix . ) and t-MAD score calculated from sWGS data. The change in TP MAF
and t-MAD score varied considerably between patients and the change in the two meas-















788 3 0.020 0.015 − . 0.013 0.019 44.53
626 2 0.069 0.069 0.00 0.034 0.032 − .
800 2.8 0.059 0.063 6.78 0.029 0.041 42.50
277 5.5 0.008 0.026 225.00 0.012 0.013 1.77
619 2 ND ND NA 0.007 0.007 1.89
864 4.1 ND ND NA 0.007 0.005 − .
156 3.5 0.121 0.118 − . 0.006 0.006 − .





























































































































































































































Figure . : The proportion (P) of DNA fragments observed by sWGS inmultiple size ranges
(P – , P – , P – , P – , P – , P – , P – ), the ratios of pro-
portions of fragments in these size ranges (P – :P – , P – :P – ) and the
proportion of fragments greater than a certain size (P> , P> ) before and after ascites
drainage.
There was also no consistent change in fragmentation features comparing sWGS data
before and after ascites collection ( igure . ).
I also analysed plasma samples collected around the time of surgery for womenwith
HGSOC. Three of these underwent primary surgery and IDS. Pre surgery, end of surgery,
hour post surgery, and daily plasma samples collected up to day post surgery were
analysed (Appendix . ) using TAm-Seq with primer panel (Appendix . ). Analysis
was performed using detection calling for the tumour speci ic TP mutation identi ied in
the patients FFPE sample. Unfortunately TP mutations were not identi ied in any of the
plasma samples.
I therefore identi ied those cases included in the CTCR-OV newly diagnosed co-
hort that had undergone primary surgery, had detectable ctDNA pre operatively and had
a plasma sample available pre cycle of adjuvant chemotherapy (n= ) (Table . ). / of
the cases had a complete resection and / were debulked to < . cm residual disease. I
performed TAm-Seq using panel (Appendix . ) for the pre-cycle plasma sample. /
of the cases did not have a detectable TP mutation in the pre adjuvant chemotherapy
plasma sample. One case did had a TP mutation detected. The MAF had dropped from
. pre surgery to . pre chemotherapy with debulking to< . cm residual disease.
Patient Residual disease post surgery Mutation MAF pre surgery MAF pre cycle 1
716 < . cm 7574012 0.224 0.058
559 complete resection 7578384 0.025 ND
650 complete resection 7578382 0.265 ND
658 < . cm 7578534 0.092 ND
870 complete resection 7578455 0.015 ND
Table . : MAF pre primary surgery and pre cycle adjuvant chemotherapy for ive CTCR-
OV HGSOC cases.
sWGS was performed for samples collected around the time of surgery (up to day
post surgery) from patients undergoing primary surgery for HGSOC (Table . ). The
change in t-MAD score was not consistent across different patients (Figure . a). OV -
had an increase in t-MAD score at the end and hours after surgery that may be a
result of surgical manipulation and release of ctDNA. This increase was seen to a lesser ex-
tent for OV - and OV - . OV - and OV - had the opposite pattern with
a drop in t-MAD score at the end of surgery which may be the result of reduced tumour
burden.








Table . : Residual disease for seven women undergoing primary suregry for HGSOC.
The size selected t-MAD scores when selecting for fragments between – bp (Fig-
ure . b) and – bp (Figure . c) were fairly similar. There was less variability in size
selected t-MAD score over time other than in OV - which maintained a large decrease
in t-MAD score at the end of surgery.
A decrease in shorter fragments (P – , P – , P – ) was seen at the end
of surgery that then gradually increased over the next hours and days (Figure . ). The
proportion of very long fragments (P> and P> ) remained relatively stable across
time points, however the proportion of fragments between – (P – ) increased
whilst the proportion of fragments between – (P – ) decreased. OV -
showed a different pattern of change in fragmentation features to the other cases around






























































































































































































































































































































Figure . : t-MAD score at multiple time points around the time of primary surgery for
HGSOC for women. a) Unselected t-MAD score. b) Size selected t-MAD score ( –

















































































































































































































































































































































































































Figure . : The proportion (P) of DNA fragments observed by sWGS inmultiple size ranges
(P – , P – , P – , P – , P – , P – , P – ), the ratios of pro-
portions of fragments in these size ranges (P – :P – , P – :P – ) and the
proportion of fragments greater than a certain size (P> , P> ) around the time of
primary surgery.
. . Collection tubes
Three tubes of blood were drawn from patients with relapsed HGSOC. One EDTA tube
and one Cell-free DNA BCT tubes were processed immediately (E.RT. h), and another Cell-
free DNA BCT was shipped via standard UK Royal Mail service back to the same collection
centre. All shipped samples were received within h from the time of collection . There
were no statistical signi icance in total cfDNA levels between the three collection methods
(Figure . a, b). TP mutations were identi ied by TAm-Seq in patients and the MAF
was not statistically signi icantly across the different collection methods (Figure . c, d).
sWGS librarieswere prepared using the Rubicon ThruPlexDNA-Seq kit for of the patients
( samples total) and sequenced on the HiSeq to further investigate the effects of
collection method on global copy number changes. There were no signi icant difference

































































Figure . : a) Total cfDNA AC/μl by tube type. b) Total cfDNA AC/μl per patient. c) MAF
by tube tube. d)MAF per patient.
. . Serum
To investigate whether size selection could be used to enrich for tumour DNA in serum
samples I performed TAm-Seq using primer panel (Appendix . ) for serum samples
from women with HGSOC before and after in-vitro size selection (PippinHT, % gel, frag-
ments – bp). There were some limitations with this experiment including the low
sequencing coverage for some samples and inconsistent results for replicates of the same
sample (Appendix . ). In some cases eg. OV - chemotherapy cycle , OV -
chemotherapy cycle and OV - chemotherapy cycle no TP mutation could be de-
tected in the unselected sample but could be detected in the post size selection sample,
suggesting that size selection for fragments between – bp may enrich for ctDNA in
these samples. However, in other cases including OV - chemotherapy cycle , OV -
chemotherapy cycle , OV - chemotherapy cycle and OV - chemotherapy
cycle size selecting for DNA fragments between – bp signi icantly reduced the TP
MAF (Appendix . ). For this reason I hypothesised that cfDNA, particularly tumour de-
rived cfDNA, in serum samples is of a different size to fragments seen in plasma samples. I
therefore proceeded to investigate serum samples collected from xenograft models.
Whole genome libraries were prepared using the Rubicon ThruPlex DNA-Seq for
serum samples obtained from the same xenograft models as discussed in section . .
(Table . ). The proportion of reads aligning to the human genome (tumour) and the pro-
portion of reads aligning to the mouse genome (non-tumour) were plotted against frag-
ment length (Figure . ). The fragmentation pro iles for serum for mouse b (Figure . b)
andmouse c (Figure . c) were similar to those seen for thematched plasma samples (Fig-
ure . b,c) with the tumour derived DNA fragments shifted towards a shorter size com-
pared to the non-tumour cfDNA fragments. However, in the serum sample for mouse a
(Figure . a) a peak was seen at bp that was not present in the plasma sample.
I thereforewanted to investigate if this bp peakwas seen in patient serum samples.
I compared the fragmentationpro iles forDNA fromplasmaand serumsamples fromHGSOC
cases and controls. Different DNA extraction and library preparation methods lead to the
preferential sequencing of different DNA fragments. I therefore also compared different
extraction and library preparation methods (Figure . ).

















































































































Figure . : Schematic illustrating experimental design for comparing cfDNA fragments in
plasma and serum samples. ml aliquots of both plasma and serum were extracted us-
ing the QIASymphony and the QIAvac Plus vacuum manifold with QIAamp Circulating
Nucleic Acid kit (manual extraction). Whole genome libraries were prepared using the Ru-
bicon ThruPlex DNA Seq kit (dsDNA library preparation) and the DNA SMARTChIP-Seq Kit
(ssDNA library preparation).
The pro iles for the plasma and serum samples with the same extraction and library
preparationmethodswere broadly similar (Figure . ). More shorter fragmentswere seen
with the single-stranded library preparation method compared to the standard double
stranded librarypreparationmethodparticularlywith theQIAsymphonyextraction. HGSOC
case plasma samples had a fragmentation pro ile shifted to smaller sizes using the double
stranded library preparation which is consistent with previous indings (unpublished).
This same patternwas observed in the serum samples. A higher peak at bpwas seen in
the healthy control serum sample compared to the other samples that is not seen to such
an extent with the matched plasma sample. Using manual extraction and single stranded
library preparation showed a slight shift to smaller sizes for the two cases compared to the
controls for both the plasma and the serum samples. However using the QIASymphony ex-
traction and single stranded library preparation there is a large bp peak for the healthy




































Figure . : Density of reads against fragment size for healthy control, two benign controls
and two HGSOC cases (plasma and serum) for different extraction and library preparation
methods. Sampleswith < million readswere excluded and the lower limit of fragment size
set at bp as below this fragment alignment is not reliable. M=manual extraction (QIAvac
Plus vacuum manifold and the QIAamp Circulating Nucleic Acid kit), Q=QIAsymphony
extraction, double=double stranded DNA library prep (Rubicon ThruPlex DNA Seq kit),
single=single stranded DNA library prep (DNA SMART ChIP-Seq Kit).
. Discussion
It has previously been shown that drainage of ascites can result in a decrease in ctDNA
measured by TP MAF (Parkinson et al. ). In this study ctDNA levels were measured
days before and days after ascites drainage. As the half life of ctDNA is in the region
of hours and not days (Diehl et al. ) to investigate the dynamics of ctDNA around the
time of ascites drainage I collected plasma samples immediately before and immediately
after drainage. Investigation of ctDNA around the time of ascites drainage using targeted
sequencing and sWGS was inconclusive. It is possible that collecting blood immediately
after completion of drainage was too soon to see the effect on ctDNA levels. Ideally blood
would have been collect two hours after drainage and/or the following day to properly
investigate the dynamics of ctDNA resulting from drainage of ascites. This will be included
in future schedules of blood collection for studies of women with HGSOC. Alternatively
ascites could have no effect on the level of ctDNA in the circulation and the observation in
(Parkinson et al. ) could have been unrelated to the ascites drainage.
It is known thatwomenwithOC that have complete cytoreduction have improved sur-
vival rates compared towomenwho are sub-optimally debulked (Bristow et al. ) . The
classi ication of the degree of cytoreduction is currently a subjective process performed by
the operating surgeon and does not take into account micro metastases that may remain.
It would therefore be useful to have an objective measure of residual tumour burden par-
ticularly if future clinical trials of additional therapy become available for those not sub
optimally debulked.
Studies have shown that an increase in ctDNA post-operatively in lung cancer and
colorectal cancer is predictive of early recurrence and death (Ng et al. ; Sun et al. ).
The hypothesis being that the presence of ctDNA post-operatively re lects residual tumour
volume. Hu et al. monitored ctDNAmore frequently following surgery for lung cancer
and found a peak in levels days post operatively. After days ctDNA levels dropped and
only remained elevated at days in patients with an early recurrence (within months).
I was therefore interested in monitoring ctDNA levels around the time of surgery for
HGSOC to identify ) if ctDNA could provide a quantitativemeasure of residual disease and
) if post operative ctDNA levels were predictive of clinical response. My working hypo-
thesis was that ctDNA levels were likely to increase immediately following surgery due to
manipulation of tumour tissue causing release of tumour-derived cfDNA into the circula-
tion. I then expected ctDNA levels to re lect residual tumour volume with women that had
been completely debulkedwith no detectable ctDNA andwomenwith residual disease po-
tentially having detectable ctDNA although the levels may be below the limit of detection
with the method applied.
Using targeted sequencing for TP I was unable to identify ctDNA in plasma samples
collected pre or post operatively from threewomenundergoing primary surgery and three
women undergoing IDS. This is likely to be a result of the limited sensitivity of the TAm-
Seq method for ctDNA detection. In ive women undergoing primary surgery with detect-
able ctDNA pre-operatively only one had ctDNA detectable before commencing adjuvant
chemotherapy. The women had post operative residual disease of < . cm, as did one
other women with non-detectable ctDNA pre adjuvant chemotherapy. Investigation of
ctDNA around the time of surgery was therefore inconclusive. It is likely this is a result
of the limitations in sensitivity of the TAm-Seqmethod. Using this method TP mutations
could only be detected in % of pre treatment plasma samples. With hindsight detect-
ing TP mutations in plasma pre IDS was optimistic accounting for the signi icant drop
seen in TP MAF following and cycles of chemotherapy (see section , page ). This
analysis was also only undertaken in a small number of cases.
sWGS also showed inconsistent results. In some cases the t-MAD score increased at
the end of surgery and two hours post-operatively, in others a reductionwas seen between
pre and post-operative samples and other cases showed no change across time points.
OV - had > cm residual disease post-operatively and had a large increase in t-MAD
score at the end of surgery. Unlike Hu et al. ctDNA levels starting dropping from day
after surgery. Further investigation of larger numbers of samples using more sensitive
methods may be informative to better understand the dynamics of ctDNA around the time
of surgery.
I wanted to look at the change in fragmentation features over the time of surgery to
see if this provided any information about the size of tumour-derived cfDNA fragments or
information relating to the mechanism of release of cfDNA fragments. The proportion of
shorter cfDNA fragments tended to immediately decrease at the end of surgery and then
increase over the following few days. If the shorter cfDNA fragments do re lect those re-
leased during proliferation this could indicate a reduction in proliferation during surgery
followed by an initial rebound cellular proliferation after surgery. The proportion of very
long fragments (> bp) remained stable across all time points however, there was a re-
duction in long fragments (between – bp) after surgery. The origin of longer cfDNA
fragments remains unknown however, it is interesting that the proportion of these frag-
ments changes with surgery potentially as a result of tissue manipulation or reduction in
tumour volume. It is also possible that having an operation can effect the amount, and type,
of cfDNA in the circulation. It is possible that pre-medications, starving before a proced-
ure, dehydration and lack of physical exercise can all effect the release of cfDNA although
these factors are yet to be studied in detail.
In this chapter I have also shown that postage of cell stabilisation tubes does not have
an impact on sWGS ctDNA analysis. This work was part of a larger study of storage and
processing of plasma samples as well as the use of cell stabilisation tubes. This work has
been accepted for publication in The Journal of Molecular Diagnostics. The result of this
work is that in future multi-site studies cell stabilisation tubes will be used for plasma
collection to standardise collection and enable central processing of samples to minimise
biases.
Plasma samples are preferred for ctDNA analysis due to the large amount of back-
ground DNA found in serum samples resulting from WBC lysis. We have found a lower
MAF in serum samples compared to matched plasma samples (unpublished). Many large
scale studies historically banked serum samples as initial processing is easier and serum
is used for protein biomarker analysis. Currently these are precluded from ctDNA studies
due to the presumed large amount of wildtype DNA causing a reduction in the signal to
noise ration potentially leading to ctDNA levels becoming undetectable. I was therefore
interested to investigate if ctDNA could be enriched in serum samples, as it can in plasma
samples, to allow use of the rich resource of banked serum samples for ctDNA analysis.
Although only a very small number of samples were investigated in-vitro size selec-
tion for DNA fragments between – bp followed by targeted sequencing did not show
an enrichment in ctDNA as it did with plasma samples. It was hypothesised that this was
due to a difference in the length of tumour-derived cfDNA fragments in serum, potentially
resulting from the processing of the sample and the presence of clotting factors. However,
fragmentation pro iles of matched plasma and serum samples from two HGSOC cases, two
benign controls and one healthy control did not support this hypothesis. It is interesting
that different extraction methods and different library preparation methods allow the re-




In this thesis I have shown that ctDNA can be detected in womenwith newly diagnosed OC
including in women with early stage disease.
Improvements to the published TAm-Seq method for targeted sequencing (Forshew
et al. ) including optimised primers and a higher depth of sequencing have led to an
improvement in the limit of ctDNA detection down to a MAF of . . Using this method I
was able to detect ctDNA in – % of women with newly diagnosed OC.
I have shown that a genomewide score of copy number aberration (t-MAD score) can
be used to quantify ctDNA in plasma samples and detect – % of OC cases.
Thesemethods althoughnot as sensitive asother recentlypublishedmethods (Bettegowda
et al. ; Phallen et al. ; Cohen et al. ) have an advantage in that they are low-
cost high-throughputmethods that do not require prior knowledge of the patients tumour
speci ic mutation and as such are methods that can be directly translated to the clinic.
However, a greater sensitivity will be required for a diagnostic biomarker. I have
therefore discussed the development of TAm-Seq V . This targeted sequencing method
performs multiple reactions in parallel, each with a limited number of starting DNA mo-
lecules to ensure that the minimum AF is suf iciently above the level of background noise.
In optimisation experiments I have shown that this method can detect down to a MAF of
. %. The limitation of thismethod is the availability of suf icientmaterial to ensure that
enoughmolecules are screened to detect low AFmutations. For this to be a viable method
to test in populations with OC larger volumes of blood will need to be routinely collected
which may not be the most ef icient way of increasing sensitivity of detection.
I have also shown that the sensitivity of ctDNA detection can be increased by lever-
aging differences in tumour derived compared to non-tumour derived cfDNA fragments.
In particular I have shown that in-vitro and in-silico size selection for shorter DNA frag-
ments ( – bp or – bp) can increase the rates of ctDNA detection using targeted
sequencing and sWGS.
Applying the size selected t-MAD score to the cohorts ofwomenwith newly diagnosed
OC increased the ctDNA detection rate to – %. Importantly the rate of ctDNA detection
was high in the cases with early stage disease: % when using the upper limit of the
healthy controls as a cut off and % when using the upper limit of the benign controls as
a cut off. A limitation of this analysis is the small number of early stage cases investigated.
Validation in larger cohorts is therefore required.
Table . outlines the percentage of OC cases in the UKOPS and CTCR-OV cohorts
detected using the various different methods library preparation and analysis methods
discussed in this thesis. Detection is variable across the different cohorts and it is not clear
currently which parameters will provide the highest rate of detection of OC cases from
healthy controls. It is likely that a combination of assays including protein biomarkers as
well as ctDNAmay provide the optimal detection for further validation in larger cohorts of




























Whole cohort 30 41 53 53 61 88 46 45 69 73
HGSOC cases 45 56 56 56 61 83 44 44 72 83
CTCR-OV04
Whole cohort 49 39 67 67 37 53 34 37 70 69
Stage 1 33 33 50 80 22 44 50 40 25 20
Stage 2 67 67 100 100 50 75 50 50 25 25
Stage 3 44 35 64 64 35 45 27 30 66 65
Stage 4 60 45 72 70 47 67 43 45 76 74
Table . : Percentage ofwomenwith newly diagnosedOC in different cohortswith detectable ctDNAusing different library preparation
and analysis methods. Cut off used for the t-MAD score and IchorCNA is the upper limit of the healthy control cohort.
In contrast to relapsed disease (Parkinson et al. ) I found no correlation between
ctDNA levels and volume of disease in women with newly diagnosed HGSOC. In NSCLC a
stronger correlationwas identi iedbetween tumourproliferation and ctDNA thanbetween
tumour volume and ctDNA (Abbosh et al. ). The relationship between tumour prolif-
eration and ctDNA therefore needs to be investigated in newly diagnosedHGSOC to further
understand the limitations of detection.
In this thesis I have also investigated the use of cervical sampling for use in the dia-
gnosis of OC. I have developedmethods for extraction and sequencing of DNA from cervical
cytology and CMA samples. Although I have been able to detect tumour DNA in samples
collected from women with cervical and endometrial cancers, this has not been the case
for OCs. It is however possible that in the future an optimised cervical sampling device
may enable the detection of tumour DNA in women with OC.
. Future directions
In the future I plan to continue to develop a panel of assays that could be used in primary
care to enable rapid triage of symptomatic womenwith the aim of diagnosing ovarian can-
cer at an earlier stage. The combination of protein biomarkers, including CA and HE ,
as well as the detection of ctDNA using targeted sequencing and the identi ication of tu-
mour speci ic cfDNA fragmentation features may contribute to this clinical advancement.
During my PhD I have investigated ctDNA assays in incident cancer cases. Ongoing
work will focus on further bioinformatics analysis of incident cancer cases with a strong
focus on combining assays to improve both sensitivity and speci icity of OC identi ication.
The combination of assays identi ied in cohorts of women with a diagnosis of OC will then
be validated in larger cohorts of women who do not already have an OC diagnosis.
I am a co-applicant on a CRUKBiomarker Project award led by Sudha Sundar from the
University of Birmingham for the Re ining Ovarian Cancer Test accuracy Scores – Genomic
(ROCkeTS-GEN) study. This is a prospective single arm diagnostic accuracy study study
of postmenopausal women with symptoms and either a raised CA or abnormal ultra-
sound scan or both. postmenopausal women will be recruited at the time of referral
to secondary care. The prevalence of OC in symptomatic postmenopasual women is %.
ctDNA analysis will therefore be performed on OC cases (of which are likely to be
HGSOC) and controls without OC. The sensitivity and speci icity of ctDNAwill be com-
pared to RMI and CA . The combination of ctDNA and CA and other protein based
biomarkers identi ied in ROCkeTS will also be investigated.
I am also a co-applicant on a CRUK Early Detection Programme Award led by Doug
Easton andNitzan Rosenfeld. The purpose of the programme is to study cohorts of women
at high genetic risk of ovarian (and breast) cancer in order to investigate the potential of
using DNA in blood or cervical samples for the earlier detection of ovarian (and/or breast)
cancers. We plan to collect annual plasma samples from over , women at high risk
of ovarian (and breast) cancer. of these women are expected to develop OC over the
-years this programme will run for. ctDNA analysis using both targeted sequencing and
sWGS will be performed on sequential samples from the women with an OC diagnosis
and women not diagnosed with a cancer during the -years. This will again provide
information about the sensitivity and speci icity of ctDNA assays in a pre-diagnosis setting.
We will also be able to look at serial samples to identify the earliest timepoint that ctDNA
could be detected prior to a cancer diagnosis.
We also plan to collect annual cervical samples from women at high risk of OC. This
will provide a larger sample set to further investigatewhether tumourDNAcanbedetected
in cervical cytology samples fromwomenwith OC. Through this study I also plan to locally
test other methods for cervical sampling that may be better optimised to collect cells and
DNA shed from the distal fallopian tube.
Finally we plan to investigate ctDNA assays in combination with p autoantibodies
and protein biomarkers in women being followed up after completion of irst line treat-
ment for HGSOC. The premise of this study is that the development of assays to detect
relapse early are potentially applicable to a diagnostic setting. Findings from this cohort
with a known cancer diagnosis can then feed into the studies with sample collections from
womenwithout a cancer diagnosis, with the aimof further improving sensitivity of disease
detection.
Validation of the combination of the best biomarkerswill then be performed in a large
study of symptomatic women in primary care.
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1. SYNOPSIS 
 
Study Title Genetic Biomarkers for Gynaecological Conditions 
Internal ref. no. CTCR-OV05 
Study Design Pilot/feasibility study 
Study Participants All women referred to Addenbrooke’s Hospital with suspected ovarian 
cancer.  
All women undergoing surgery for ovarian or endometrial cancer. 
Planned Sample Size 230 
Follow-up duration Five years (routine follow up for ovarian cancer) or until the patient is 
discharged from clinic in cases of relapsed ovarian cancer. 
Planned Study 
Period 
3 years  
Primary Objective To determine if somatic mutations can be detected in blood samples 
obtained from women with ovarian cancer at the time of diagnosis? 
Secondary 
Objectives 
To determine if mutations detected in plasma samples at diagnosis can 
be detected in physician taken and self-taken cervical samples? 
 
To determine if changes in the levels of somatic mutations in blood 
samples during and after surgery can be used as a marker of post-
operative residual disease? 
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2. BACKGROUND AND RATIONALE 
 
OC is the most common cause of death from gynaecologically related cancers1.  The 
majority of women (60%) are diagnosed with late (stage III-IV) disease which has a 
significant impact on survival with 5-year relative survival rates of 6%, 22% and 92% for 
stage IV, stage II and stage I disease respectively1. Difficulties in the diagnosis of OC are 
related to the non-specific symptoms of the disease resulting in delayed investigations, a 
significant proportion (>50%) of early stage disease without an elevated CA125 resulting in 
missed diagnoses2 and a significant number of benign gynaecological and non-
gynaecological conditions, particularly in premenopausal women, with an elevated CA125 
leading to inappropriate investigation and referral.  
Current guidelines recommend measuring serum CA125 in all women with suspected OC 
followed by a transvaginal ultrasound scan (TVUS) in those with elevated levels3. In 
combination these are used to calculate a Risk of Malignancy Index (RMI), which guides 
referral and subsequent management4.  
 
Despite decades of effort, CA125 remains the single-best biomarker for OC with models 
derived from the most promising markers failing to show improvement over serum CA125 
alone5,6. There is therefore a pressing need to explore complementary strategies, prominent 
among which is the simultaneous detection of circulating tumour DNA (ctDNA). It is known 
that blood contains free circulating DNA and in cancer patients a small fraction of this 
includes fragments of tumour DNA.  Somatic mutations are highly specific biomarkers of 
cancer and detection of these via ctDNA in plasma samples this could provide a powerful 
non-invasive method for OC diagnosis. The gene TP53 encodes the tumour suppressor 
protein p53, a transcription factor that regulates the expression of proteins involved in 
apoptosis and genomic integrity. The Brenton laboratory have identified TP53 mutations in at 
least 96% of HGSOC tissue samples7. The Rosenfeld and Brenton laboratories have 
identified mutations in TP53 in ctDNA from plasma samples from 20/38 (53%) of patients 
with advanced HGSOC8.   
 
As mutations in TP53 are pathognomonic of HGSOC, assays for mutant ctDNA could be 
used, in combination with other variables in the RMI score, as a non-invasive method to 
improve specificity of OC diagnosis especially early stage or low volume disease.  We 
therefore propose to collect blood samples from all women referred to Addenbrooke’s 
Hospital with suspected ovarian cancer and sequence DNA for somatic mutations which will 
be correlated with clinical diagnosis.  
 
It is currently hypothesized that OC originates in the fallopian tube epithelium. Molecular 
alterations specific to OC have been identified in tubal tissue. It is therefore possible that 
detection of cells and DNA shed from this site could be utilised in the diagnosis of OC. 
Recent papers have shown that tumour DNA and common somatic mutations can be 
detected in liquid based cytology (LBC) samples9 and cervical mucous samples10 from 
patients with both endometrial and ovarian cancers. We propose to collect cervical samples 
from all women referred to Addenbrooke’s Hospital with suspected ovarian cancer and 
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ctDNA has a potential role as a biomarker for monitoring tumour dynamics and response to 
treatment. Recently it has been demonstrated that that there is a significant correlation 
between ctDNA levels and tumour burden in 30 women with metastatic breast cancer11 and 
that whole exome sequencing of ctDNA can be used to track genomic evolution of cancers in 
response to systemic chemotherapy12. Post-operative levels of circulating tumour DNA in 
plasma samples from patients with colorectal cancer appear to be related to the degree of 
resection with patients undergoing more extensive resection having lower post-operative 
levels13. Currently there is no objective measure of post-operative residual disease in OC 
however, the degree of surgical resection is a strong prognostic factor. We propose to collect 
normal and abnormal tissue, plasma and cervical samples from women undergoing surgery 
for ovarian and endometrial cancer to compare mutation status in pre and post-operative 
samples to investigate the kinetics of ctDNA in response to surgery. 
 
3. OBJECTIVES 
3.1 Primary Objective 
Can somatic mutations be detected in blood samples obtained from women with ovarian 
cancer at the time of diagnosis? 
3.2 Secondary Objectives 
Can mutations detected in plasma samples at diagnosis be detected in physician taken and 
self taken cervical samples? 
Can changes in the levels of somatic mutations in blood samples during and after surgery be 
used as a marker of marker of post-operative residual disease? 
4. STUDY DESIGN 
 




1. Patients referred to Addenbrooke's Hospital with suspected gynaecological cancers will be 
identified at the time of receipt of the referral letter. They will be sent a cover letter briefly 
outlining this clinical study with their routine out-patient clinic appointment letter by the 
clinical care team. 
 
2. At the time of routine outpatient clinic appointment with the gynaecological oncology team 
patients will be asked by the clinician if they would like to discuss the study further with a 
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3.The principal investigator or suitably qualified, delegated member of the 
trial/research/clinical care team will be available at the time of outpatient clinic appointment 
to discuss the study with the patient and talk through the patient information sheet and 
answer any questions. 
 
4. Written consent will be taken by the principal investigator or suitably qualified, delegated 
member of the trial/research/clinical care team from those patients who wish to participate. 
The principal investigator is an obstetrics and gynaecology trainee but is not a member of the 
clinical team that will be investigating and treating the patient. The principle investigator has 
attended good clinical practice and valid informed consent training courses. If appropriate 
written consent will be taken on the same day as the outpatient clinic.  The principal 
investigator or suitably qualified, delegated member of the trial/research/clinical care team 
will ensure that the patient has had sufficient time to consider participation, fully understands 
the study and has had an opportunity to discuss participation with family and friends if 
required. Some patients will require further time to consider participation in the study 
therefore for those patients returning for further investigations and/or surgery patients will be 
given the option of further discussion about the study and/or consenting and collection of 
samples at future attendance at Addenbrooke’s Hospital. Those patients discharged from 
Addenbrooke’s Hospital that require further time to consider participation in the study will be 
offered the option of returning at a time appropriate for them with reimbursement of travel 
expenses. 
 
5. Following the consent process the principal investigator or suitably qualified, delegated 
member of the trial/research/clinical care team will take a blood sample (up to 30ml, 
approximately 6 teaspoons) and cervical samples from women that have consented to 
participate. If patients require routine blood tests these will be taken at the same time to 
minimise risks of discomfort and bruising. A chaperone will be present at the time of 
collection of the cervical samples.  
 
6. Patients that are required to undergoing surgery for suspected/confirmed ovarian or 
endometrial cancer will be identified via the MDT.  
 
7. Patients will be seen by the principal investigator or suitably qualified, delegated member 
of the trial/research/clinical care team at the time of pre-operative assessment clinic. The 
second  part of the study will be discussed with the patient with the second patient 
information sheet and any questions will be answered.  
 
8. Written consent will be taken by the principal investigator or suitably qualified, delegated 
member of the trial/research/clinical care team from those patients who wish to participate.  
 
9.Patients will be asked to collect and bring a urine sample with them on the day of surgery. 
 
10. At the time of surgery all patients will routinely have a cannula inserted for intravenous 
access prior to the start of surgery. A blood sample (up to 30ml, approximately 6 teaspoons) 
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surgery and 2 hours after surgery has been completed by the principal investigator or 
suitably qualified, delegated member of the trial/research/clinical care team. 
 
11. Cervical samples will be taken from the patient following induction of anaesthesia prior to 
the commencement of surgery by the principal investigator or suitably qualified, delegated 
member of the trial/research/clinical care team. 
 
12. Patients would normally have as much cancer as possible removed at the time of 
surgery. Samples of both normal and abnormal tissue surplus to diagnosis will be collected 
by the operating surgeon.  
 
13. Further blood samples (up to 30ml, approximately 6 teaspoons) will be taken daily whilst 
the patient is an inpatient in hospital by the principal investigator or suitably qualified, 
delegated member of the trial/research/clinical care team. These will be taken at the time of 
routine blood tests where possible.  
 
14. If patients have had previous gynaecological surgery, or proceed to further 
gynaecological surgery in the future, any stored surplus tissue samples in the Addenbrooke’s 
tissue bank will be requested for comparison to collected blood and cervical, and tissue 
where applicable, samples collected during the study.  
 
 
4.2 Primary and Secondary Endpoints/Outcome Measures 
Primary Endpoints 
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Secondary Endpoints 
-Detection and frequency of somatic mutations in cervical samples. 
-Correlation of change in frequency of somatic mutations with surgical outcome and clinical 
response.  
 
4.3 Study Participants  
4.3.1 Overall Description of Study Participants 
 
• Women referred to Addenbrooke’s Hospital with suspected ovarian cancer. 
• Women undergoing surgery for suspected/confirmed ovarian or endometrial cancer. 
4.3.2 Inclusion Criteria 
 
• Participant is willing and able to give informed consent for participation in the study. 
• Female, aged 18 years or above. 
• Referred with suspected ovarian cancer or undergoing surgery for suspected/confirmed 
ovarian or endometrial cancer. 
 
4.3.3 Exclusion Criteria 
The participant may not enter the study if ANY of the following apply: 
• Age under 18 years. 
4.4 Study Procedures 
All participants will have a blood sample up to 30ml (approximately 6 teaspoons) taken at the 
time of referral for suspected ovarian cancer. At the same time cervical samples will be 
collected during a speculum examination.  
Patients will be asked to collect and bring a urine sample on the day of surgery. At the time 
of surgery further cervical samples will be collected. Blood samples up to 30ml 
(approximately 6 teaspoons) will be collected at the start of surgery, at the end of surgery, 2 
hours post operatively and daily whilst the patient remains in hospital.  
 
4.4.1 Informed Consent 
 
Patients will be sent a cover letter with the routine clinic appointment letter detailing that a 
clinical study is ongoing, that they may be approached for participation in the study, the 
purpose of the study and that the study will involve the collection of blood and cervical 
samples. The contact details of the research nurse are provided in case the patients requires 
any further information about the study prior to attending clinic.   
 
At the time of routine outpatient clinic appointment with the gynaecological oncology team 
patients will be asked by the clinician if they would like to discuss the study further with a 
member of the research team who will be available at the time of the clinic appointment. 
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qualified, delegated member of the clinical care team at the time of the outpatient 
appointment. All patients will be informed of the aims of the study. They will be informed as 
to the strict confidentiality of their patient data, but that their medical records may be 
reviewed for research purposes by authorized individuals other than their treating physician. 
It will be emphasized that the participation is voluntary and that the patient is allowed to 
refuse further participation in the protocol whenever he/she wants. This will not prejudice the 
patient’s subsequent care. Participants will be given the opportunity to ask any questions and 
only once all of their queries have been answered will consent be taken by the principal 
investigator or suitably qualified, delegated member of the clinical care team from those 
patients willing to participate.  
 
Patients will be given as much time as is required to consider participation in the study. In 
some cases it will be appropriate to take consent and collect samples on the same day as 
the initial clinic appointment. This approach as been discussed with patient advocates 
through Target Ovarian Cancer and has been deemed appropriate if patients feel they have 
had sufficient time to consider participation. However, in some case this will not be 
appropriate and will therefore be deferred until further attendance at Addenbrookes Hospital 
for those patients undergoing further investigation and/or surgery. For those patients that are 
not required to return for clinical reasons we will provide reimbursement for travel expenses 
for those patients wishing to return at a later date for consenting to the research study and 
collection of samples. Documented informed consent will be obtained for all patients included 
in the study before they are registered in the study. This will be done in accordance with the 
national and local regulatory requirements. 
 
4.4.2 Study Assessments 
 
Clinical data will be collected and stored on NHS computers. DNA will be extracted and 
sequenced from all clinical samples. Sequencing data will be correlated with linked 
anonymised clinical data, including CA125, imaging findings, diagnosis, histology, response 
to treatment and relapse, at CRUK Cambridge Institute. 
4.5 Definition of End of Study  
The end of study is the date of the last visit of the last participant.  
5. INTERVENTIONS  
See study procedures. 
 
6. SAFETY REPORTING   
Any serious adverse events (an adverse event that results in death, is life-threatening, 
requires hospitalisation or prolongation of existing hospitalisation, results in persistent or 
significant disability or incapacity) that occur during the study will be reported to the 
sponsors.  
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7.1 The Number of Participants 
To establish if sensitivity differs significantly from 66.7% but to be 80% certain with a 
probability of 0.05 that a sensitivity as low as 56.1% would be excluded requires 161 
subjects with ovarian cancer. 
To establish if specificity differs significantly from 90.9% but to be 80% certain with a 
probability of 0.05 that a specificity as low as 80.0% would be excluded requires 69 subjects 
without ovarian cancer. 
 
 
7.2 Analysis of Endpoints 
Comparison of the presence and frequency of somatic mutations across clinical samples for 
each participant. Correlation with clinical diagnosis.  
Comparison of mutation status in pre and post operative clinical samples. Correlation with 
extent of surgical resection and survival.   
8. ETHICS 
8.1 Participant Confidentiality 
 
All clinical information regarding participants collected during the course of the study will be 
kept strictly confidential. Each participant will be allocated a unique study number at study 
entry and will be identified by this number on all study related documentation throughout the 
course of the trial and data analysis process. This will be kept on an individual computer, 
access restricted to named individuals and password protection. All the data will be held on 
an NHS computer and will conform to the Department of Data Security Policy and Department 
Compliance with the Data Protection Act (1998). Anonymised data may be sent to the 
laboratory personnel University of Cambridge Computers at CRUK Cambridge Institute, but 
this will not contain any personal data. Any data transferred will be done according to the NHS 
Code of Practice on Confidentiality. 
 
8.2 Other Ethical Considerations 
This study involves the collection of clinical samples from patients at the time of referral and 
primary surgery for suspected ovarian cancer.   
Patients with suspected ovarian cancer are referred to the hospital as a two week wait 
referral meaning they are seen in out-patient clinic within two weeks of the referral being 
received. Not all patients will be aware that they have been referred for suspected ovarian 
cancer. For this reason ovarian cancer has specifically not been mentioned on any of the 
documentation (ie. cover letter, patient information sheet, consent form) that potential 
participants will receive. All patients will be seen, as per routine clinical care, by an 
experienced oncologist prior to being asked if they would be interested in participating in the 
research study.  
 
It is unlikely that this study will produce findings of clinical significance for the participants or 
their relatives. In the unlikely event that clinically significant information does become 
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study reveals information that might affect family members this will also be referred to the 
patients treating clinician. Genetic testing is not currently undertaken routinely in clinical 
practice. If clinically relevant and the patient consents to undergo genetic testing this is done 
following appropriate genetic counselling. We therefore feel it is important to know, although 
this is unlikely, whether the participant would want to be informed if the research reveals any 
genetic information that might affect family members. We have therefore included this as an 
optional point in the consent form. If participants would like to be informed of any information 
that might affect family members this information will be provided to participants after 
appropriate genetic counselling arranged by the treating clinician. This optional question in 
the consent form is included in an ethically approved study being undertaken at 
Addenbrooke’s Hospital. Importantly approximately 10% of participants have not ticked this 
box indicating that they would not wish to be informed of this information should it become 
available.  
DATA HANDLING AND RECORD KEEPING 
 
Patient initials, date of birth and hospital number, NHS number, relevant medical history, 
disease pathology, treatments and treatment outcomes will be stored in a database on NHS 
computers. Patients will consent for this data to be stored on their consent forms. This data 
will be kept on an individual computer, access restricted to named individuals and password 
protection. Each participant will be allocated a unique study number at study entry and all 
biological samples and study documentation will be identified by this number throughout the 
course of the trial and data analysis process.  
 
9. FINANCING AND INSURANCE 
The study is being funded by the Medical Research Council and Target Ovarian Cancer. The 
study will be sponsored jointly by the Cambridge University Hospitals NHS Foundation Trust 
and The University of Cambridge.  
 
10.  ABREVIATIONS  
CRUK – cancer research UK  
ctDNA – circulating tumour DNA 
HGSOC – high grade serous ovarian cancer 
LBC – liquid based cytology 
MDT – multidisciplinary team 
OC – ovarian cancer 
RMI – risk of malignany index 
TVUS – transvaginal ultrasound scan 
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Genetic Biomarkers for Gynaecological 
Conditions 
 
We would like to invite you to take part in a research study. Before you decide 
it is important for you to understand why the research is being done and what 
it would involve for you.  Please take time to read the following information 
carefully and discuss it with friends and relatives if you wish. 
 
• Part 1 tells you the purpose of this study and what will happen if you take 
part 
• Part 2 gives you more detailed information about the conduct of the study 
 
Please ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. Thank 




What is the purpose of the study? 
The purpose of this study is to identify new ways of diagnosing ovarian 
conditions. You may have already had a blood test and an ultrasound scan 
arranged by your GP and although they give us a lot of information about 
possible ovarian conditions sometimes it would be useful to have more 
information to help decide what is the best course of management and 
treatment for women. We are hoping that by collecting information from blood 
tests and cervical samples (not currently used in the diagnosis of ovarian 
conditions) we will be able improve the investigation of women referred by 
their GP with possible ovarian conditions. We are hoping to be able to identify 
ovarian conditions at the earliest time point possible to ensure that women 
receive the best treatment possible.  
 
Why have I been invited?  
You have been invited as you have been referred to see a gynaecologist as 
your GP suspects that you may have an ovarian condition. We would like to 
collect blood and cervical samples from all women referred to Addenbrooke’s 
Hospital with suspected ovarian conditions. These samples will all be taken at 
the same time as your routine outpatient clinic appointment. 
 
Do I have to take part? 
No. Taking part in this research study is entirely voluntary and it is up to you 
to decide whether or not to take part.  We will describe the study to you and 
go through this information sheet, which we will then give to you.  We will then 
ask you to sign a consent form to show you have agreed to take part.  You 
are free to withdraw at any time, without having to give a reason. A decision 
not to take part or a decision to withdraw at any time will not affect the 
standard of care that you receive. 
 
 
What will happen to me if I take part? What will I have to do? 
If you agree to take part in this study we would like to ask if we can take one 
additional blood sample of up to 30ml of blood (approximately 6 teaspoons). 
This will be taken at the same time as your routine blood tests if possible. We 
would also like to ask if we can collect some additional cervical samples 
including samples of cells and mucous from your cervix. The cervical samples 
will be collected in the same way as a routine cervical smear test. 
 
With your permission we would like to inform your GP that you are 
participating in this study.  
 
We would like to ask if we can obtain further information about your medical 
history and progress from your medical records and would like to ask 
permission to obtain this information from your GP (located via NHS 
databases) if required. If relevant we would also like to ask permission to 
update our records using the Eastern Cancer Registration and Information 
Centre (ECRIC). In order to do this, we will need to use your full name and/or 
NHS number.  
 
If you have already had surgery for a gynaecological condition, or will be 
having surgery in the future, there may be stored surplus tissue samples of 
yours in Addenbrooke’s tissue bank (or your local hospital histopathology 
department). We would like to be able to study these as well for our research.  
 
If you agree to participate in this study you will be asked to sign a consent 
form. This information would remain strictly confidential ie. all information that 
could identify you would be removed, before being given to the researchers. 
Under no circumstances will you be identified in any way in any publication or 
report arising from this study. Further information is given in Part 2 of this 
information sheet.  
 
What are the possible disadvantages and risks of taking part? 
Risks of blood tests include possible minor discomfort, and occasional 
bruising or bleeding. Additional blood tests could increase these risks slightly 
but all blood tests will be taken at the same time as routine blood tests where 
possible to minimise these risks. The procedure is done under sterile 
conditions by experienced doctors or nurses. 
 
The cervical samples will be collected in the same way as a routine cervical 
smear test so may be associated with some minor discomfort but should be 
painless. Some women can experience a small amount of bleeding (spotting) 
following collection of cervical samples. The samples will be collected by an 
experienced doctor and a chaperone will be present whilst these samples are 
taken.  
 
What are the possible benefits of taking part? 
There are no immediate clinical benefits to you taking part in this study but the 
information we obtain could be used to improve the investigation of women 
with possible ovarian conditions in the future. 
 
Expenses and payments 
If you choose to come back to Addenbrooke’s Hospital for a visit purely 
related to this research study ie. to consent to participate in the study or for us 
to collect samples for the research study, your travel expenses will be 
reimbursed.  
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will 
be handled in confidence. Full details on this (and details of how any 
complaints about the way you have been dealt with will be addressed) are 
included in Part 2 of this information sheet.  
 
This completes Part 1. If the information in Part 1 has interested you and 
you are considering participation, please read the additional information 
in Part 2 before making any decision.  
 
 Part 2 
 
Will my information be kept confidential? 
Yes. The study involves us collecting blood and cervical samples and 
obtaining information about your relevant medical history and the outcomes of 
your investigations from your medical records. This information will be 
collected by a clinical fellow and/or research nurse and will be stored securely 
and is kept strictly confidential. You will be registered on the study by your 
NHS number, hospital number, initials and date of birth and assigned a 
unique code number. Other information on the NHS site will be stored in a 
separate database and refer to you only by your code number.  
 
Samples will be taken to the Cancer Research UK (CRUK) Cambridge 
Institute for processing. So that we can link all of your samples, your hospital 
number, NHS number and date of birth will be securely encoded and linked to 
the unique sample numbers. At no point will any un-encoded information that 
could identify you be linked to your samples on the CRUK Cambridge Institute 
database. 
 
In order retrieve any surplus stored tissue samples from Addenbrooke’s 
Tissue Bank or other hospital histopathology departments we will need to use 
your full name, and/or NHS number/hospital number and date of birth, 
however only encoded information will be linked to your actual samples, as 
above. 
 
All databases are separately password-protected, as are the computers. This 
information will be stored in accordance with the Data Protection Act of 1998 
and is only accessible by authorised personnel. Occasionally we may need to 
access your medical records in order to update the information. This will be 
done by clinical staff or designated personnel from the trial office. The 
sponsor and/or members of the NHS Trust Research and Development 
Department may require access for audit and monitoring purposes.  
 
With your agreement, we may ask your GP and any other doctors involved in 
your care to provide information on your progress. If we do need to contact 
your GP or another hospital (if your main care is not at Addenbrooke’s) for 
any follow-up information, we will need to use your full name in our 
correspondence if you have agreed to provide this. If you change address and 
we lose touch with your GP, we may then locate your new GP through the 
NHS database.  
 
If relevant we would also like to ask for permission to update our records 
using the Eastern Cancer Registration and Information Centre (ECRIC). In 
order to do this, we will need to use your full name and/or NHS number.  
 
Under no circumstances will you be identified in any way in any report or 
publication arising from the study. 
 
What will happen to the samples I give?  
All samples will be coded (‘anonymised’) which means that the laboratory 
researchers who are carrying out tests on your tumour samples will not be 
able to trace them back to you. However, the trials office will keep a 
confidential record of the codes used for your samples and can access your 
notes should the need arise.  
 
The samples will then be sent for analysis at the CRUK Cambridge Institute 
on the Addenbrooke’s Hospital Site. We will be studying DNA in the blood and 
cervical samples to look at molecular markers of ovarian conditions that may 
be useful for diagnosis. Samples will be stored at the CRUK Cambridge 
Institute and if you agree these may be used in future research that has 
received full ethics committee approval.  
 
It is unlikely that any new information will be generated from this study that will 
influence your treatment or reveal genetic information that might affect family 
members. However, if any relevant information does become available during 
the course of the study this will be given to the doctor looking after you in the 
hospital. If you wish to be informed of this information your doctor will arrange 
this with the appropriate genetic counselling.  
 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time without giving a reason. A 
decision not to take part or a decision to withdraw at any time will not affect 
the standard of care that you receive. Please note that if you do choose to 
withdraw from the study, we would still like to keep stored blood or tissue for 
future research purposes. However, should you not wish us to do this, you 
can withdraw your consent and you should tell your doctor or nurses of your 
wishes. Any stored blood or tissue samples that can still be identified as yours 
will be destroyed if you wish.  
 
What if there is a problem?  
We will try to address any concerns you might have about any aspect of this 
study. If there are any problems, you should ask to speak with the 
researchers who will do their best to answer your questions (Telephone: 
Charlotte Hodgkin, Senior Research Nurse, 01223 348084). If you remain 
unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details on this can be obtained by contacting the 
Hospital PALS (Patient Advice and Liaison Service) on 01223 216756. 
 
In the unlikely even that something goes wrong and you are harmed as a 
result of participating in this study, compensation will be available through the 
NHS Indemnity scheme.  
 
What will happen to the results of the study? 
The results of this study will be published in scientific or medical journals and 
may be presented at scientific or medical meetings.  Please be assured it will 
not be possible to identify you in any report or publication. If you would like to 
obtain a copy of the published results please contact the research nurse 
directly who will be able to arrange this for you. 
 
Who is organising (sponsoring) and funding the study? 
This study is sponsored by Cambridge University Hospitals NHS Foundation 
Trust and The University of Cambridge. The study is being funded by the 
Medical Research Council and Target Ovarian Cancer. 
 
Who has reviewed this study? 
All research within the NHS is reviewed by an independent group of people 
called a Research Ethics Committee, to protect your interests.  This study has 
been reviewed and given favourable opinion by NRES Committee East of 
England - Cambridge East. 
 
Further information and contact details 
If you require any further information about this study please do not hesitate to 
contact the Research Nurse below.  Further advice on research and conduct 
of studies can be obtained from Addenbrooke’s Hospital PALS on 01223 
216756. 
 
The Senior Research Nurse is:   
Charlotte Hodgkin 
Cambridge Trials Centre,  
S4 (Box 279) 
Addenbrooke’s Hospital, Hills Road, Cambridge CB2 OQQ  
Telephone: 01223 348084 
 
Thank you for taking the time to read this Patient information Sheet.  
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CTCR-OV05                                  Patient Consent Form 1                  
Referral        Version 2: December 2014 
 
copies required:   1 copy for researcher; 1 copy for patient; 1 copy to be kept with patient’s hospital notes 
 
Doctor/ Person taking consent 
Signed ….…………………………………………………….… 
Print name ….…………………………………………………. Date:  …………………………… 
Patient 
Signed ….…………………………………………………….… 
Print name ….…………………………………………………. Date:  …………………………… 
Consent for CTCR-OV05  
                                                    Please initial boxes 
 
1. I confirm that I have read the information sheet dated ….. (version…..) for the above 
study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily.  
                
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. 
 
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by responsible individuals from the Cambridge Trials Unit, 
from regulatory authorities or from the NHS trust where it is relevant to my taking part 
in research. I give permission for these individuals to have access to my records. 
 
4. I understand that the information collected about me will be used to support other 
research in the future, and may be shared anonymously with other researchers.  
 
5. I understand that my participation in this study will involve the collection of personal 
details, information about my treatment and medical history. I understand that all data 
collected about me will be held under the provisions of the 1998 Data Protection Act 
and stored in manual and electronic files in secure encoded format.  
 
6. I give permission for my GP to be notified of my participation in this research. If 
necessary, I give permission for information about my progress to be obtained from 
my GP (located via NHS databases if required), and if relevant through the Eastern 
Cancer Registration and Information Centre and understand that this will be done 
using my full name and/or NHS/hospital number. 
 
7. I agree to the identification and analysis of previously collected tissue, or tissue that will 
be collected in the future, and understand that this will be done using my full name 
and/or NHS/hospital number.   
8. I agree to the collection and storage of additional blood, urine and cervical samples 
for future research into ovarian conditions, including DNA analysis. 
9. I agree to the linkage of securely encoded encrypted personal details from samples 
collected on this study, and previous stored samples. 
10.  I agree to take part in the above study 
 
 
11. OPTIONAL: I wish to be informed if research on my blood reveals genetic information 
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Genetic Biomarkers for Gynaecological 
Conditions 
 
We would like to invite you to take part in a research study. Before you decide 
it is important for you to understand why the research is being done and what 
it would involve for you.  Please take time to read the following information 
carefully and discuss it with friends and relatives if you wish. 
 
• Part 1 tells you the purpose of this study and what will happen if you take 
part 
• Part 2 gives you more detailed information about the conduct of the study 
 
Please ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. Thank 




What is the purpose of the study? 
This study has two purposes. The first is to identify new ways of diagnosing 
gynaecological conditions. You are undergoing surgery for a possible 
gynaecological condition and we are hoping that by collecting information 
from blood tests and urine and cervical samples we will be able improve the 
investigation and treatment of women referred to the hospital with possible 
gynaecological conditions. The second is to see if we can develop a method 
of telling how successful surgery has been and whether any further treatment 
will be required.  
 
Why have I been invited?  
 
You have been invited as you are undergoing surgery for a possible 
gynaecological condition. We would like to collect additional tissue, blood, 
urine and cervical samples from around the time of the operation from women 
undergoing surgery at Addenbrooke’s Hospital for possible gynaecological 
conditions. These samples will be taken during the general anaesthetic or at 
the same time as your routine care where possible. 
 
Do I have to take part? 
No. Taking part in this research study is entirely voluntary and it is up to you 
to decide whether or not to take part.  We will describe the study to you and 
go through this information sheet, which we will then give to you.  We will then 
ask you to sign a consent form to show you have agreed to take part.  You 
are free to withdraw at any time, without having to give a reason. A decision 
not to take part or a decision to withdraw at any time will not affect the 
standard of care that you receive. 
 
What will happen to me if I take part? What will I have to do? 
If you agree to take part in this study, you will not need to attend the hospital 
for any extra visits. Firstly we would like to ask you to bring an additional urine 
sample with you on the day of surgery. 
 
Normally at surgery if any abnormal tissue is identified the surgeon will try and 
remove as much of it as possible. They may take some small samples from 
normal looking areas in the abdomen for comparison. These samples will be 
sent to the pathology laboratory. With your permission, we would like to take 
some spare samples of normal and abnormal looking tissue, if present, for our 
research.  
 
We would like to ask if we can take some additional blood samples from 
around the time of your operation and after your operation whilst you are still 
in hospital. We would be asking to take three blood samples of up to 30ml of 
blood (approximately 6 teaspoons) during your operation and a further blood 
sample of up to 30ml of blood (approximately 6 teaspoons) each day whilst 
you remain in hospital after your operation. These will be taken at the same 
time as your routine blood tests where possible.  
 
We would also like to ask if we can collect some additional cervical samples 
including samples of cells and mucous from your cervix at the time of your 
operation. Your operation will be done under a general anaesthetic, this 
means you will be asleep during the operation. The cervical samples will be 
collected during this time in the same way as a routine cervical smear test.  
 
With your permission we would like to inform your GP that you are 
participating in this study.  
 
We would like to ask if we can obtain further information about your medical 
history and progress from your medical records and would like to ask 
permission to obtain this information from your GP (located via NHS 
databases) if required. If relevant we would also like to ask permission to 
update our records using the Eastern Cancer Registration and Information 
Centre (ECRIC). In order to do this, we will need to use your full name and/or 
NHS number. 
 
If you have already had surgery for a gynaecological condition there may be 
stored surplus tissue samples of yours in Addenbrooke’s tissue bank (or your 
local hospital histopathology department). We would like to be able to study 
these as well for our research.  
 
If you agree to participate in this study you will be asked to sign a consent 
form. This information would remain strictly confidential ie. all information that 
could identify you would be removed, before being given to the researchers. 
Under no circumstances will you be identified in any way in any publication or 
report arising from this study. Further information is given in Part 2 of this 
information sheet.  
 
What are the possible disadvantages and risks of taking part? 
Risks of blood tests include possible minor discomfort, and occasional 
bruising or bleeding. Additional blood tests could increase these risks slightly 
but all blood tests will be taken at the same time as routine blood tests where 
possible to minimise these risks. The procedures are done under sterile 
conditions by experienced doctors or nurses. 
 
The cervical samples will be collected in the same way as a routine cervical 
smear test during the general anaesthetic so will not be associated with any 
increased pain or discomfort. Collecting cervical samples will not affect the 
surgery in any way.  
 
For patients having additional tissue samples collected during surgery, there 
will be no significant additional risks to the surgery, and it will not affect the 
surgery in any way.  
 
What are the possible benefits of taking part? 
There are no immediate clinical benefits to you taking part in this study but the 
information we obtain could be used to improve the investigation and 
treatment of women with possible gynaecological conditions in the future. 
 
Expenses and payments 
There are no expenses or payments associated with this study. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will 
be handled in confidence. Full details on this (and details of how any 
complaints about the way you have been dealt with will be addressed) are 
included in Part 2 of this information sheet.  
 
This completes Part 1. If the information in Part 1 has interested you and 
you are considering participation, please read the additional information 
in Part 2 before making any decision.  
 
 Part 2 
 
Will my information be kept confidential? 
Yes. The study involves us collecting blood, urine, cervical and tissue 
samples and obtaining information about your relevant medical history and 
the outcomes of your treatment from your medical records. This information 
will be collected by a clinical fellow and/or research nurse and will be stored 
securely and is kept strictly confidential. You will be registered on the study by 
your NHS number, hospital number, initials and date of birth and assigned a 
unique code number. Other information on the NHS site will be stored in a 
separate database and refer to you only by your code number.  
 
Samples will be taken to the Cancer Research UK (CRUK) Cambridge 
Institute for processing. So that we can link all of your samples, your hospital 
number, NHS number and date of birth will be securely encoded and linked to 
the unique sample numbers. At no point will any un-encoded information that 
could identify you be linked to your samples on the CRUK Cambridge Institute 
database. 
 
In order retrieve any surplus stored tissue samples from Addenbrooke’s 
Tissue Bank or other hospital histopathology departments we will need to use 
your full name, and/or NHS number/hospital number and date of birth, 
however only encoded information will be linked to your actual samples, as 
above. 
 
All databases are separately password-protected, as are the computers. This 
information will be stored in accordance with the Data Protection Act of 1998 
and is only accessible by authorised personnel. Occasionally we may need to 
access your medical records in order to update the information. This will be 
done by clinical staff or designated personnel from the trial office. The 
sponsor and/or members of the NHS Trust Research and Development 
Department may require access for audit and monitoring purposes.  
 
We would like to collect information about participants for some years to come 
in order that we can keep track of how you have responded to treatment. With 
your agreement, we may ask your GP and any other doctors involved in your 
care to provide information on your progress. If we do need to contact your 
GP or another hospital (if your main care is not at Addenbrooke’s) for any 
follow-up information, we will need to use your full name in our 
correspondence if you have agreed to provide this. If you change address and 
we lose touch with your GP, we may then locate your new GP through the 
NHS database. With your permission we would also like to be able to keep in 
contact with you personally, to see how you are getting on and to let you know 
about any future research we are carrying out.   
 
If relevant we would also like to ask for permission to update our records 
using the Eastern Cancer Registration and Information Centre (ECRIC). In 
order to do this, we will need to use your full name and/or NHS number.  
 
Under no circumstances will you be identified in any way in any report or 
publication arising from the study. 
 
What will happen to the samples I give?  
All samples will be coded (‘anonymised’) which means that the laboratory 
researchers who are carrying out tests on your samples will not be able to 
trace them back to you. However, the trials office will keep a confidential 
record of the codes used for your samples and can access your notes should 
the need arise.  
 
The samples will then be sent for analysis within Addenbrooke’s Hospital, and 
at the CRUK Cambridge Institute on the Addenbrooke’s Hospital Site. We will 
be studying DNA in the blood, urine, cervical and tissue samples to look at 
molecular markers of gynaecological conditions that may be useful for 
diagnosis and measuring the extent of abnormal tissue removed at the time of 
surgery. Samples will be stored at the CRUK Cambridge Institute and if you 
agree these may be used in future research that has received full ethics 
committee approval.  
 
It is unlikely that any new information will be generated from this study that will 
influence your treatment or reveal genetic information that might affect family 
members. However, if any relevant information does become available during 
the course of the study this will be given to the doctor looking after you in the 
hospital. If you wish to be informed of this information your doctor will arrange 
this with the appropriate genetic counselling.  
 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time without giving a reason. A 
decision not to take part or a decision to withdraw at any time will not affect 
the standard of care that you receive. Please note that if you do choose to 
withdraw from the study, we would still like to keep stored blood or tissue for 
future research purposes. However, should you not wish us to do this, you 
can withdraw your consent and you should tell your doctor or nurses of your 
wishes. Any stored blood or tissue samples that can still be identified as yours 
will be destroyed if you wish.  
 
 
What if there is a problem?  
We will try to address any concerns you might have about any aspect of this 
study. If there are any problems, you should ask to speak with the 
researchers who will do their best to answer your questions (Telephone: 
Charlotte Hodgkin, Senior Research Nurse, 01223 348084). If you remain 
unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details on this can be obtained by contacting the 
Hospital PALS (Patient Advice and Liaison Service) on 01223 216756. 
 
In the unlikely even that something goes wrong and you are harmed as a 
result of participating in this study, compensation will be available through the 
NHS Indemnity scheme.  
 
What will happen to the results of the study? 
The results of this study will be published in scientific or medical journals and 
may be presented at scientific or medical meetings.  Please be assured it will 
not be possible to identify you in any report or publication. If you would like to 
obtain a copy of the published results please contact the research nurse 
directly who will be able to arrange this for you. 
 
Who is organising (sponsoring) and funding the study? 
This study is sponsored by Cambridge University Hospitals NHS Foundation 
Trust and The University of Cambridge. The study is being funded by the 
Medical Research Council and Target Ovarian Cancer . 
 
Who has reviewed this study? 
All research within the NHS is reviewed by an independent group of people 
called a Research Ethics Committee, to protect your interests.  This study has 
been reviewed and given favourable opinion by NRES Committee East of 
England - Cambridge East. 
Further information and contact details 
If you require any further information about this study please do not hesitate to 
contact the Research Nurse below.  Further advice on research and conduct 
of studies can be obtained from Addenbrooke’s Hospital PALS on 01223 
216756. 
 
The Senior Research Nurse is:   
Charlotte Hodgkin 
Cambridge Trials Centre,  
S4 (Box 279) 
Addenbrooke’s Hospital, Hills Road, Cambridge CB2 OQQ  
Telephone: 01223 348084 
 
Thank you for taking the time to read this Patient information Sheet.  
 
 




                  
CTCR-OV05                                  Patient Consent Form 1                  
Surgery        Version 2:December 2014 
 
copies required:   1 copy for researcher; 1 copy for patient; 1 copy to be kept with patient’s hospital notes 
 
Doctor/ Person taking consent 
Signed ….…………………………………………………….… 
Print name ….…………………………………………………. Date:  …………………………… 
Patient 
Signed ….…………………………………………………….… 
Print name ….…………………………………………………. Date:  …………………………… 
Consent for CTCR-OV05  
                                                    Please initial boxes 
 
1. I confirm that I have read the information sheet dated ….. (version…..) for the above 
study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily.       
         
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. 
 
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by responsible individuals from the Cambridge Trials Unit, 
from regulatory authorities or from the NHS trust where it is relevant to my taking part 
in research. I give permission for these individuals to have access to my records. 
 
4. I understand that the information collected about me will be used to support other 
research in the future, and may be shared anonymously with other researchers.  
 
5. I understand that my participation in this study will involve the collection of personal 
details, information about my treatment and medical history. I understand that all data 
collected about me will be held under the provisions of the 1998 Data Protection Act 
and stored in manual and electronic files in secure encoded format.  
 
6. I give permission for my GP to be notified of my participation in this research. If 
necessary, I give permission for information about my progress to be obtained from my 
GP (located via NHS databases if required), and if relevant through the Eastern Cancer 
Registration and Information Centre and understand that this will be done using my 
full name and/or NHS/hospital number. 
 
7. I agree to the identification and analysis of previously collected tissue and understand 
that this will be done using my full name and/or NHS/hospital number.   
8. I agree to the collection and storage of surplus and additional normal and abnormal 
tissue at the time of operation for a possible gynaecological condition. 
9. I agree to the collection and storage of additional blood, urine and cervical samples 
for future research into ovarian diseases, including DNA analysis. 
10. I agree to the linkage of securely encoded encrypted personal details from samples 
collected on this study, and previous stored samples. 
11.  I agree to take part in the above study 
 
 
12. OPTIONAL: I wish to be informed if research on my blood reveals genetic information 
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Study Title Molecular analysis of cervical smear samples 
Internal ref. no. A093481 
Study Design Pilot/feasibility study 
Study Participants All routine cervical smear samples showing non-cervical glandular 
abnormalities. 
Planned Sample Size 120 




Primary Objective Can somatic mutations be detected in cervical smear samples? 
Secondary 
Objectives 
Is the detection of somatic mutations in cervical smear samples a 
sensitive method for the diagnosis of ovarian cancer? 
Intervention (s) None 
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2. BACKGROUND AND RATIONALE 
Ovarian cancer (OC) is the most common cause of death in women with gynaecological 
cancers1. Due to the non-specific symptoms of OC the majority of women (60%) are 
diagnosed with advanced disease which is associated with poor survival. 5-year survival 
rates are 43% overall and over 90% for early stage tumours1.  
 
Current guidelines recommend measuring serum CA125 in all women with suspected OC 
followed by a transvaginal ultrasound scan (TVUS) in those with elevated levels2. In 
combination these are used to calculate a Risk of Malignancy Index (RMI), which guides 
referral and subsequent management3. False positive elevations are a particular problem in 
premenopausal women, who are the group most likely to present with adnexal masses. 
Although CA125 levels are elevated in 80% of cases of advanced OC <50% of cases of 
early stage cancer have an elevated CA125 resulting in missed diagnoses4.  
 
Despite decades of effort, CA125 remains the single-best biomarker for OC with models 
derived from the most promising markers failing to show improvement over serum CA125 
alone5,6. Due to the current difficulties of early diagnosis of OC and poor outcome in patients 
diagnosed with late stage disease there is therefore a pressing need to explore 
complementary strategies.  
 
One such strategy is the detection of circulating tumour DNA in blood samples.  It is known 
that blood contains free circulating DNA and in cancer patients a small fraction of this 
includes fragments of tumour DNA. DNA shed from ovarian tumours contains somatic 
mutations, which are highly specific biomarkers of cancer.  It has been shown that somatic 
mutations in ctDNA can be detected in blood samples obtained from women with advanced 
OC7.  
 
It is currently hypothesized that OC originates in the fallopian tube epithelium. Molecular 
alterations specific to OC have been identified in tubal tissue. It is therefore possible that 
detection of cells and DNA shed from this site could be utilised in the diagnosis of OC. It has 
recently been shown that tumour DNA and common somatic mutations can be detected in 
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cervical smear samples8 and cervical mucous samples9 from patients with both endometrial 
and ovarian cancers. 
 
Routine cervical screening was introduced as a method of detecting premalignant changes 
that could progress to cervical cancer. However, a small number of routine cervical smear 
samples show glandular abnormalities which suggest possible endometrial or ovarian 
abnormalities. We propose to collect all routine cervical smear samples showing glandular 
abnormalities to look for a panel of somatic mutations know to be associated with 
endometrial and ovarian cancer. If such mutations could be detected via tumour DNA in 
cervical smear samples this could theoretically be utilised particularly in primary care as a 
minimally invasive method for ovarian cancer diagnosis and screening. 
 
3. OBJECTIVES 
3.1 Primary Objective 
To determine if somatic mutations can be detected in routine cervical smear samples 
showing non-cervical glandular abnormalities. 
3.2 Secondary Objectives 
Correlation of the presence of somatic mutations with clinical diagnosis to determine if the 
detection of somatic mutations in cervical smear samples is a sensitive method for the 
diagnosis of ovarian cancer? 
4. STUDY DESIGN 
 




1. Liquid-based cervical sample identified by West Anglia Pathology Service Cervical 
Cytology Laboratory as  ‘?glandular neoplasia (non-cervical)’, code 0.  
 
2. Liquid-based cervical sample identified by West Anglia Pathology Service Cervical 
Cytology Laboratory as ‘?Glandular neoplasia of endocervical type’ (code 6) for inclusion in 
control group.  
 
3. Patient name, date of birth, NHS number and cytology classification recorded on 
password protected spreadsheet stored on cytology server network.  
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4. Sample allocated a unique code number.  Recorded on password protect 
spreadsheet stored on cytology server network.  
 
5. Patient identifiable information removed from liquid-based cervical sample and 
sample labelled with unique code number. 
 
6. At the time the liquid-based cervical sample would normally be disposed of as waste 
(ie. 2-3 weeks from time of collection) courier arranged by staff at the West Anglia Pathology 
Service Cervical Cytology Laboratory for transport of sample to Cancer Research UK 
Cambridge Institute.  
 
7. Sample collected by courier and transported to Cancer Research UK Cambridge 
Institute (CRUK CI) for collection by researcher. 
 
8. Researchers at CRUK CI informed by email (elizabeth.moore@cruk.cam.ac.uk) that 
sample has been sent. Information to be provided: unique code number, cytology 
classification, date of transfer.  
 
9. Beverley Haynes at Cambridge University Hospitals Tissue Bank informed by email 
(beverley.haynes@addenbrookes.nhs.uk ) of transfer of sample to CRUK CI. Information to 
be provided: unique code number, date of transfer.  
 
10.   DNA will be extracted from cervical smear samples by researchers at CRUK Cambridge 
Institute and sequenced for a panel of mutations known to be associated with ovarian and 
endometrial cancer. 
 
11.   There will be no change in clinical practice and all women with a cervical smear 
showing non-cervical glandular abnormalities will be referred via their GP to a gynaecologist 
for further investigation and treatment as required.  
 
12. Outcome diagnosis is obtained by West Anglia Pathology Service Cervical Cytology 
Laboratory as per current practice. When available this will be recorded on the password 
protect database stored on the cytology server network.  
 
13.   The unique code number and outcome diagnosis will provided to researchers at CRUK 
CI (elizabeth.moore@cruk.cam.ac.uk) for correlation with sequencing data. 
 
4.2 Study Participants  
4.2.1 Overall Description of Study Participants 
-All routine cervical smear samples classified by West Anglia Pathology Service Cervical 
Cytology Laboratory as showing non-cervical glandular abnormalities. 
-Cervical smear samples identified by West Anglia Pathology Service Cervical Cytology 
Laboratory as showing cervical glandular abnormalities will be used as controls.  
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4.2.2 Inclusion Criteria 
 
• All routine cervical smear samples showing non-cervical glandular abnormalities. 
• Routine cervical smear samples showing cervical glandular abnormalities will be 
included as controls. 
 
4.2.3 Exclusion Criteria 
 
The participant may not enter the study if ANY of the following apply: 
• West Anglia Pathology Service Cervical Cytology Laboratory are required to keep the 
cervical smear sample for clinical reasons. 
4.3 Study Procedures 
 
 
4.3.1 Informed Consent 
Individual women will not be contacted for consent to use their samples in this clinical study. 
As per routine clinical practice GPs are informed by the cytology service of the identification 
of a non-cervical glandular smear and referral to a gynaecologist for further investigation and 
management as clinically appropriate is advised. This procedure will not change. Samples 
provided to researchers will be annonymised and no researchers at CRUK Cambridge 
Institute will have access to any patient identifiable data. The clinical significance of a 
mutation being identified for an individual women is not yet currently understood. Specifically 
we are not looking for germline mutations so it is extremely unlikely that the research will 
reveal any genetic information that is of significance to family members.  Molecular data 
produced will therefore not be provided to the woman or treating clinician and will therefore 
not influence clinical investigation or management in any way.  
The West Anglia Pathology Service Cervical Cytology Laboratory analyse approximately 
100,000 cervical smear samples per year from six Clinical Commissioning Groups. Of these 
only 0.04% (40 samples per year) will be classified as showing non-cervical glandular 
abnormalities. It is therefore not feasible to consent all women undergoing a cervical smear 
for potential use in this study. Once a non-cervical glandular smear has been identified 
women are referred via the GP to see a gynaecologist at their local hospital. As referral to a 
gynaecologist is done by the GP to their local hospital we are unable to access this 
appointment data. We are therefore unable to contact women to discuss participation in this 
study at the time of referral to the gynaecologist particularly since the cervical smear samples 
will be disposed of 2-3 weeks after collection. 
4.3.2 Study Assessments 
DNA will be extracted from cervical smear samples and sequenced for a panel of mutations 
known to be associated with endometrial and ovarian cancer. The presence and frequency of 
somatic mutations detected will be correlated with clinical diagnosis. The sensitivity of 
molecular analysis of cervical smear samples for the diagnosis of ovarian cancer will be 
calculated. If promising this study will be extended to include a larger cohort of samples from 
other cervical cytology laboratories to assess the utility of population based cervical smears 
in screening for OC.   
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4.4 Definition of End of Study  
The end of study is the date of the last clinical diagnosis of the last participant.  
5. STATISITICS 
5.1 The Number of Participants 
Approximately 0.04% of routine cervical smears are thought to show non-cervical glandular 
abnormalities. Based on the number of smears the West Anglia Pathology Service Cervical 
Cytology Laboratory process we would expect to receive approximately 40 samples a year 
eligible for inclusion. This study will run over 3 years. We would therefore expect to obtain 
approximately 120 samples in total.  
CA125 is currently the first line test in primary care for women with suspected ovarian 
cancer. Sensitivity and specificity for CA125 with a cut off of 35IU/ml is estimated at 76.2% 
95% CI (60.5%, 87.9%) and 81.2% 95% CI (72.2%, 88.3%) respectively. (Jacobs I et al. A 
risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the 
accurate preoperative diagnosis of ovarian cancer.British Journal of Obstetrics and 
Gynaecology 1990; 97; 922-929). 
To establish if sensitivity differs significantly from 76.2% but to be 80% certain with a 
probability of 0.05 that a sensitivity as low as 60.5% would be excluded requires 63 subjects 
with the disease. To establish if specificity differs significantly from 81.2 % but to be 80% 
certain with a probability of 0.05 that a specificity as low as 72.2% would be excluded 
requires 162 subjects without the disease.  (Arkin CF, Wachtel, MS. How many patients are 
necessary to assess test performance? JAMA 1990; 263; 275-78.) 
As this is a pilot study our sample size is 120 based on the number of samples we expect to 
be able to collect over three years. If the performance characteristics of molecular analysis 
are comparable to CA125 (sensitivity not less than 60% and specificity not less than 70%) 
we would look to extend this project to other sites to reach the required sample size of 225. 
 
6. ETHICS 
6.1 Participant Confidentiality 
All samples and clinical diagnosis data will be provided to the researchers in an anonymised 
form, identified only by the unique code number. Patient name, date of birth, NHS number, 
cytology classification and clinical diagnosis will be stored in a password protected database 
on the cytology server network. Access to this database will be restricted to named 
individuals. 
 
7. DATA HANDLING AND RECORD KEEPING 
All samples will be anonymised to researchers and will be allocated a unique study number 
by which all data will be stored at CRUK Cambridge Institute on University of Cambridge 
computers.  
8. FINANCING AND INSURANCE 
This study is being sponsored by Cambridge University Hospitals NHS Trust and The 
University of Cambridge. The University of Cambridge will provide insurance for the 
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management, conduct and design of the study. The study is being funded by the Medical 
Research Council and Target Ovarian Cancer. 
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. Mutation calls for UKOPS FFPE using TAm-Seq
JBLAB number FFPE Block ID OTTA ID Histology Chromosome Gene Position Effect Ref Mutant Indel cDNA.effect Protein.effect
12201 R07-11403-REMA2 TUKO01230 high grade serous
12202 R07-20333-3A TUKO01594 endometrioid 17 TP53 7578406 nonsynonymous C T c.G524A p.R175H
12203 UH07-20421-2 TUKO01595 high grade serous
12204 R08 05206 10 TUKO01897 high grade serous
12205 UR08-11153 A1 TUKO01891 high grade serous 17 TP53 7577538 nonsynonymous C T c.G743A p.R248Q
12206 R08-14573-2 TUKO01892 high grade serous 17 TP53 7578461 nonsynonymous C A c.G469T p.V157F
12207 077 40703 1H TUKO01893 unknown 17 TP53 7577028 deletion TGCTCCCTG c.902_909delCAGGGAGC p.P301Hfs*2
12208 H06-18278-F TUKO01211 mucinous 17 TP53 7578271 nonsynonymous T G c.A578C p.H193P
12209 H07-18627-1B TUKO01208 high grade serous 17 TP53 7577108 nonsynonymous C A c.G830T p.C277F
12210 10758/06 2J TUKO01894 MMMT 17 TP53 7578271 nonsynonymous T C c.A578G p.H193R
12211 R07-4984 A TUKO00579 endometrioid
12212 R07-12950 A1 No OTTA ID high grade serous
12213 R07-18229-A1 TUKO01222 high grade serous 17 TP53 7578433 nonsynonymous G A c.C497T p.S166L
12214 07/26988 2O TUKO01552 endometrioid 12 KRAS 25398284 nonsynonymous C T c.G35A p.G12D
12215 H06-10510-4A TUKO00193 high grade serous 17 TP53 7578190 nonsynonymous T C c.A659G p.Y220C
12216 H06-16736-3G TUKO01133 adenoca NOS 7 EGFR 55259529 nonsynonymous G A c.G2587A p.G863S
unknown 17 TP53 7578493 stopgain C T c.G437A p.W146*
12217 H06-17939-2E TUKO00876 high grade serous 17 TP53 7578271 nonsynonymous T C c.A578G p.H193R
12218 H06-19212-3C TUKO00877 high grade serous
12219 17028/07 2A TUKO01510 high grade serous 17 TP53 7577570 nonsynonymous C T c.G711A p.M237I
12220 R07-6470-RESA11 TUKO00595 endometrioid
12221 R08-02196 No OTTA ID mixed clear cell/endometrioid
12222 07 36137 1G TUKO01547 clear cell 3 PIK3CA 178952085 nonsynonymous A T c.A3140T p.H1047L
12223 07 37790 1H TUKO01468 clear cell 3 PIK3CA 178952085 nonsynonymous A G c.A3140G p.H1047R
unknown 10 PTEN 89725077 nonsynonymous C T c.C1060T p.P354S
12224 H07-8844-1G TUKO01099 clear cell 17 TP53 7577142 nonsynonymous C T c.G796A p.G266R
12225 13956/06 1S TUKO01209 clear cell
12226 14646-06 1H TUKO01900 clear cell 7 EGFR 55266458 nonsynonymous G A c.G2750A p.G917E
unknown 3 PIK3CA 178952085 nonsynonymous A G c.A3140G p.H1047R
12227 6865-07 1H TUKO00763 mucinous 12 KRAS 25398284 nonsynonymous C T c.G35A p.G12D
unknown 17 TP53 7578176 insertion c.672+1G>T
12228 H07-12969-1Q TUKO01899 seromucinous 12 KRAS 25398284 nonsynonymous C G c.G35C p.G12A
12229 H07-14592-2K TUKO01174 MMMT
12230 15748-06 1P TUKO00477 low grade serous 7 BRAF 140453136 nonsynonymous A T c.T1799A p.V600E
12231 10310/07 1G TUKO01101 clear cell
12232 13385/07 1C TUKO01047 MMMT 17 TP53 7577115 nonsynonymous A C c.T823G p.C275G
unknown 3 PIK3CA 178952085 nonsynonymous A G c.A3140G p.H1047R
12233 R08 3560 A2 TUKO01896 high grade serous 17 TP53 7578271 nonsynonymous T C c.A578G p.H193R
12234 17308-06 1G TUKO00438 endometrioid 12 KRAS 25398285 nonsynonymous C T c.G34A p.G12S
unknown 3 PIK3CA 178952085 nonsynonymous A G c.A3140G p.H1047R
12235 R08 03843 A1 TUKO01904 mucinous 17 TP53 7578535 nonsynonymous T C c.A395G p.K132R
12236 R08 4332 A1 No OTTA ID mucinous 17 TP53 7578268 nonsynonymous A T c.T581A p.L194H
12237 R08-16687-2 TUKO01898 mucinous
12238 07/32430 1J TUKO01173 mucinous
12239 08-6484-1M TUKO01470 mucinous
12240 H07-477-1E TUKO01527 low grade serous 7 BRAF 140453136 nonsynonymous A T c.T1799A p.V600E
12241 H07-4056-1C TUKO00620 serous grade not known 7 BRAF 140453136 nonsynonymous A T c.T1799A p.V600E
H06-16635-2C TUKO00574 high grade serous 17 TP53 7578406 nonsynonymous C T c.G524A p.R175H
H07-803-2D TUKO01186 unknown 17 TP53 7578469 nonsynonymous C A c.G461T p.G154V
H07-16791-1C TUKO01194 unknown 17 TP53 7577111 nonsynonymous G C c.C827G p.A276G
2685/06 1A TUKO00031 high grade serous 17 TP53 7577141 nonsynonymous C T c.G797A p.G266E
14468/06 H TUKO00520 unknown 17 TP53 7576928 insertion c.920+1A>G
17106-06 1B TUKO00895 high grade serous 17 TP53 7578210 synonymous T C c.A639G c.R213R
unknown 17 TP53 7577094 nonsynonymous G A c.C844T p.R282W
unknown 10 PTEN 89717708 stopgain C T c.C733T p.Q245*
1567-07 1A TUKO01032 high grade serous 17 TP53 7578262 nonsynonymous C G c.G587C p.R196P
4870-07 1G TUKO00847 high grade serous 17 TP53 7578188 stopgain C A c.G661T p.E221*
unknown 10 PTEN 89711925 synonymous G A c.G543A p.L181L
7547-07 1G TUKO00827 high grade serous 17 TP53 7578271 nonsynonymous T C c.A578G p.H193R
9803/07 1L TUKO01106 high grade serous 12 KRAS 25398284 nonsynonymous C A c.G35T p.G12V
10868/07 C TUKO01084 high grade serous 17 TP53 7577124 nonsynonymous C T c.G814A p.V272M
14708/07 2A TUKO01094 unknown 17 TP53 7577574 nonsynonymous T G c.A707C p.Y236S




SampleName Plasma	sample	ID FFPE	block	ID OTTA	ID Type Chr Position Ref Mutant Indel Base MAF Matches	FFPE	Mutation
JBLAB_12250 116005 R07	12950	A1 No	OTTA	ID sample
JBLAB_12272 119949 R08	4332	A1 No	OTTA	ID sample
JBLAB_12285 114788 UR07	14789	A2 No	OTTA	ID sample
JBLAB_12292 121196 R08-02196-RES9 no	OTTA	ID sample 17 7577091 G A 0.200 No	FFPE	mutation
JBLAB_12292 121196 R08-02196-RES9 No	OTTA	ID sample 12 25398237 A G 0.175 No	FFPE	mutation
JBLAB_12250 116005 R07	12950	A1 No	OTTA	ID library
JBLAB_12272 119949 R08	4332	A1 No	OTTA	ID library
JBLAB_12285 114788 UR07	14789	A2 No	OTTA	ID library 10 89717629 C T 0.145 No	FFPE	sample
JBLAB_12285 114788 UR07	14789	A2 No	OTTA	ID library 10 89653817 G T 0.150 No	FFPE	sample
JBLAB_12285 114788 UR07	14789	A2 No	OTTA	ID library 10 89692912 T C 0.076 No	FFPE	sample
JBLAB_12292 121196 R08-02196-RES9 No	OTTA	ID library 10 89720772 G A 0.107 No	FFPE	mutation
JBLAB_12292 121196 R08-02196-RES9 No	OTTA	ID library 17 7577091 G A 0.269 No	FFPE	mutation
JBLAB_12292 121196 R08-02196-RES9 No	OTTA	ID library 17 7579425 C T 0.050 No	FFPE	mutation
JBLAB_12245 103618 2685/06	1A TUKO00031 sample
JBLAB_12245 103618 2685/06	1A TUKO00031 library 17 7577141 C T 0.090 Y
JBLAB_12245 103618 2685/06	1A TUKO00031 library 17 7579580 G A 0.043 N
JBLAB_12245 103618 2685/06	1A TUKO00031 library 10 89711899 C T 0.046 N
JBLAB_12246 102055 H06-10510-4A TUKO00193 sample
JBLAB_12246 102055 H06-10510-4A TUKO00193 library 17 7578190 T C 0.096 Y
JBLAB_12246 102055 H06-10510-4A TUKO00193 library 17 7577649 INS G 0.062 N
JBLAB_12246 102055 H06-10510-4A TUKO00193 library 17 7578546 INS G 0.012 N
JBLAB_12246 102055 H06-10510-4A TUKO00193 library 10 89717718 INS TG 0.056 N
JBLAB_12266 109163 17308-06	1G TUKO00438 sample 3 178952085 A G 0.135 Y
JBLAB_12266 109163 17308-06	1G TUKO00438 sample 12 25398285 C T 0.087 Y
JBLAB_12266 109163 17308-06	1G TUKO00438 library 3 178952085 A G 0.069 Y
JBLAB_12266 109163 17308-06	1G TUKO00438 library 12 25398285 C T 0.071 Y
JBLAB_12266 109163 17308-06	1G TUKO00438 library 17 7577057 INS C 0.009 N
JBLAB_12266 109163 17308-06	1G TUKO00438 library 10 89653820 INS A 0.017 N
JBLAB_12263 107979 15748-06	1P TUKO00477 sample
JBLAB_12263 107979 15748-06	1P TUKO00477 library
JBLAB_12258 102174 H06-16635-2C TUKO00574 sample
JBLAB_12258 102174 H06-16635-2C TUKO00574 library 10 89692940 INS G 0.175 N
JBLAB_12277 112211 R07-4984A TUKO00579 sample 17 7579546 DEL G 0.020 No	FFPE	mutation
JBLAB_12277 112211 R07-4984A TUKO00579 library 17 7579554 G A 0.030 No	FFPE	mutation
JBLAB_12278 112347 R07-6470-RESA11 TUKO00595 sample
JBLAB_12278 112347 R07-6470-RESA11 TUKO00595 library
JBLAB_12268 102357 H07-4056-1C TUKO00620 sample
JBLAB_12268 102357 H07-4056-1C TUKO00620 library 12 25398237 A G 0.226 N
JBLAB_12279 109878 6865-07	1H TUKO00763 sample
JBLAB_12279 109878 6865-07	1H TUKO00763 library 10 89720683 C G 0.035 N
JBLAB_12280 109898 7547-07	1G TUKO00827 sample
JBLAB_12280 109898 7547-07	1G TUKO00827 library 17 7572968 INS A 0.051 N
JBLAB_12276 109677 4870-07	1G TUKO00847 sample 17 7578188 C A 0.116 Y
JBLAB_12276 109677 4870-07	1G TUKO00847 library 17 7578188 C A 0.100 Y
JBLAB_12260 102197 H06-17939-2E TUKO00876 sample 17 7578271 T C 0.409 Y
JBLAB_12260 102197 H06-17939-2E TUKO00876 library 17 7578271 T C 0.531 Y
JBLAB_12260 102197 H06-17939-2E TUKO00876 library 10 89711903 INS TG 0.028 N
JBLAB_12264 102235 H06-19212-3C TUKO00877 sample
JBLAB_12264 102235 H06-19212-3C TUKO00877 library 17 7573936 INS C 0.020 No	FFPE	mutation
JBLAB_12265 109130 17106-06	1B TUKO00895 sample
JBLAB_12265 109130 17106-06	1B TUKO00895 library 17 7577094 G A 0.041 Y
JBLAB_12265 109130 17106-06	1B TUKO00895 library 12 25398234 INS A 0.009 N	
JBLAB_12265 109130 17106-06	1B TUKO00895 library 10 89692782 INS T 0.077 N	
JBLAB_12269 109350 1567-07	1A TUKO01032 sample 17 7578262 C G 0.232 Y
JBLAB_12269 109350 1567-07	1A TUKO01032 library 17 7578262 C G 0.217 Y
JBLAB_12269 109350 1567-07	1A TUKO01032 library 3 178936051 INS A 0.020 N	
JBLAB_12251 114379 13385/07	1C TUKO01047 sample 17 7577115 A C 0.263 Y
JBLAB_12251 114379 13385/07	1C TUKO01047 library
JBLAB_12290 114186 10868/07	C TUKO01084 sample 12 25398237 A G 0.236 N	
JBLAB_12290 114186 10868/07	C TUKO01084 library 17 7579546 INS G 0.033 N	
JBLAB_12248 113029 H07-8844-1G TUKO01099 sample
JBLAB_12248 113029 H07-8844-1G TUKO01099 library
JBLAB_12282 114081 10310/07	1G TUKO01101 sample
JBLAB_12282 114081 10310/07	1G TUKO01101 library
JBLAB_12281 114085 9803/07	1L TUKO01106 sample
JBLAB_12281 114085 9803/07	1L TUKO01106 library
JBLAB_12261 102184 H06-16736-3G TUKO01133 sample
JBLAB_12261 102184 H06-16736-3G TUKO01133 library
JBLAB_12294 111798 07/32430	1J TUKO01173 sample
JBLAB_12294 111798 07/32430	1J TUKO01173 library
JBLAB_12284 113109 H07-14592-2K TUKO01174 sample 17 7578290 C T 0.111 No	FFPE	mutation
SampleName Plasma	sample	ID FFPE	block	ID OTTA	ID Type Chr Position Ref Mutant Indel Base MAF Matches	FFPE	Mutation
JBLAB_12284 113109 H07-14592-2K TUKO01174 library 17 7578290 C T 0.075 No	FFPE	mutation
JBLAB_12284 113109 H07-14592-2K TUKO01174 library 17 7573966 INS G 0.034 No	FFPE	mutation
JBLAB_12293 113157 H07-18627-1B TUKO01208 sample 17 7577108 C A 0.084 Y
JBLAB_12293 113157 H07-18627-1B TUKO01208 library 17 7577108 C A 0.240 Y
JBLAB_12257 107793 13956/06	1S TUKO01209 sample
JBLAB_12257 107793 13956/06	1S TUKO01209 library 12 25398262 DEL A 0.016 No	FFPE	mutation
JBLAB_12259 102194 H06-18278-F TUKO01211 sample
JBLAB_12259 102194 H06-18278-F TUKO01211 library 17 7578464 G A 0.079 N	
JBLAB_12259 102194 H06-18278-F TUKO01211 library 10 89725078 C T 0.062 N	
JBLAB_12259 102194 H06-18278-F TUKO01211 library 10 89624308 DEL T 0.057 N	
JBLAB_12255 116478 R07-18229-A1 TUKO01222 sample 10 89717628 G A 0.441 N	
JBLAB_12255 116478 R07-18229-A1 TUKO01222 library
JBLAB_12249 112196 R07-11403-REMA2 TUKO01230 sample
JBLAB_12249 112196 R07-11403-REMA2 TUKO01230 library
JBLAB_12286 118518 07	37790	1H TUKO01468 sample 12 25398237 A G 0.232 N	
JBLAB_12286 118518 07	37790	1H TUKO01468 library 10 89692844 DEL AA 0.267 N	
JBLAB_12253 118607 08-6484-1M TUKO01470 sample
JBLAB_12253 118607 08-6484-1M TUKO01470 library 17 7577140 INS C 0.075 No	FFPE	mutation
JBLAB_12287 117956 17801/07	2H TUKO01493 sample
JBLAB_12287 117956 17801/07	2H TUKO01493 library
JBLAB_12256 117896 17028/07	2A TUKO01510 sample
JBLAB_12256 117896 17028/07	2A TUKO01510 library 17 7579850 DEL T 0.044 N
JBLAB_12267 102274 H07-477-1E TUKO01527 sample
JBLAB_12267 102274 H07-477-1E TUKO01527 library 10 89653851 INS TGA 0.055 N
JBLAB_12254 118512 07	36137	1G TUKO01547 sample
JBLAB_12254 118512 07	36137	1G TUKO01547 library 17 7579409 DEL G 0.009 N
JBLAB_12252 111751 07/26988	2O TUKO01552 sample
JBLAB_12252 111751 07/26988	2O TUKO01552 library 10 89717630 C T 0.220 N	
JBLAB_12252 111751 07/26988	2O TUKO01552 library 17 7577583 DEL G 0.013 N	
JBLAB_12252 111751 07/26988	2O TUKO01552 library 10 89685226 INS T 0.098 N	
JBLAB_12252 111751 07/26988	2O TUKO01552 library 10 89720680 DEL T 0.056 N	
JBLAB_12289 116355 R07-20333-3A TUKO01594 sample
JBLAB_12289 116355 R07-20333-3A TUKO01594 library 10 89711901 C T 0.523 N
JBLAB_12289 116355 R07-20333-3A TUKO01594 library 10 89690895 C T 0.168 N
JBLAB_12288 116379 UH07-20421-2 TUKO01595 sample 17 7578413 C A 0.146 No	FFPE	mutation
JBLAB_12288 116379 UH07-20421-2 TUKO01595 library 17 7578413 C A 0.104 No	FFPE	mutation
JBLAB_12283 123230 UR08-11153	A	1 TUKO01891 sample 17 7577538 C T 0.121 Y
JBLAB_12283 123230 UR08-11153	A	1 TUKO01891 library
JBLAB_12271 123253 R08-14573-2 TUKO01892 sample
JBLAB_12271 123253 R08-14573-2 TUKO01892 library
JBLAB_12247 107615 10758/06	2J TUKO01894 sample 17 7578271 T C 0.237 Y
JBLAB_12247 107615 10758/06	2J TUKO01894 library 17 7578271 T C 0.195 Y
JBLAB_12275 119975 R08	3560	A2 TUKO01896 sample 10 89725053 T C 0.026 N
JBLAB_12275 119975 R08	3560	A2 TUKO01896 library
JBLAB_12274 123195 R08	05206	10 TUKO01897 sample 17 7577498 C A 0.291 No	FFPE	mutation
JBLAB_12274 123195 R08	05206	10 TUKO01897 library 17 7577498 C A 0.390 No	FFPE	mutation
JBLAB_12274 123195 R08	05206	10 TUKO01897 library 17 7572995 DEL G 0.040 No	FFPE	mutation
JBLAB_12274 123195 R08	05206	10 TUKO01897 library 10 89692981 INS G 0.523 No	FFPE	mutation
JBLAB_12270 123277 R08-16687-2 TUKO01898 sample 12 25398237 A G 0.170 No	FFPE	mutation
JBLAB_12270 123277 R08-16687-2 TUKO01898 library
JBLAB_12291 113084 H07-12969-1Q TUKO01899 sample
JBLAB_12291 113084 H07-12969-1Q TUKO01899 library 17 7576835 G A 0.047 N	
JBLAB_12291 113084 H07-12969-1Q TUKO01899 library 10 89692797 INS C 0.030 N	
JBLAB_12262 107895 14646-06	1H TUKO01900 sample
JBLAB_12262 107895 14646-06	1H TUKO01900 library 10 89720775 C T 0.465 N	
JBLAB_12262 107895 14646-06	1H TUKO01900 library 17 7577118 DEL A 0.018 N	
JBLAB_12273 122982 R08	03843	A1 TUKO01904 sample
JBLAB_12273 122982 R08	03843	A1 TUKO01904 library 17 7572990 INS T 0.082 N
l
Sample Name Patient Id Type Chr Position Ref Mutant Barcode_1 Barcode_2 MAF Error Detected
JBLAB_12245 TUKO00031 sample 17 7577141 C T FLD0097 FLD0121 0.001361 0.001381789 FALSE
JBLAB_12245 TUKO00031 library 17 7577141 C T FLD0203 FLD0227 0.090944 0.001138821 TRUE
JBLAB_12246 TUKO00193 sample 17 7578190 T C FLD0098 FLD0122 0.1164595 0.002834168 TRUE
JBLAB_12246 TUKO00193 library 17 7578190 T C FLD0204 FLD0228 0.098622 0.002855301 TRUE
JBLAB_12247 TUKO01894 sample 17 7578271 T C FLD0099 FLD0123 0.23786425 0.000175222 TRUE
JBLAB_12247 TUKO01894 library 17 7578271 T C FLD0205 FLD0229 0.194914 0.00017485 TRUE
JBLAB_12248 TUKO01099 sample 17 7577142 C T FLD0100 FLD0124 0.01486025 0.001600774 TRUE
JBLAB_12248 TUKO01099 library 17 7577142 C T FLD0206 FLD0230 0.010095 0.001638061 FALSE
JBLAB_12251 TUKO01047 sample 17 7577115 A C FLD0103 FLD0127 0.26347 0.000227617 TRUE
JBLAB_12251 TUKO01047 sample 3 178952085 A G FLD0103 FLD0127 0.26347 0.000541479 TRUE
JBLAB_12251 TUKO01047 library 17 7577115 A C FLD0209 FLD0233 0.18018 0.000238161 TRUE
JBLAB_12251 TUKO01047 library 3 178952085 A G FLD0209 FLD0233 0.18018 0.000325236 TRUE
JBLAB_12252 TUKO01552 sample 12 25398284 C T FLD0104 FLD0128 0.0491965 0.001408396 TRUE
JBLAB_12252 TUKO01552 library 12 25398284 C T FLD0210 FLD0234 0.007888 0.001359644 TRUE
JBLAB_12254 TUKO01547 sample 3 178952085 A T FLD0106 FLD0130 0.0002495 0.000541479 FALSE
JBLAB_12254 TUKO01547 library 3 178952085 A T FLD0212 FLD0236 0.000183 0.000325236 FALSE
JBLAB_12255 TUKO01222 sample 17 7578433 G A FLD0107 FLD0131 0.00039725 0.001572223 FALSE
JBLAB_12255 TUKO01222 library 17 7578433 G A FLD0213 FLD0237 0.000743 0.001031628 FALSE
JBLAB_12256 TUKO01510 sample 17 7577570 C T FLD0108 FLD0132 0.03659475 0.00123582 TRUE
JBLAB_12256 TUKO01510 library 17 7577570 C T FLD0214 FLD0238 0.000872 0.001076814 FALSE
JBLAB_12258 TUKO00574 sample 17 7578406 C T FLD0110 FLD0134 0.01329525 0.002254892 TRUE
JBLAB_12258 TUKO00574 library 17 7578406 C T FLD0241 FLD0265 0.00298 0.003091521 FALSE
JBLAB_12259 TUKO01211 sample 17 7578271 T G FLD0111 FLD0135 0.00005775 0.000175222 FALSE
JBLAB_12259 TUKO01211 library 17 7578271 T G FLD0242 FLD0266 0.000044 0.00017485 FALSE
JBLAB_12260 TUKO00876 sample 17 7578271 T C FLD0112 FLD0136 0.40903625 0.000175222 TRUE
JBLAB_12260 TUKO00876 library 17 7578271 T C FLD0243 FLD0267 0.545642 0.00017485 TRUE
JBLAB_12261 TUKO01133 sample 7 55259529 G A FLD0113 FLD0137 0.0474065 0 TRUE
JBLAB_12261 TUKO01133 sample 17 7578493 C T FLD0113 FLD0137 0.0474065 0.001108214 TRUE
JBLAB_12261 TUKO01133 library 7 55259529 G A FLD0244 FLD0268 0.035563 0 TRUE
JBLAB_12261 TUKO01133 library 17 7578493 C T FLD0244 FLD0268 0.035563 0.001110341 TRUE
JBLAB_12262 TUKO01900 sample 7 55266458 G A FLD0114 FLD0138 0.016153 0 TRUE
JBLAB_12262 TUKO01900 sample 3 178952085 A G FLD0114 FLD0138 0.016153 0.000541479 TRUE
JBLAB_12262 TUKO01900 library 7 55266458 G A FLD0245 FLD0269 0.004137 0 TRUE
JBLAB_12262 TUKO01900 library 3 178952085 A G FLD0245 FLD0269 0.004137 0.000325236 TRUE
JBLAB_12263 TUKO00477 sample 7 140453136 A T FLD0115 FLD0139 0.00036825 0.000247788 TRUE
JBLAB_12263 TUKO00477 library 7 140453136 A T FLD0246 FLD0270 0.00021 0.00018023 TRUE
JBLAB_12265 TUKO00895 sample 17 7578210 T C FLD0117 FLD0141 0.52998175 0.004167561 TRUE
JBLAB_12265 TUKO00895 sample 17 7577094 G A FLD0117 FLD0141 0.52998175 0.003816157 TRUE
JBLAB_12265 TUKO00895 sample 10 89717708 C T FLD0117 FLD0141 0.52998175 0.001065201 TRUE
JBLAB_12265 TUKO00895 library 17 7578210 T C FLD0248 FLD0272 0.523769 0.003644538 TRUE
JBLAB_12265 TUKO00895 library 17 7577094 G A FLD0248 FLD0272 0.523769 0.003610661 TRUE
JBLAB_12265 TUKO00895 library 10 89717708 C T FLD0248 FLD0272 0.523769 0.000938832 TRUE
JBLAB_12266 TUKO00438 sample 12 25398285 C T FLD0118 FLD0142 0.087477 0.001765522 TRUE
JBLAB_12266 TUKO00438 sample 3 178952085 A G FLD0118 FLD0142 0.087477 0.000541479 TRUE
. Speci ic variantmutation calls forUKOPSplasmaus-
ing TAm-Seq
li
Sample Name Patient Id Type Chr Position Ref Mutant Barcode_1 Barcode_2 MAF Error Detected
JBLAB_12266 TUKO00438 library 12 25398285 C T FLD0249 FLD0273 0.065399 0.002083602 TRUE
JBLAB_12266 TUKO00438 library 3 178952085 A G FLD0249 FLD0273 0.065399 0.000325236 TRUE
JBLAB_12267 TUKO01527 sample 7 140453136 A T FLD0119 FLD0143 0.00009475 0.000247788 FALSE
JBLAB_12267 TUKO01527 library 7 140453136 A T FLD0250 FLD0274 0.000179 0.00018023 FALSE
JBLAB_12268 TUKO00620 sample 7 140453136 A T FLD0145 FLD0169 0.00036825 0.000247788 TRUE
JBLAB_12268 TUKO00620 library 7 140453136 A T FLD0251 FLD0275 0.000676 0.00018023 TRUE
JBLAB_12269 TUKO01032 sample 17 7578262 C G FLD0146 FLD0170 0.23182725 0.000202268 TRUE
JBLAB_12269 TUKO01032 library 17 7578262 C G FLD0252 FLD0276 0.21737 0.000147171 TRUE
JBLAB_12271 TUKO01892 sample 17 7578461 C A FLD0148 FLD0172 0 3.68701E-05 FALSE
JBLAB_12271 TUKO01892 library 17 7578461 C A FLD0254 FLD0278 0.000326 3.30116E-05 TRUE
JBLAB_12272 R08 4332 A1 sample 17 7578268 A T FLD0149 FLD0173 0.00048325 0.000651232 FALSE
JBLAB_12272 R08 4332 A1 library 17 7578268 A T FLD0255 FLD0279 0.000787 0.000548336 TRUE
JBLAB_12273 TUKO01904 sample 17 7578535 T C FLD0150 FLD0174 0.01515 0.005395687 TRUE
JBLAB_12273 TUKO01904 library 17 7578535 T C FLD0256 FLD0280 0.003603 0.004871951 FALSE
JBLAB_12275 TUKO01896 sample 17 7578271 T C FLD0152 FLD0176 0.00617375 0.000175222 TRUE
JBLAB_12275 TUKO01896 library 17 7578271 T C FLD0258 FLD0282 0.021145 0.00017485 TRUE
JBLAB_12276 TUKO00847 sample 17 7578188 C A FLD0153 FLD0177 0.1169525 5.62495E-05 TRUE
JBLAB_12276 TUKO00847 sample 10 89711925 G A FLD0153 FLD0177 0.1169525 0.002322851 TRUE
JBLAB_12276 TUKO00847 library 17 7578188 C A FLD0259 FLD0283 0.098876 4.58496E-05 TRUE
JBLAB_12276 TUKO00847 library 10 89711925 G A FLD0259 FLD0283 0.098876 0.002104682 TRUE
JBLAB_12279 TUKO00763 sample 12 25398284 C T FLD0156 FLD0180 0.00158875 0.001408396 TRUE
JBLAB_12279 TUKO00763 sample 17 7578176 FLD0156 FLD0180 0.00158875 #N/A FALSE
JBLAB_12279 TUKO00763 sample 17 7578176 INS 1 FALSE
JBLAB_12279 TUKO00763 library 12 25398284 C T FLD0262 FLD0286 0.001071 0.001359644 FALSE
JBLAB_12279 TUKO00763 library 17 7578176 FLD0262 FLD0286 0.001071 0 TRUE
JBLAB_12279 TUKO00763 library 17 7578176 INS 1 FALSE
JBLAB_12280 TUKO00827 sample 17 7578271 T C FLD0157 FLD0181 0.0045595 0.000175222 TRUE
JBLAB_12280 TUKO00827 library 17 7578271 T C FLD0263 FLD0287 0.003685 0.00017485 TRUE
JBLAB_12281 TUKO01106 sample 12 25398284 C A FLD0158 FLD0182 0.000099 0.001408396 FALSE
JBLAB_12281 TUKO01106 library 12 25398284 C A FLD0289 FLD0313 0.000581 0.001359644 FALSE
JBLAB_12283 TUKO01891 sample 17 7577538 C T FLD0160 FLD0184 0.12103725 0.002176205 TRUE
JBLAB_12283 TUKO01891 library 17 7577538 C T FLD0291 FLD0315 0.064318 0.002722134 TRUE
JBLAB_12286 TUKO01468 sample 3 178952085 A G FLD0163 FLD0187 0.01175625 0.000541479 TRUE
JBLAB_12286 TUKO01468 sample 10 89725077 C T FLD0163 FLD0187 0.01175625 0.001736959 TRUE
JBLAB_12286 TUKO01468 library 3 178952085 A G FLD0294 FLD0318 0.004957 0.000325236 TRUE
JBLAB_12286 TUKO01468 library 10 89725077 C T FLD0294 FLD0318 0.004957 0.001097507 TRUE
JBLAB_12287 TUKO01493 sample 17 7574003 G A FLD0164 FLD0188 0.03223925 0.002236027 TRUE
JBLAB_12287 TUKO01493 library 17 7574003 G A FLD0295 FLD0319 0.035589 0.001918542 TRUE
JBLAB_12289 TUKO01594 sample 17 7578406 C T FLD0166 FLD0190 0.00654775 0.002254892 TRUE
JBLAB_12289 TUKO01594 library 17 7578406 C T FLD0297 FLD0321 0.001732 0.003091521 FALSE
JBLAB_12290 TUKO01084 sample 17 7577124 C T FLD0167 FLD0191 0.002137 0.001586276 TRUE
JBLAB_12290 TUKO01084 library 17 7577124 C T FLD0298 FLD0322 0.002153 0.001595454 TRUE
JBLAB_12291 TUKO01899 sample 12 25398284 C G FLD0194 FLD0218 0.00191025 0.001408396 TRUE
JBLAB_12291 TUKO01899 library 12 25398284 C G FLD0299 FLD0323 0.000106 0.001359644 FALSE
JBLAB_12293 TUKO01208 sample 17 7577108 C A FLD0196 FLD0220 0.0846355 0.000117562 TRUE
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. Speci ic variant calls for CTCR-OV plasma using
TAm-Seq
OV04 Chr Position Ref Mutant Type Length	 Base MAF Background	error Mutation	detected
34 17 7577570 C T 0.003 0.001 Y
72 17 7578275 G A 0.004 0.002 Y
74 17 7578526 C T 0.072 0.002 Y
75 17 7576855 G A 0.006 0.001 Y
95 17 7578290 C T 0.001 0.002 N
127 17 7577120 C T 0.008 0.003 Y
133 17 7578493 C T 0.001 0.001 N
167 17 7577539 G A 0.008 0.000 Y
176 17 7577536 T C 0.007 0.005 Y
191 17 7577538 C T 0.003 0.003 N
194 17 7577095 G C 0.000 0.000 N
217 17 7578204 A C 0.028 0.000 Y
254 17 7578555 C T 0.001 0.001 N
259 17 7577560 A C 0.002 0.000 Y
260 17 7577106 G A 0.159 0.001 Y
266 17 7578542 G C 0.077 0.000 Y
280 17 7577578 INS 1 C 0.000 NA N
294 17 7578423 C T 0.001 0.001 T
314 17 7578190 T C 0.021 0.004 Y
316 17 7578442 T C 0.003 0.002 Y
318 17 7577120 C T 0.010 0.003 Y
319 17 7576852 C T 0.035 0.001 Y
333 17 7577114 C T 0.001 0.001 T
334 17 7577570 C T 0.001 0.001 F
338 17 7578212 G A 0.011 0.003 Y
348 17 7578212 G A 0.008 0.003 Y
362 17 7578413 C A 0.006 0.000 Y
364 17 7578266 T A 0.030 0.000 Y
375 17 7578190 T C 0.008 0.004 Y
382 17 7578279 INS 1 G 0.000 NA N
392 17 7573999 INS 19 CTCGGAACATCTCGAAGCG 0.000 NA N
399 17 7578263 G A 0.055 0.003 Y
402 17 7579511 C T 0.001 0.002 N
409 17 7577610 T G 0.433 0.000 Y
410 17 7573926 C T 0.001 0.001 N
414 17 7577539 G A 0.003 0.000 Y
416 17 7577022 G A 0.161 0.002 Y
428 17 7578403 C G 0.084 0.002 Y
434 17 7577118 INS 1 T 0.000 NA N
444 17 7578203 C T 0.198 0.001 Y
452 17 7578406 C T 0.067 0.002 Y
461 17 7576852 C T 0.050 0.001 Y
467 17 7577114 C T 0.029 0.001 Y
473 17 7578442 T C 0.107 0.002 Y
475 17 7577120 C A 0.013 0.003 Y
485 17 7576897 G A 0.580 0.002 Y
488 17 7578190 T C 0.013 0.004 Y
489 17 7578280 G A 0.005 0.002 Y
495 17 7578406 C T 0.008 0.002 Y
516 17 7577539 G A 0.007 0.000 Y
525 17 7577517 A G 0.019 0.003 Y
527 17 7577581 A T 0.605 0.000 Y
539 17 7577157 T G 0.000 0.001 N
551 17 7578265 A G 0.005 0.004 Y
588 17 7577574 T C 0.050 0.002 Y
606 17 7577556 C T 0.005 0.002 Y
611 17 7577120 C A 0.235 0.003 Y
622 17 7578433 G C 0.000 0.000 N
627 17 7577121 G A 0.009 0.003 Y
629 17 7577121 G A 0.030 0.003 Y
645 17 7578508 C T 0.047 0.002 Y
648 17 7577539 G C 0.259 0.000 Y
670 17 7577142 C T 0.005 0.002 Y
686 17 7577497 A C 0.184 0.000 Y
701 17 7578406 C T 0.310 0.002 Y
707 17 7577517 A C 0.001 0.003 N
709 17 7578263 G A 0.003 0.003 T
711 17 7578190 T C 0.152 0.004 Y
713 17 7574003 G A 0.377 0.003 Y
714 17 7578554 A T 0.033 0.000 Y
715 17 7577079 C A 0.075 0.000 Y
716 17 7574012 C A 0.224 0.001 Y
740 17 7578496 A T 0.044 0.000 Y
749 17 7577559 G A 0.003 0.001 Y
751 17 7577539 G A 0.003 0.002 T
758 17 7578535 T C 0.010 NA T
776 17 7578461 C A 0.001 NA T
788 17 7577509 C A 0.043 NA T
791 17 7574003 G A 0.006 0.003 T
805 17 7578176 C A 0.023 NA T
847 17 7577094 G A 0.005 0.004 Y
853 17 7577529 A T 0.024 0.000 Y
870 17 7578455 DEL 9 GCGGACGCG 0.013 NA Y
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Enhanced detection of circulating tumor DNA by fragment size analysis  
 
One sentence summary: Selective sequencing or in silico analysis for differences in DNA 
fragment size can improve the detection of circulating tumor DNA 
 
Authors: Florent Mouliere1, 2, †, Dineika Chandrananda1, 2, †, Anna M. Piskorz1, 2, †, Elizabeth 
K. Moore1, 2, 3, †, James Morris1, 2, Lise Barlebo Ahlborn4, 5, Richard Mair1, 2, 6, Teodora 
Goranova1, 2, Francesco Marass1, 2, 7, 8, Katrin Heider1, 2, Jonathan C. M. Wan1, 2, Anna 
Supernat1, 2, 9, Irena Hudecova1, 2, Ioannis Gounaris1, 2, 3, Susana Ros1, 2, Mercedes Jimenez-
Linan2, 3, Javier Garcia-Corbacho10, Keval Patel1, 2, Olga Østrup5, Suzanne Murphy1, 2, 
Matthew D. Eldridge1, 2, Davina Gale1, 2, Grant D. Stewart2, 11, Johanna Burge2, 11, Wendy N. 
Cooper1, 2, Michiel S. van der Heijden12, 13, Charles E. Massie1, 2, Colin Watts14, Pippa 
Corrie3, Simon Pacey3, 15, Kevin Brindle1, 2, 16, Richard D. Baird17, Morten Mau-Sørensen4, 
Christine A. Parkinson1, 2, 3, 18, 19, Christopher G. Smith1, 2, James D. Brenton1, 2, 3, 18, 19, #, *, 
Nitzan Rosenfeld1, 2, #, *. 
  
Affiliations: 
1.    Cancer Research UK Cambridge Institute, University of Cambridge, CB2 0RE, Cambridge, UK. 
2.    Cancer Research UK Major Centre – Cambridge, Cancer Research UK Cambridge Institute, CB2 0RE, Cambridge, UK. 
3.    Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ, Cambridge, UK. 
4.    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, DK-2100, Denmark. 
5.    Centre for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, DK-2100, Denmark. 
6.    Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, CB2 0QQ, Cambridge, UK. 
7.    Department of Biosystems Science and Engineering, ETH Zurich, 4058, Basel, Switzerland. 
8.    Swiss Institute of Bioinformatics, 4058, Basel, Switzerland. 
9.    Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical 
University of Gdańsk, 80-211, Poland. 
10.    Clinical Trials Unit, Clinic Institute of Haematological and Oncological Diseases, Hospital Clinic de Barcelona, 170 08036, 
Barcelona, Spain. 
11.    Academic Urology Group, Department of Surgery, University of Cambridge, CB2 0QQ, Cambridge, UK. 
12.    Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands. 
13.    Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands. 
14.    Institute of Cancer Genomics Science, University of Birmingham, B15 2TT, Birmingham, UK. 
15.    Department of Oncology, University of Cambridge, CB2 0XZ, Cambridge, UK. 
16.    Department of Biochemistry, University of Cambridge, CB2 1QW, Cambridge, UK. 
17.    Early Phase Clinical Trials and Breast Cancer Research Teams, Cancer Research UK Cambridge Centre, CB2 0QQ, 
Cambridge, UK. 
18.    Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, CB2 0XZ, Cambridge, UK. 
19.    NIHR Cambridge Biomedical Research Centre, CB2 0QQ, Cambridge, UK. 
*Correspondence to:  James D. Brenton (james.brenton@cruk.cam.ac.uk) and Nitzan 
Rosenfeld (nitzan.rosenfeld@cruk.cam.ac.uk). 







Abstract: Existing methods to improve detection of ctDNA have focused on sensitivity 
of mutation detection and not the biological properties of plasma cell-free DNA (cfDNA). We 
hypothesized that differences in fragment lengths of circulating DNA could be exploited to 
enhance sensitivity for detecting the presence of ctDNA and for non-invasive genomic 
analysis of cancer. We surveyed ctDNA fragment sizes in 344 plasma samples from 200 
cancer patients using low-pass whole-genome sequencing (0.4×). To establish the size 
distribution of mutant ctDNA, tumor-guided personalized deep sequencing was performed in 
in 19 patients. We detected enrichment of ctDNA in fragment sizes between 90–150 bp, and 
developed methods for in vitro and in silico size selection of these fragments. Selecting 
fragments between 90–150 bp improved detection of tumor DNA by more than 2-fold median 
enrichment in >95% of cases, and by more than 4-fold enrichment in >10% of cases. 
Analysis of size-selected cfDNA identified clinically actionable mutations and copy number 
alterations that were otherwise not detected. Identification of patients with advanced cancer 
was improved by predictive models integrating fragment length and copy number analysis of 
cfDNA with AUC>0.99 compared to AUC<0.80 without fragmentation features. Increased 
detection of cfDNA from patients with glioma, renal and pancreatic cancer patients was 
achieved with AUC>0.91, compared to AUC<0.5 without fragmentation features. Fragment-
size analysis and selective sequencing of specific fragment sizes can boost ctDNA 
detection, and could be an alternative to deeper mutation sequencing for clinical 





Blood plasma of cancer patients contains circulating tumor DNA (ctDNA), but this valuable 
source of information is diluted by much larger quantities of DNA of non-cancerous origins: 
ctDNA therefore represents only a small fraction of the total cell-free DNA (cfDNA) (1, 2). 
High-depth targeted sequencing of selected genomic regions can be used to detect low 
levels of ctDNA, but broader analysis with methods such as whole exome sequencing 
(WES) and shallow whole genome sequencing (sWGS) are only generally informative when 
ctDNA levels are ~10% or greater (3–5). The concentration of ctDNA can exceed 10% of the 
total cfDNA in patients with advanced-stage cancers (6–8), but is much lower in patients with 
low tumor burden (9–12) and in patients with some cancer types such as gliomas and renal 
cancers (6). Current strategies to improve ctDNA detection rely on increasing depth of 
sequencing coupled with various error-correction methods (2, 13, 14). However, approaches 
that focus only on mutation analysis do not take advantage of the potential differences in 
chromatin organization or fragment size in ctDNA (15–17). Results of ever-deeper 
sequencing are also confounded by the likelihood of false positive results from detection of 
mutations from non-cancerous cells or clonal expansions in normal epithelia, or clonal 
hematopoiesis of indeterminate potential (CHIP) (13, 18, 19). 
  
The cell of origin and the mechanism of cfDNA release into blood can mark cfDNA with 
specific fragmentation signatures, potentially providing precise information about cell type, 
gene expression, oncogenic potential or action of treatment (15, 16, 20). cfDNA fragments 
3 
commonly show a prominent mode at 167 bp, suggesting release from apoptotic caspase-
dependent cleavage (21–24) (Fig. 1A). Circulating fetal DNA has been shown to be shorter 
than maternal DNA in plasma, and these size differences have been used to improve 
sensitivity of non-invasive prenatal diagnosis (22, 25–27). The size distribution of tumor-
derived cfDNA has only been investigated in a few studies, encompassing a small number of 
cancer types and patients, and shows conflicting results (28–33). A limitation of previous 
studies is that determining the specific sizes of tumor-derived DNA fragments requires 
detailed characterization of matched tumor-derived alterations (30, 33), and the broader 
understanding and implications of potential biological differences have not previously been 
explored. 
  
We hypothesized we could improve sensitivity for non-invasive cancer genomics by selective 
sequencing of ctDNA fragments, and leveraging differences in the biology that determines 
DNA fragmentation. As a proof of concept, we established a pan-cancer catalogue of cfDNA 
fragmentation features in plasma samples from patients with different cancer types and 
healthy individuals to identify biological features enriched in tumor-derived DNA. We 
developed methods for selecting specific sizes of cfDNA fragments prior to sequencing, and 
investigated the impact of combining cfDNA size selection with genome-wide sequencing to 




Surveying the fragmentation features of tumor cfDNA. 
We generated a catalogue of cfDNA fragmentation features (Fig. 1A) from 344 plasma 
samples from 200 patients with 18 different cancer types, and additional 65 plasma samples 
from healthy controls (Fig. 1B, Suppl. Fig. 1, Suppl. Table 1 and Suppl. Table 2). The size 
distribution of cfDNA fragments in cancer patients differed in the size ranges of 90–150 bp, 
180–220 bp and 250–320 bp compared to healthy individuals (Fig. 1B and Suppl. Fig. 2). 
cfDNA fragment sizes in plasma of healthy individuals, and in plasma of patients with late 
stage glioma, renal, pancreatic and bladder cancers, were significantly longer than in other 
late stage cancer types including breast, ovarian, lung, melanoma, colorectal and 
cholangiocarcinoma (p<0.001, Kruskal-Wallis; Fig. 1C). Sorting the 18 cancer types 
according to the proportion of cfDNA fragments in the size range 20–150 bp was very similar 
to ordering by Bettegowda et al. based on the concentrations of ctDNA measured by 
individual mutation assays (Fig. 1D) (6). In contrast to previous reports (6, 34), this sorting 
analysis was performed without any prior knowledge of the presence of mutations or somatic 
copy number alterations (SCNAs), yet allowed the investigation of ctDNA content in different 
cancers.  
  
Sizing up mutant ctDNA. 
4 
We determined the size profile of mutant ctDNA in plasma using two high specificity 
approaches. First, we inferred the specific size profile of ctDNA and non-tumor cfDNA with 
sWGS from the plasma of mice bearing human ovarian cancer xenografts (Fig. 2A). We 
observed a shift in ctDNA fragment sizes to less than 167 bp (Fig. 2B). Second, the size 
profile of mutant ctDNA was determined in plasma from 19 cancer patients, using deep 
sequencing with patient-specific hybrid-capture panels developed from whole-exome 
profiling of matched tumor samples (Fig. 2C). By sequencing hundreds of mutations at a 
depth >300× in cfDNA, allele-specific reads from mutant and normal DNA were obtained. 
Enrichment of DNA fragments carrying tumor-mutated alleles was observed in fragments 
~20–40 bp shorter than nucleosomal DNA sizes (multiples of 167 bp) (Fig. 2D). We 
determined that mutant ctDNA is generally more fragmented than non-mutant cfDNA, with a 
maximum enrichment of ctDNA in fragments between 90 and 150 bp (Suppl. Fig. 3), as well 
as enrichment in the size range 250–320 bp. These data also indicated that mutant DNA in 
plasma of patients with advanced cancer (pre-treatment) is consistently shorter than 
predicted mono-, and di-nucleosomal DNA fragment lengths (Fig. 2D). 
  
Selecting tumor-derived DNA fragments. 
These data indicated that ctDNA is shorter than non-tumor cfDNA and suggested that 
biological differences in fragment lengths could be harnessed to improve ctDNA detection. 
We determined the feasibility of selective sequencing of shorter fragments using in vitro size 
selection with a bench-top microfluidic device followed by sWGS, in 48 plasma samples from 
35 patients with high-grade serous ovarian cancer (HGSOC) (Fig. 3A) (Suppl. Fig. 4 and 
Suppl. Fig. 5). We assessed the accuracy and quality of the size selection with the plasma 
from 20 healthy individuals (Fig. 3B and Suppl. Fig. 6). We also explored the utility of in 
silico size selection of fragmented DNA using read-pair positioning from unprocessed sWGS 
data (Fig. 3A). In silico size selection was performed once reads were aligned to the 
genome reference, by selecting the paired-end reads that corresponded to the fragments 
lengths in a 90–150 bp size range. Fig. 3C, Fig. 3D and Fig. 3E illustrate the effect of in vitro 
size selection for one HGSOC case (see all 5 samples in Suppl. Fig. 7 and Suppl. Fig. 8).  
First, we identified SCNAs in plasma cfDNA before treatment, when the concentration of 
ctDNA was high (Fig. 3C). Only a small number of focal SCNAs were observed in the 
subsequent plasma sample collected 3 weeks after initiation of chemotherapy (without size 
selection, Fig. 3D). In vitro size selection of the same post-treatment plasma sample showed 
a median increase of 6.4 times in the amplitude of detectable SCNAs without size selection. 
Selective sequencing of shorter fragments in this sample resulted in the detection of multiple 
other SCNAs that were not observed without size selection (Fig. 3E), and a genome-wide 
copy-number profile that was similar to that obtained before treatment when ctDNA levels 
were 4 times higher (Fig. 3C). In silico size selection also enriched ctDNA but to a lower 
extent than using in vitro size selection (Suppl. Fig. 7). We concluded that selecting short 
DNA fragments in plasma can enrich tumor content on a genome-wide scale. 
  
Quantifying the impact of size selection. 
5 
To quantitatively assess the enrichment after size selection on a genome-wide scale, we 
developed a metric from sWGS data (<0.4× coverage) called t-MAD (trimmed Median 
Absolute Deviation from copy-number neutrality, see Fig. 4A). All sWGS data were 
downsampled to 10 million sequencing reads for comparison. To define the detection 
threshold, we measured the t-MAD score for sWGS data from 65 plasma samples from 46 
healthy individuals and took the maximal value (median=0.01, range 0.004–0.015). We 
compared t-MAD to the mutant allele fraction (MAF) in the high ctDNA cancer types 
assessed by digital PCR (dPCR) or WES in 97 samples. We observed a high correlation 
(Pearson correlation, r=0.80) (Fig. 4B) between t-MAD and MAF, for samples with t-MAD 
greater than the detection threshold (0.015), or with MAF>0.025. Suppl. Fig. 9 shows that 
the slope of t-MAD versus MAF fit lines differed between cancer types (range 0.17–1.12) 
reflecting likely differences in the extent of SCNAs. We estimated the sensitivity of t-MAD for 
detecting low ctDNA levels using a spike-in dilution of DNA from a patient with a TP53 
mutation into DNA from a pool of 7 healthy individuals (Suppl. Fig. 10) which confirmed that 
the t-MAD score was linear with ctDNA levels down to MAF of ~0.01. In addition, t-MAD 
scores greater than the detection threshold (0.015) for samples were present even in 
samples with a MAF as low as 0.004. t-MAD was also strongly correlated with tumor volume 
determined by RECIST1.1 (Pearson correlation, r=0.6, p<0.0001, n=35) (Suppl. Fig. 11). 
 
Using t-MAD we detected ctDNA from 69% (130/189) of the samples from cancer types 
where ctDNA levels have been shown to be high (Fig. 4C). From cancer types for which 
ctDNA levels are suspected to be low (glioma, renal, bladder, pancreatic), we detected 
ctDNA in 17% (10/57) of the cases (Fig. 4C). We used in silico size selection of the DNA 
fragments between 90–150 bp from the high ctDNA cancers (n=189) and healthy controls 
(n=65) to improve the sensitivity for detecting t-MAD (Fig. 4D). Receiver operating 
characteristic (ROC) analysis comparing the t-MAD score for the samples revealed an area 
under the curve (AUC) of 0.90 after in silico size selection, against an AUC of 0.69 without 
size selection (Fig. 4D).  
 
We explored whether size selected sequencing could improve the detection of response or 
disease progression. We used sWGS of longitudinal plasma samples from six cancer 
patients (Fig. 4E, F) and in silico size selection of the cfDNA fragments between 90–150bp. 
In two patients, size selected samples indicated tumor progression 60 and 87 days before 
detection by imaging or unselected t-MAD analysis (Fig. 4E, F). Other longitudinal samples 
exhibited improvements in the detection of ctDNA with t-MAD and size selection (Fig. 4F). 
Confirmation in large clinical studies will be necessary to determine the potential of selective 
sequencing of ctDNA for clinical applications.  
Identifying more clinically relevant mutations with size 
selection. 
We next tested whether size selection could increase the sensitivity for detecting new 
mutations in cfDNA. To test effects on copy number aberrations, we studied 35 patients with 
HGSOC as this is the archetypal copy-number driven cancer (35). t-MAD was used to 
quantify the enrichment of ctDNA with in vitro size selection in 48 plasma samples, including 
samples collected before and after initiation of chemotherapy treatment. In vitro size 
selection resulted in an increase in the calculated t-MAD score from the sWGS data for 
6 
47/48 of the plasma samples (98%, t-test, p=0.06) with a mean 2.5 and median 2.1-fold 
increase (Fig. 5A and Suppl. Table 6). We compared the t-MAD scores against those 
obtained by sWGS for the plasma samples from healthy individuals. 44 of the 48 size-
selected HGSOC plasma samples (92%) had a t-MAD score greater than the highest t-MAD 
value determined in the in vitro size selected healthy plasma samples (Fig. 5A, Suppl. Fig. 
12 and Suppl. Fig. 6), compared to only 24 out of 48 without size selection (50%). ROC 
analysis comparing the t-MAD score for the samples from the cancer patients (pre- and post-
treatment initiation, n=48) and healthy controls (n=46) revealed an AUC of 0.97 after in vitro 
size selection, with maximal sensitivity and specificity of 90% and 98%, respectively. This 
was significantly superior to detection by sWGS without size selection (AUC=0.64) (Fig 5B).  
 
We then determined if this improved sensitivity resulted in the detection of SCNAs with 
potential clinical value. Across the genome, t-MAD scores evaluating SCNAs were higher 
after size selection in 33/35 (94%) HGSOC patients, and the absolute level of the copy 
number (log2 ratio) values significantly increased after in vitro size selection (t-test for the 
means, p=0.003) (Fig. 5C). We compared the relative copy number values for 15 genes 
frequently altered in HGSOC (Suppl. Table 3). Analysis of plasma cfDNA after size 
selection revealed a large number of SCNAs that were not observed in the same samples 
without size selection (Fig. 5D), including amplifications in key genes such as NF1, TERT, 
and MYC (Suppl. Fig. 13).  
 
We also tested whether similar enrichment was seen for substitutions, to exclude the 
possiblity that size selection might only increase the sensitivity for sWGS analysis. We 
performed whole exome sequencing of plasma cfDNA from 23 patients with 7 cancer types 
(Suppl. Fig. 1). We used the WES data to compare the size distributions of fragments 
carrying mutant or non-mutant alleles (Fig. 6A), and to test whether size selection could 
identify additional mutations. We first selected 6 patients with HGSOC and performed WES 
of plasma DNA with and without in vitro size selection in the 90–150 bp range, analysing 
time-points before and after initiation of treatment (36). In addition, in silico size selection for 
the same range of fragment sizes was performed (Fig. 6A). Analysis of the MAF of SNVs 
revealed statistically significant enrichment of the tumor fraction with both in vitro size 
selection (mean 4.19-fold, median 4.27-fold increase, t-test, p<0.001) and in silico size 
selection (mean 2.20-fold, median 2.25-fold increase, t-test, p<0.001) (Fig. 6A and Suppl. 
Fig. 14). Three weeks after initiation of treatment, ctDNA levels are often lower (36), we 
therefore further analyzed post-treatment plasma samples using Tagged-Amplicon Deep 
Sequencing (TAm-Seq) (37). We observed enrichment of MAFs by in vitro size selection 
between 0.9 and 118 times (mean 2.1 times, median 1.5 times) compared to the same 
samples without size selection (Suppl. Fig. 15).  
 
Size selection with both in vitro and in silico methods increased the number of mutations 
detected by WES by an average of 53% compared to no size selection (Fig. 6B). We 
identified a total of 1023 mutations in the non-size-selected samples. An additional 260 
mutations were detected by in vitro size selection, and an additional 310 mutations were 
called after in silico size selection (Fig. 6B and Suppl. Table 4). To exclude the possibility 
that the improved sensitivity for mutation detection was a result of sequencing artefacts, we 
validated whether new mutations were also detectable in tumor specimens. We used in silico 
size selection in an independent cohort of 16 patients where matched tumor tissue DNA was 
available (Suppl. Table 5). In silico size selection enriched the MAF for nearly all mutations 
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(2061/2133, 97%), with an average increase of MAF of ×1.7 (Fig. 6C). For 13 of 16 patients 
(81%) we identified additional mutations in plasma after in silico size selection. Of these 82 
additional mutations, 23 (28%) were confirmed to be present in the matched tumor tissue 
DNA (Fig. 6D). Notably, this included mutations in key cancer genes including BRAF, 
ARID1A, and NF1 (Suppl. Fig. 16).  
 
Detecting cancer by supervised machine learning 
combining cfDNA fragmentation and somatic alteration 
analysis. 
It is important to note that although in vitro and in silico size selection increase the sensitivity 
of detection, they also result in a loss of cfDNA for analysis. Regions of the cancer genome 
which are not altered by mutation also excluded and cannot contribute to the analysis 
(Suppl. Fig. 17). We hypothesized that leveraging other biological properties of the cfDNA 
fragmentation profile could enhance the detection of ctDNA. 
 
We defined other cfDNA fragmentation features from sWGS data including (1) the proportion 
of fragments in multiple size ranges, (2) the ratios of proportions of fragments in different 
sizes and (3) the amplitude of oscillations in fragment-size density with 10 bp periodicity (see 
Methods and Fig. 7A). These fragmentation features were compared between cancer 
patients and healthy individuals (Suppl. Fig. 18) and the feature representing the proportion 
(P) of fragments between 20–150 bp exhibited the highest AUC (0.819). Principal 
component analysis (PCA) of the samples represented by t-MAD and fragmentation features 
showed a separation between healthy and cancerous samples and that fragment features 
clustered with t-MAD scores (Fig. 7B).   
 
We next explored the potential of fragmentation features to enhance the detection of tumor 
DNA in plasma samples. A predictive analysis was performed using the t-MAD score and 9 
fragmentation features across 304 samples (239 from cancers patients and 65 from healthy 
controls) (Fig. 7C) (Suppl. Fig. 19 and Suppl. Table 2). The 9 fragmentation features 
determined from sWGS included five features based on the proportion (P) of fragments in 
defined size ranges: P(20–150), P(100–150), P(160–180), P(180–220), P(250–320); three 
features based on ratios of those proportions: P(20–150)/P(160–180), P(100–150)/P(163–
169), P(20–150)/P(180–220); and a further feature based on the amplitude of the oscillations 
having 10 bp periodicity observed below 150 bp.  
 
Variable selection and the classification of samples as “healthy” or “cancer” were performed 
using logistic regression (LR) and random forests (RF) trained on 153 samples, and 
validated on two datasets of 94 and 83 independent samples (Fig. 7C). The best feature set 
for the LR model included t-MAD, 10 bp amplitude, P(160–180), P(180–220) and  P(250–
320). The same five variables were independently identified using the RF model (with some 
differences in their ranking). Suppl. Fig. 20 shows performance metrics for the different 
algorithms on training set data using cross-validation. Using t-MAD alone in the validation 
pan-cancer dataset (Fig. 7D and Suppl. Fig. 19), we could distinguish cancer samples from 
healthy individuals with AUC=0.764. Using the LR model improved the classification of the 
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samples to AUC=0.908. The RF model (trained on the 153-sample training set) could 
distinguish cancer from healthy individuals even more accurately in the validation data set 
(n=94) with AUC=0.994. On the second validation dataset containing low-ctDNA cancer 
samples (n=83) (Fig. 7E), t-MAD alone or the LR performed less well, with AUC values of 
0.421 and 0.532 respectively. However, the RF model was still able to distinguish samples 
from low-ctDNA cancer samples from healthy controls with AUC=0.914. At a specificity of 
95%, the RF model correctly classified as cancer 64/68 (94%) of the samples from high-
ctDNA cancers (colorectal, cholangiocarcinoma, ovarian, breast, melanoma), and 37/57 
(65%) of the samples from low-ctDNA cancers (pancreatic, renal, glioma) (Fig. 7F). In a 
second iteration of model training, we omitted t-MAD, using only the 4 fragmentation 
features (Suppl. Fig. 21). The RF model could still distinguish cancer from healthy controls 
albeit with slightly reduced AUCs (0.989 for cancer types with high levels of ctDNA and 
0.891 for cancer types with low levels of ctDNA), suggesting that the cfDNA fragmentation 
pattern is most important predictive component. 
Discussion: 
Our results indicate that exploiting fundamental properties of cfDNA with fragment specific 
analyses can provide more sensitive analysis of ctDNA. We based the selection criteria on a 
biological observation that ctDNA fragment size distribution is shifted from normal cfDNA. 
Our work builds on a comprehensive survey of plasma cfDNA fragmentation patterns across 
200 patients with multiple cancer types and 65 healthy individuals. We identified features 
that could determine the presence and amount of ctDNA in plasma samples, without a priori 
knowledge of somatic aberrations. Although this catalogue is the first of its kind, we caution 
that it is limited to double-stranded DNA from plasma samples, and is subject to potential 
biases incurred by the DNA extraction and sequencing methods we used. Additional 
biological effects could contribute to further selective analysis of cfDNA. Other bodily fluids 
(urine, cerebrospinal fluid, saliva), different nucleic acids and structures, altered mechanisms 
of release into circulation, or sample processing methods could exhibit varying fragment size 
signatures and could offer additional exploitable biological patterns for selective sequencing.  
  
Previous work has reported the size distributions of mutant ctDNA, but only considered 
limited genomic loci, cancer types, or cases (30, 32, 33). We identified the size differences 
between mutant and non-mutant DNA on a genome-wide and pan-cancer scale. We 
developed a method to size mutant ctDNA without using high-depth WGS. By sequencing 
>150 mutations per patient at high depth we obtained large numbers of reads that could be 
unequivocally identified as tumor-derived, and thus determined the size distribution of 
mutant ctDNA and non-mutant cfDNA in cancer patients. A potential limitation of our 
approach is that capture-based sequencing is biased by probe capture efficiency and 
therefore our data may not accurately reflect ctDNA fragments <100bp or >300bp. 
  
Our work provides strong evidence that the modal size of ctDNA for many cancer types is 
less than 167bp, which is the length of DNA wrapped around the chromatosome. In addition,  
our work also shows that there is a high level of enrichment of mutant DNA fragments at 
sizes greater than 167 bp, notably in the range 250–320 bp. These longer fragments may 
explain previous observations that longer ctDNA can be detected in the plasma of cancer 
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patients (29, 32). The origin of these long fragments is still unknown, and their observation 
could be linked to technical factors. However, it is likely that mechanisms of compaction and 
release of cfDNA into circulation, which may differ depending on its origin, will be reflected 
by different fragment sizes (38). Improving the characterization of these fragments will be 
important, especially for future work combining ctDNA analysis with other entities in blood 
such as microvesicles and tumor-educated platelets (39, 40). Fragment specific analyses not 
only increase the sensitivity for detection of rare mutations, but could be used to track 
modifications in the size distribution of ctDNA. Future work should address whether this 
approach could be used to elucidate mechanistic effects of treatment on tumor cells, for 
example by distinguishing between necrosis and apoptosis based on fragment size (41). 
  
Genome-wide and exome sequencing of plasma DNA at multiple time-points during cancer 
treatment have been proposed as non-invasive means to study cancer evolution and for the 
identification of possible resistance mechanisms to treatment (3). However, WGS and WES 
approaches are costly and have thus far been applicable only in samples for which the tumor 
DNA fraction was >5–10% (3–5, 42). We demonstrated that we could exploit the differences 
in fragment lengths using in vitro and in silico size selection to enrich for tumor content in 
plasma samples which improved mutation and SCNA detection in sWGS and WES data. We 
demonstrated that size selection improved the detection of mutations that are present in 
plasma at low allelic fractions, while maintaining low sequencing depth by sWGS and WES. 
Size selection can be achieved with simple means and at low cost, and is compatible with a 
wide range of downstream genome-wide and targeted genomic analyses, greatly increasing 
the potential value and utility of liquid biopsies. 
  
Size selection can be applied in silico, which incurs no added costs, or in vitro, which adds a 
simple and low-cost intermediate step that can be applied to either the extracted DNA or the 
libraries created from it. This approach, applied prospectively to new studies, could boost the 
clinical utility of ctDNA detection and analysis, and creates an opportunity for re-analysis of 
large volumes of existing data (4, 34, 43). The limitation of this technique is a potential loss 
of material and information, since some of the informative fragments may be found in size 
ranges that are filtered out or de-prioritized in the analysis. This may be particularly 
problematic if only a few copies of the fragments of interest are present in plasma. Despite 
potential loss of material, we demonstrated that classification algorithms can learn from 
cfDNA fragmentation features and SCNAs analysis and improve the detection of ctDNA with 
a cheap sequencing approach (Fig. 7). Moreover, the cfDNA fragmentation features alone 
can be leveraged to classify cancer and healthy samples with a high accuracy (AUC=0.989 
for high ctDNA cancers, and AUC=0.891 for low ctDNA cancers) (Suppl. Fig. 21). 
  
Analysis of fragment sizes could provide improvements in other applications. Introducing 
fragment size information on each read could enhance mutation-calling algorithms from high 
depth sequencing, to identify tumor-derived mutations from other sources such as somatic 
variants or background sequencing noise. In addition, cfDNA analysis in patients with CHIP 
is likely to be structurally different from ctDNA released during tumor cell proliferation (18, 
19). Thus, fragmentation analysis or selective sequencing strategies could be applied to 
distinguish clinically relevant tumor mutations from those present in clonal expansions of 
normal cells. This will be critical for the development of cfDNA-based methods for 
identification of patients with early stage cancer. 
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Size selection could also have an impact on the detection of other types of DNA in body 
fluids or to enrich signals for circulating bacterial or pathogen DNA and mitochondrial DNA. 
These DNA fragments are not associated with nucleosomes and are often highly fragmented 
below 100bp. Filtering such fragments may prove to be important in light of the recently 
established link between the microbiome and treatment efficiency (17, 44). Moreover, recent 
work highlights a stronger correlation between ctDNA detection and cellular proliferation, 
rather than cell-death (45). We hypothesize that the mode of the distribution of ctDNA 
fragment sizes at 145bp could reflect cfDNA released during cell proliferation, and the 
fragments at 167bp may reflect cfDNA released by apoptosis or maturation/turnover of blood 
cells. The effect of other cancer hallmarks (46) on ctDNA biology, structure, concentration 
and release is yet unknown. 
  
In summary, ctDNA fragment size analysis, via size selection and machine learning 
approaches, boosts non-invasive genomic analysis of tumor DNA. Size selection of shorter 
plasma DNA fragments enriches ctDNA, and leads to the identification of a greater number 
of genomic alterations with both targeted and untargeted sequencing at a minimal additional 
cost. Combining cfDNA fragment size analysis and the detection of SCNAs with a non-linear 
classification algorithm improved the discrimination between samples from cancer patients 
and healthy individuals. As the analysis of fragment sizes is based on the structural property 
of ctDNA, size selection could be used with any downstream sequencing applications. Our 
work could help overcome current limitations of sensitivity for liquid biopsy, supporting 
expanded clinical and research applications. Our results indicate that exploiting the 
endogenous biological properties of cfDNA provides an alternative paradigm to deeper 
sequencing of ctDNA. 
Materials and Methods: 
Study design. 344 plasma samples from 200 patients with multiple cancer types were 
collected along with plasma from 65 healthy controls. Among the patients, 172 individuals 
were recruited through prospective clinical studies at Addenbrooke’s Hospital, Cambridge, 
UK, approved by the local research ethics committee (REC reference numbers: 
07/Q0106/63; and NRES Committee East of England - Cambridge Central 03/018). Written 
informed consent was obtained from all patients and blood samples were collected before 
and after initiation of treatment with surgery or chemotherapeutic agents. DNA was extracted 
from 2 mL of plasma using the QIAamp circulating nucleic acid kit (Qiagen) or QIAsymphony 
(Qiagen) according to the manufacturer’s instructions. In addition, 28 patients were recruited 
as part of the Copenhagen Prospective Personalized Oncology (CoPPO) program (Ref: 
PMID: 25046202) at Rigshospitalet, Copenhagen, Denmark, approved by the local research 
ethics committee. Baseline tumor tissue biopsies were available from all 28 patients, 
together with re-biopsies collected at relapse from two patients, and matched plasma 
samples. Brain tumor patients were recruited at the Addenbrooke’s Hospital, Cambridge, 
UK, as part of the BLING study (REC – 15/EE/0094). Bladder cancer patients were recruited 
at the Netherlands Cancer Institute, Amsterdam, The Netherlands, and approval according 
to national guidelines was obtained (N13KCM/CFMPB250) (47). 65 plasma samples were 
obtained from healthy control individuals using a similar protocol (Seralab). Plasma samples 
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have not been freezed-thawed more than 2 times to reduce artifactual fragmentation of 
cfDNA. Study flowchart of the work is described in Suppl. Fig. 1. 
 
In vitro size selection. Between 8-20 ng of DNA were loaded into a 3% agarose cassette 
(HTC3010, Sage Bioscience) and size selection was performed on a PippinHT (Sage 
Bioscience) according to the manufacturer’s protocol. Quality controls of in vitro size 
selection were performed on 20 healthy controls samples and detailed in Suppl. Fig. 6. We 
observed an increase in duplicate reads with in vitro size selection, and therefore duplicate 
reads have been removed for any downstream size selection analysis in the manuscript. To 
determine the sequencing noise, we used a QC metric called the median absolute pairwise 
difference (MAPD) algorithm. MAPD measures the absolute difference between the log2 CN 
ratios of every pair of neighboring bins and then takes the median across all bins. Higher 
MAPD scores reflect greater noise, typically associated with poor-quality samples. All 
samples exhibit a MAPD score of 0.01 (+-0.01), irrespective of the size selection condition. 
  
TAm-Seq. Tagged-Amplicon Deep Sequencing libraries were prepared as previously 
described (34), using primers designed to assess single nucleotide variants (SNV) and small 
indels across selected hotspots and the entire coding regions of TP53. Libraries were 
sequenced using MiSeq or HiSeq 4000 (Illumina). 
  
sWGS. Indexed sequencing libraries were prepared using commercially available kits 
(ThruPLEX-Plasma Seq and/or Tag-Seq, Rubicon Genomics). Libraries were pooled in 
equimolar amounts and sequenced to <0.4x depth of coverage on a HiSeq 4000 (Illumina) 
generating 150-bp paired-end reads. Sequence data were analyzed using an in-house 
pipeline that consists of the following; Paired end sequence reads were aligned to the 
human reference genome (GRCh37) using BWA-mem following the removal of 
contaminating adapter sequences (48). PCR and optical duplicates were marked using 
MarkDuplicates (Picard Tools) feature and these were excluded from downstream analysis 
along with reads of low mapping quality and supplementary alignments. When necessary, 
reads were down-sampled to 10 million in all samples for comparison purposes. 
  
Somatic copy number aberration analysis: The analysis was performed in R using a 
software suite for shallow Whole Genome Sequencing copy number analysis named 
CNAclinic (https://github.com/sdchandra/CNAclinic) as well as the QDNAseq pipeline (49). 
Sequencing reads were randomly sampled to 10 million reads per dataset and allocated into 
equally sized (30 Kbp) non-overlapping bins throughout the length of the genome. Read 
counts in each bin were corrected to account for sequence GC content and mappability, and 
bins overlapping ‘blacklisted’ regions (derived from the ENCODE project + 1000 Genomes 
database) prone to artefacts were excluded from downstream analysis.  Read counts in test 
samples were normalized by the counts from an identically processed healthy individual and 
log2 transformed to obtained copy number ratio values per genomic bin. Read counts in 
healthy controls were normalized by their median genome-wide count. Next, bins were 
segmented using both Circular Binary Segmentation and Hidden Markov Model algorithms, 
and an averaged log2R value per bin was calculated.  
 
An in-house empirical blacklist of aberrant read count regions was constructed as follows: 65 
sWGS datasets from healthy plasma were used to calculate median read counts per 30 Kbp 
genomic bin as a function of GC content and mappability. A 2D LOESS surface was applied 
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and the difference between the actual count and the LOESS fitted values were calculated. 
The median of these residual values across the 65 controls were calculated per genomic bin. 
Regions with median residuals greater than 4 standard deviations were blacklisted. The 
averaged segmental log2R values in each test sample that overlap this cfDNA blacklist were 
trimmed and the median absolute value was calculated. This score is defined as t-MAD or 
the trimmed median absolute deviation from log2R = 0. The R code to reproduce this 
analysis is provided in https://github.com/sdchandra/tMAD. 
  
WES. Indexed sequencing libraries were prepared as described above (see Methods, 
sWGS). Plasma DNA libraries from each sample were made and pooled together for exome 
capture (TruSeq Exome Enrichment Kit, Illumina). Pools were concentrated using a 
SpeedVac vacuum concentrator (Eppendorf). Exome enrichment was performed following 
the manufacturer’s protocol. Enriched libraries were quantified using quantitative PCR 
(KAPA library quantification, KAPA Biosystems), and DNA fragments sizes observed by 
Bioanalyzer (2100 Bioanalyzer, Agilent Genomics) and pooled in equimolar ratio for paired-
end next generation sequencing on a HiSeq4000 (Illumina). Sequencing reads were de-
multiplexed allowing zero mismatches in barcodes. Paired-end alignment to the GRCh37 
reference genome was performed using BWA-mem for all exome sequencing data including 
germline, plasma and tumor tissue DNA where generated. PCR duplicates were marked 
using Picard. Base quality score recalibration and local realignment were performed using 
Genome Analysis Tool Kit (GATK). 
  
Mutation calling. MAFs for each single-base locus were calculated with MuTect2 for all 
bases with PHRED quality ≥30. After MuTect2, we applied filtering parameters so that a 
mutation was called if no mutant reads for an allele were observed in germline DNA at a 
locus that was covered at least 10x, and if at least 4 reads supporting the mutant were found 
in the plasma data with at least 1 read on each strand (forward and reverse). At loci with 
<10x coverage in normal DNA and no mutant reads, mutations were called in plasma if a 
prior plasma sample showed no evidence of a mutation and was covered adequately (10x or 
more). We aggregated mutations called before and after size selection with a method called 
Integrated Signal Amplification for Non-invasive Interrogation of Tumors. This method 
combines different subsets of mutations called from the same plasma DNA sample using 
different processing approaches. The mutation aggregation as used in this study is 
formalized as follows: aggregated mutations = mutations detected without size selection U 
(mutations detected with in vitro size selection U mutations detected with in silico size 
selection). 
  
In silico size selection: Paired-end reads are generated by sequencing DNA from both 
ends of the fragments present in the library. The original length of the DNA can be inferred 
using the mapping locations of the read ends in the genome. Once alignment is complete, 
Samtools software is used to select paired reads that correspond to fragment lengths in a 
specific range. Mutect2 is used to call mutations from this in silico size selected data as 
described in the previous section. 
  
Tumor-guided capture sequencing. Matched tumor tissue DNA and plasma DNA samples 
of 19 patients collected from the RigsHospitalet (Copenhagen, Denmark) with advanced 
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cancer were sequenced by WES. Variants were called from these samples as previously 
described (see Methods, Mutation calling). Hybrid-based capture for longitudinal plasma 
samples analysis were designed to cover these variants for each patient using SureDesign 
(Agilent). A median of 160 variants were included per patient, and in addition, 41 common 
genes of interest for pan-cancer analysis were included in the tumor-guided sequencing 
panel. Indexed sequencing libraries were prepared as described above (see Methods, 
sWGS). Plasma DNA libraries from each sample were made and pooled together for tumor-
guided capture sequencing (SureSelect, Agilent). Pools were concentrated using a 
SpeedVac vacuum concentrator (Eppendorf). Capture enrichment was performed following 
the manufacturer’s protocol. Enriched libraries were quantified using quantitative PCR 
(KAPA library quantification, KAPA Biosystems), and DNA fragments sizes controlled by 
Bioanalyzer (2100 Bioanalyzer, Agilent Genomics) and pooled in equimolar ratio for paired-
end next generation sequencing on a HiSeq4000 (Illumina). Sequencing reads were de-
multiplexed allowing zero mismatches in barcodes. Paired-end alignment to the GRCh37 
reference genome was performed using BWA-mem for all exome sequencing data including 
germline, plasma and tumor tissue DNA where generated. PCR duplicates were marked 
using Picard. Base quality score recalibration and local realignment were performed using 
Genome Analysis Tool Kit (GATK). 
  
Classification analysis. The preliminary analysis was carried out on 304 samples (182 high 
ctDNA cancer samples, 57 low ctDNA cancer samples and 65 healthy controls). For each 
sample the following features were calculated from sWGS data: t-MAD, amplitude_10bp, 
P(20-150), P(160-180), P(20-150)/P(160-180), P(100-150), P(100-150)/P(163-169), P(180-
220), P(250-320), P(20-150)/P(180-220). The data was arranged in a matrix where the rows 
represent each sample and the columns held the aforementioned features with an extra 
“class” column with the binary labels of “cancer”/“healthy”. The following analysis was carried 
out in R utilising RandomForest, caret, and pROC packages. The pairwise correlations 
between the features were calculated to assess multi-collinearity in the dataset (Suppl. Fig. 
19). A single variable was selected for removal from pairs with Pearson correlation > 0.75. 
Highly correlated fragmentation features that were composite of individual variables already 
in the dataset such as P(20-150)/P(180-220), were prioritized for removal. The features were 
also assessed for zero variance and linear dependencies but none were flagged. After this 
pre-processing the following 5 variables were selected for further analysis: t-MAD, 
amplitude_10bp, P(160-180), P(180-220) and P(250-320). All 57 low ctDNA samples were 
set aside for validation of the models. The data matrix for the remaining high ctDNA cancer 
samples and healthy controls (n = 247) were randomly partitioned in a 60:40 split into 1 
training and 1 validation dataset with the different cancer types and healthy samples 
represented in similar proportions. Hence, the training data contained 153 samples 
(cancer=114, healthy=39) while the first validation set of high ctDNA cancers contained 94 
samples (cancer=68, healthy=26). This validation dataset was only utilized for final 
assessment of the classifiers. 
 
Classification of samples as healthy or cancer was performed using one linear and one non-
linear machine learning algorithm, namely logistic regression (LR), and random forest (RF). 
Each algorithm was paired with recursive feature selection in order to identify the best 
predictor variables. This analysis was carried out with caret within the framework of 5 
repeats of 10-fold cross-validation on the training set. The algorithm was configured to 
explore all possible subsets of the features. The optimal model for each classifier was 
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selected using ROC metric. Separately, a logistic regression model was trained only using t-
MAD as a predictor in order to assess the difference in performance without the addition of 
fragmentation features. Finally, the 68 high ctDNA cancer samples, 57 low ctDNA cancer 
samples and 26 healthy controls set aside for validation were used to test the classifiers, 
utilizing area under the curve in a ROC analysis to quantify their performance.  
 
A secondary analysis was carried out on the same training and validation cohorts with the 
only difference being the features used in the model. Here, we tested predictive ability of 
fragmentation features without the addition of information from SCNAs (i.e. t-MAD). Hence 
the features utilized were: amplitude_10bp, P(160-180), P(180-220) and P(250-320). 
 
  
Quantification of the 10bp periodic oscillation. The amplitude of the 10 bp periodic 
oscillation observed in the size distribution of cfDNA samples was determined from the 
sWGS data as follows. Local maxima and minima in the range 75 bp to 150 bp were 
identified. The average of their positions across the samples was calculated (for minima:  84, 
96, 106, 116, 126, 137, 148, and maxima: 81, 92, 102, 112, 122, 134, 144). To compute the 
amplitude of the oscillations with 10 bp periodicity observed below 150 bp, we calculated the 
sum of the heights of the maxima and subtracted the sum of the minima. The larger this 
difference, the more distinct the peaks. The height of the x bp peak is defined as the number 
of fragments with length x divided by the total number of fragments. To define local maxima, 
we selected the positions y such that y was the largest value in the interval [y-2, y+2]. The 




Materials and Methods 
Figure S1: flowchart of the study design. 
Figure S2: size distribution of cfDNA determined by sWGS depending on the cancer type. 
Figure S3: insert size distribution of mutant cfDNA determined with hybrid-capture 
sequencing for 19 patients. 
Figure S4: distribution of inserts sizes determined by sWGS for each plasma samples from 
the 13 ovarian cancer patients of the OV04 cohort collected before and after treatment. 
Figure S5: quality control assessment of the in vitro size selection was estimated with sWGS 
and targeted sequencing. 
Figure S6: quality control assessment of the in vitro and in silico size selection on a batch of 
20 healthy controls 
Figure S7: SCNA analysis without and with size selection of the segmental log2ratio 
determined after sWGS (<0.4x coverage) for the patient OV04-83.  
Figure S8: SCNA analysis of the segmental log2ratio determined after sWGS using on 
genome wide scale (<0.4x coverage) for the OV04 samples. 
Figure S9: Comparison of the MAF and t-MAD score depending on the cancer type for 
available matched data.  
Figure S10: spike-in dilution of cfDNA extracted from the plasma of a breast cancer patient 
in DNA from a healthy control. 
Figure S11: comparison of the available RECIST volume (in mm) determined by CT-scan to 
the tMAD score and fragmentation features.  
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Figure S12: t-MAD analysis of the 48 plasma samples collected from 35 ovarian patients 
was analyzed with and without size selection.  
Figure S13: SCNA analysis of the segmental log2ratio determined after sWGS using a list of 
29 genes frequently mutated in recurrent ovarian cancer from the plasma samples collected 
at baseline and after treatment for 13 patients. 
Figure S14: MAF for each single nucleotide variants (SNVs) called by WES on the OV04 
samples without and with size selection.  
Figure S15: analysis of the effect of size selection on ovarian cancer samples with TAm-Seq. 
Figure S16: Mutations detected for 9 genes of clinical importance by WES with and without 
size selection of the short DNA fragments.  
Figure S17: Size distribution of non-mutant DNA is affected by the concentration in ctDNA. 
Figure S18: ROC curve comparing the individual fragmentation features on the cohort of 
cancer samples collected from high ctDNA cancer-types. 
Figure S19: comparison of t-MAD score to the 9 fragmentation features. 
Figure S20: performance metrics for the 50 random sub-samples of cross-validation for the 
logistic regression on t-MAD score and fragmentation features; random forest (RF) model on 
training set data from sWGS (n=153; 114 cancer samples, and 39 healthy controls). 
Figure S21: LR and RF models detect cancer from healthy controls using only fragmentation 
features. 
Tables S1: summary table of the patients and samples included in the study. 
Tables S2: table of the level of the 9 fragmentation features determined by sWGS on the 
samples included in the study. 
Tables S3: table of the log2ratio levels observed by sWGS of the plasma samples from the 
OV04 cohort. 
Tables S4: mutations called by WES of the 6 patients selected from the OV04 cohort. 
Tables S5: mutations called by WES of the 16 patients from the CoPPO cohort. 
Tables S6: t-MAD score for the 48 plasma samples of the OV04 cohort before and after in 
vitro size selection. 
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Figure 1: Survey of plasma DNA fragmentation with genome-wide sequencing on a 
pan-cancer scale. A, The size profile of cfDNA can be determined from paired-end 
sequencing of plasma samples and reflects its organization around the nucleosome. cfDNA 
is released in the blood circulation by various means, each of which leaves a signature on 
the fragment sizes. We inferred the size profile of cfDNA by analyzing with sWGS (n=344 
plasma samples from 65 healthy controls and 200 cancer patients), and the size profile of 
mutant ctDNA by personalized capture sequencing (n=18 plasma samples). B, Fragment 
size distributions of 344 plasma samples from 200 cancer patients. Patients are split into two 
groups based on previous literature (3), orange representing cancer samples previously 
observed to have low levels of ctDNA (renal, bladder, pancreatic, and glioma) and blue 
representing cancer samples observed to have higher ctDNA levels (breast, melanoma, 
ovarian, lung, colorectal, cholangiocarcinoma, and others, see Suppl. Table 1). C, Proportion 
of cfDNA fragments below 150bp by cancer grouping defined in B. The Kruskal-Wallis test 
for difference in size distributions indicated a significant difference between the group of 
cancer types releasing high amounts of ctDNA, and the group releasing low amounts as well 
as the group of healthy individuals (p<0.001). D, Proportion of cfDNA fragments below 150 
bp by cancer type (all samples). Cancer types represented by fewer than 4 individuals are 




Figure 2: Determining the size profile of mutant ctDNA with animal models and 
personalized capture sequencing. A, A mouse model with xenografted human tumor cells 
enabled the discrimination of DNA fragments released by cancer cells (reads aligning to the 
human genome) from the DNA released by healthy cells (reads aligning to the mouse 
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genome), with the use of sWGS. B, Fragment size distribution, from the plasma extracted 
from a mouse xenografted with a human ovarian tumor, showing ctDNA originating from 
tumor cells (red) and cfDNA from non-cancerous cells (blue). Two vertical lines indicate 
145bp and 167bp. The fraction of reads shorter than 150 bp is indicated. C, Design of 
personalized hybrid-capture sequencing panels developed to specifically determine the size 
profiles of mutant DNA and non-mutant DNA in plasma from 19 patients with late stage 
cancers. Capture panels included somatic mutations identified in tumor tissue by WES. A 
mean of 165 mutations per patient were then analyzed from matched plasma samples. 
Reads were aligned and separated into fragments that carry either the reference or the 
mutant sequence. Fragment sizes for paired-end reads were calculated. D, Size profiles of 
mutant DNA and non-mutant DNA in plasma from 19 patients with late stage cancers were 




Figure 3: Enhancing the tumor fraction from plasma sequencing with size selection.  
A, Plasma samples collected from ovarian cancer patients were analyzed in parallel without 
size selection, or using either in silico and in vitro size selection. B, accuracy of the in vitro 
and in silico size selection determined on a cohort of 20 healthy controls. The size 
distribution before size selection is shown in green, after in silico size selection (with sharp 
cutoff at 90 and 150 bp) in blue and after in vitro size selection in orange. C, SCNA analysis 
with sWGS from plasma DNA of an ovarian cancer patient collected before initiation of 
treatment, when ctDNA MAF was 0.271 for a TP53 mutation as determined by TAm-Seq. 
Inferred amplifications are shown in blue and deletions in orange. Copy number neutral 
regions are in grey. D, SCNA analysis of a plasma sample from the same patient as panel C 
collected three weeks after treatment start. The MAF for the TP53 mutation was 0.068, and 
ctDNA was not detected at this time-point by sWGS (before size selection). E, Analysis of 
the same plasma sample as D after in vitro size selection of fragments between 90 bp and 
150 bp in length. The MAF for the TP53 mutation increased to 0.402 after in vitro size 
selection, and SCNAs were clearly apparent by sWGS. More SCNAs are detected in 
comparison to C and D (e.g. in chr2, chr9, chr10). SCNAs were also detected in this sample 
after in silico size selection (Suppl. Fig. 7).  
 
 
Figure 4: Quantifying the ctDNA enrichment by sWGS with in silico size selection and 
t-MAD. A, Workflow to quantify tumor fraction from SCNA as a genome-wide score named t-
MAD. B, Correlation between the MAF of SNVs determined by digital PCR or hybrid-capture 
sequencing and t-MAD score determined by sWGS. Data included 97 samples from cancer 
patients of multiples cancer types with matched MAF measurements and t-MAD scores. 
Pearson correlation (coefficient r) between MAF and t-MAD scores was calculated for all 
cases with MAF>0.025 and t-MAD>0.015. Linear regression indicated a fit with a slope of 
0.44 (purple solid line).  C, Comparison of t-MAD scores determined from sWGS between 
healthy samples, samples collected from patients with cancer types that exhibit low amounts 
of ctDNA in circulation and from patients with cancer types that exihibit high amounts of 
ctDNA in circulation (as in Fig. 1). All samples for which t-MAD could be calculated have 
been included.  D, ROC analysis comparing the classification of these plasma samples from 
high ctDNA cancer samples (n=189) and plasma samples from healthy controls (n=65) using 
t-MAD had an area under curve (AUC) of 0.69 without size selection (black solid curve). 
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After applying in silico size selection to the samples from the cancer patients, we observed 
an AUC of 0.90 (black dashed curve). E, Determination of t-MAD from longitudinal plasma 
samples of a colorectal cancer patient. t-MAD was analyzed before and after in silico size 
selection of the DNA fragments 90-150bp, and then compared to the RECIST status for this 
patient. F, Application of in silico size selection to 6 patients with long follow-up. t-MAD score 
was determined before and after in silico size selection of the short DNA fragments. Dark 
blue circles indicate samples in which ctDNA was detected both with and without in silico 
size selection. Light blue circles indicate samples where ctDNA was detected only after in 
silico size selection. Empty circles indicate samples where ctDNA was not detected by either 
analysis. Times when RECIST status was assessed are indicated by a red bar for 
progression, or an orange bar for regression or stable disease. 
 
 
Figure 5: Quantifying the ctDNA enrichment by sWGS with in vitro size selection. A, 
The effect of in vitro size selection on the t-MAD score. For each of 48 plasma samples 
collected from 35 patients, the t-MAD score was determined from the sWGS after in vitro 
size selection (y axis) and without size selection (x axis). In vitro size selection increased the 
t-MAD score for nearly all samples, with a median increase of 2.1-fold (range from 1.1 to 6.4 
fold). t-MAD scores determined from sWGS for 46 samples from healthy individuals were all 
<0.015 both before and after in vitro size selection. B, ROC analysis comparing the 
classification of these plasma samples from cancer samples (n=48) and plasma samples 
from healthy controls (n=46) using t-MAD had an area under curve (AUC) of 0.64 without 
size selection (green curve). After applying in silico size selection to the samples from the 
cancerous and healthy patients, we observed an AUC of 0.78 (blue curve), and after in vitro 
size selection, an AUC of 0.97 (orange curve). C, Comparison of t-MAD scores determined 
from sWGS between matched ovarian cancer samples with and without in vitro size 
selection. The t-test for the difference in means indicate a significant increase in tumor 
fraction (measured by t-MAD) with in vitro size selection (p<0.0001). D, Detection of SCNAs 
across 15 genes frequently mutated in recurrent ovarian cancer, measured in plasma 
samples collected during treatment for 35 patients. Patients were ranked from left to right by 
increasing tumor fraction as quantified by tMAD (before in vitro size selection). SCNAs are 
labelled as detected for a gene if the relative copy number in that region was greater than 
0.05. Empty squares represent copy number neutral regions, bottom left triangles in light 
blue indicate that SCNAs were detected without size selection and top right triangles in dark 
blue represent SCNAs detected after in vitro size selection. 
 
 
Figure 6: Improving the detection of somatic alterations by WES in multiple cancer 
types with size selection. A, Analysis of the MAF of mutations detected by WES in 6 
patients with HGSOC without size selection and with in vitro and in silico size selection. B, 
Comparison of size-selected WES data with non-selected WES data to assess the number 
of mutations detected in plasma samples from 6 patients with HGSOC. For each patient, the 
first bar in light blue shows the number of mutations called without size selection, the second 
bar quantifies the number of mutations called after the addition of those identified with in 
silico size selection, and the third, dark blue bar shows the number of mutations called after 
addition of mutations called after in vitro size selection. C, Patients (n=16) were 
retrospectively selected from a cohort with different cancer types (colorectal, 
cholangiocarcinoma, pancreatic, prostate) enrolled in early phase clinical trials. Matched 
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tumor tissue DNA was available for each plasma sample, and 2 patients also had a biopsy 
collected at relapse. WES was performed on tumor tissue DNA and plasma DNA samples, 
and in silico size selection was applied to the data. 2061/2133, 97% of the shared mutations 
detected by WES showed higher MAF after in silico size selection. D, Mutations detected 
only after in silico selection of WES data from 16 patients (as in C) compared to mutations 
called by WES of the matched tumor tissue. Three of 16 patients had no additional 
mutations identified after in silico size selection. Of the 82 mutations detected in plasma after 
in silico size selection, 23 (28%) had low signal  levels in tumor WES data and were not 
initially identified in those samples. 
 
 
Figure 7: Enhancing the potential for ctDNA detection by combining SCNAs and 
fragment-size features. A, Schematic illustrating the selection of different size ranges and 
features in the distribution of fragment sizes. For each sample, fragmentation features 
included the proportion (P) of fragments in specific size ranges, the ratio between certain 
ranges and a quantification of the amplitude of the 10bp oscillations in the 90-145 size bp 
range calculated from the periodic “peaks” and “valleys” (see Methods). B, Principal 
Component Analysis (PCA) comparing cancer and healthy samples using data from t-MAD 
scores and the fragmentation features. Fragmentation features shown in grey are not 
included in the following steps. C, Workflow for the predictive analysis combining SCNAs 
and fragment size features (see Methods). Plasma DNA sWGS data from healthy controls 
was split into a training set (60% of samples) and a validation set (used in both Validation 
data 1 and Validation set 2). sWGS data from plasma samples from a pan-cancer cohort of 
182 samples from patients with cancer types with high levels of ctDNA (colorectal, 
cholangiocarcinoma, lung, ovarian, breast) was split into a training set (60% of samples) and 
a validation set (Validation data 1, together with the healthy individual validation set). A 
further dataset of sWGS from 57 samples from cancer types exhibiting low levels of ctDNA 
(glioma, renal, pancreatic) was used as Validation data 2, together with the healthy individual 
validation set. D, ROC curves for Validation data 1 (samples from cancer patients with high 
ctDNA levels=68, healthy=26) for 3 predictive models built on the pan-cancer training cohort 
(cancer=114, healthy=39). The beige curve represents the ROC curve for classification with 
t-MAD only, the long dashed green line represents the logistic regression model combining 
the top 5 features based on recursive feature elimination (t-MAD score, 10bp amplitude, 
P(160-180), P(180-220) and P(250-320)), and the dashed red line shows the result for a 
random forest classifier trained on the combination of the same 5 features, independently 
chosen for the best RF predictive model. E, ROC curves for Validation data 2 (samples from 
cancer patients with low ctDNA levels=57, healthy=26) for the same 3 classifiers as D. The 
beige curve represents the model using t-MAD only, the long-dashed green represents the 
logistic regression model combining the top 5 features (t-MAD score, 10bp amplitude, P(160-
180), P(180-220),  and P(250-320)), and the dashed red shows the result for a random 
forest classifier trained on the combination of same 5 predictive features. F, Plot 
representing the probability of classification as cancer with the RF model for all samples in 
both validation datasets. Samples are separated by cancer type and sorted within each by 
the RF probability of classification as cancer. The dashed horizontal line indicates 50% 
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. TAm-Seq V optimisations
. . Enzyme
Q HS (NEBM ), Ultra II (NEBM ), FastStart High Fidelity Enzyme Blend (Roche).
Master mix was prepared for each primer pool as outlined below to give μl total volume
per reaction and PCR performed in well plates.
Master mix for Q5 HS per reaction
Q5 HS 0.1 μl Final conc 0.02 U/μl
dNTPs 0.2 μl Final conc 200 μ
F and R primer mix (2 μ ) 2.5 μl Final conc 0.5 μ
5× Q5 buffer 2.0 μl Final conc 1x
DNA 1.0 μl 50 copies
H2O 4.2 μl
Master mix for Ultra II per reaction
Ultra II master mix 5.0 μl Final conc 1× Unit/U/μl
F and R primer mix (2 μ ) 2.5 μl Final conc 0.5 μ
DNA 1.0 μl 50 copies
H2O 1.5 μl
Master mix for Roche per reaction
10× FastStart High Fidelity Reaction Buffer without MgCl2 (Roche) 0.50 μl
25 m MgCl2 (Roche) 0.90 μl
DMSO (Roche) 0.25 μl
10 m Grade Nucleotide Mix (Roche) 0.10 μl
5 U/μl FastStart High Fidelity Enzyme Blend (Roche) 0.05 μl
20× Access Array Loading Reagent (Fluidigm) 0.25 μl
DNA (50 copies/μl) 1.00 μl
H2O 1.45 μl
cviii
. . Annealing temperature and extension time
Based on previous protocols in the lab and manufacturer recommendations different PCR
cycling parameters were tested. For the Q HS enzyme different PCR protocols were
performed as outlined below.
∘C 30 sec
∘C 10 sec
30 cycles∘C 4 min
∘C 30 sec
∘C 10 sec




For theUltra II enzyme three different PCRprotocols, including a touchdownprotocol,
were performed as outlined below.
∘C 30 sec
∘C 10 sec





4 cycles∘C 30 sec
∘C 45 sec
∘C 10 sec
4 cycles∘C 30 sec
∘C 45 sec
∘C 10 sec
4 cycles∘C 30 sec
∘C 45 sec
∘C 10 sec


































. . Primer concentrations
Two different primer concentrations were investigated: n , n . Master mix out-
lined below.
Master mix for 500 n primer concentration
Ultra II master mix 2.50 μl Final conc 1× U/μl
F and R primer mix (2 μ ) 1.25 μl Final conc 500 n
DNA 1.00 μl 50 copies
H2O 0.25 μl
Master mix for 100 n primer concentration
Ultra II master mix 2.50 μl Final conc 1× U/μl
F and R primer mix (2 μ ) 0.25 μl Final conc 100 n
DNA 1.00 μl 50 copies
H2O 1.00 μl
cxii
. . Puri ication irst round PCR product
PippinHT % agarose gel selecting for: – bp, – bp and – bp.
. . Barcoding
Three different barcoding reactions using the Fluidigm barcodes were investigated as out-
lined below.
Master mix for Roche barcoding per reaction
10× FastStart High Fidelity Reaction Buffer without MgCl2 (Roche) 1.00 μl
25 m MgCl2 (Roche) 1.80 μl
DMSO (Roche) 0.50 μl
10 m PCR Grade Nucleotide Mix (Roche) 0.20 μl
5 U/μl FastStart High Fidelity Enzyme Blend (Roche) 0.10 μl
H2O 3.40 μl
2 μ barcode 2.00 μl
DNA (direct from Pippin) 1.00 μl
Protocol for Roche barcoding
∘C 10 min
∘C 15 sec
15 cycles∘C 30 sec
∘C 1 min
∘C 3 min
Master mix for Q5 HS barcoding per reaction
Q5 HS 0.1 μl
dNTPs 0.2 μl
5× Q5 buffer 2.0 μl
H2O 4.2 μl
2 μ barcode 2.5 μl
DNA (direct from Pippin) 1.0 μl
cxiii
Protocol for Q5 HS barcoding
∘C 30 sec
∘C 10 sec
15 cycles∘C 30 sec
∘C 8 sec
∘C 2 min
Master mix for Ultra II barcoding per reaction
Ultra II master mix 5 μl
2 μ barcode 4 μl
DNA (direct from Pippin) 1 μl
Protocol for Ultra II barcoding
∘C 30 sec
∘C 10 sec
15 cycles∘C 75 sec
∘C 5 min
cxiv
. . Puri ication of inal PCR product
AMPure bead puri ication μl of PCR product+ μl H O. Sample:bead ratio : . . Eluted
in μl H O.
PippinHT μl of PCR product+ μl H O. % agarose gel selecting for – bp.
. . Primer pooling
Coverage in some amplicons particularly and remained poor across all exper-
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Amplicon 
Figure . : Primer pooling strategies. Darker lines indicate ends of exons. Strategy :
Standard. Strategy : Standard strategy mixing pools in ratio of : pool :pool . Strategy
: Swapping amplicon with and amplicon with . Strategy : Swapping amplicon
with and amplicon with . Strategy : Manual improvements to in house pooling
pipeline. Strategy : In house pooling pipeline with distance penalty< bp
cxv
. Mutation calls in cervical cytology samples
cxvi
Sample JBLAB	ID Cytology	Grade Mutation	Analysis Clinical	Outcome	
CRUK-CYT1 9201 6 EGFR	mutation	 cervical	adenocarcinoma
CRUK-CYT2 9202 6 no	mutation CIN2	and	high	grade	CGIN
CRUK-CYT3 9203 6 EGFR	mutation cervical	adenocarcinoma
CRUK-CYT4 9204 6 EGFR	mutation high	grade	CGIN
CYT003c 9205 6 PIK3CA	mutation CIN1	and	high	grade	CGIN
CYT004d 9206 6 no	mutation CIN3
CRUK-CYT5 9207 6 no	mutation CIN1	and	high	grade	CGIN
CRUK-CYT6 9208 0 PIK3CA,	TP53	mutation high-grade	serous	endometrial	carcinoma
CRUK-CYT7 9209 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT8 9210 0 KRAS	mutation	 Outcome	know	-	non-cervical
CRUK-CYT9 9211 6 no	mutation	 CIN3	and	high	grade	CGIN
CRUK-CYT10 9212 0 no	mutation	 normal	endometrium	(pipelle)
CRUK-CYT11 9213 6 no	mutation	 cervical	adenocarcinoma
CRUK-CYT12 9214 6 no	mutation	 CGIN
CRUK-CYT13 9215 6 no	mutation	 CIN1	and	high	grade	CGIN
CRUK-CYT14 9216 6 KRAS	mutation	 high	grade	CGIN
CRUK-CYT15 9217 6 no	mutation	 CIN1	and	high	grade	CGIN
CRUK-CYT16 9218 6 no	mutation normal	LLETZ
CRUK-CYT17 9219 6 PTEN	mutation normal	LLETZ
CRUK-CYT18 9220 0 PTEN	mutation	 Endometrial	adenocarcinoma
CRUK-CYT19 9221 6 no	mutation	 cervical	adenocarcinoma		
CRUK-CYT20 9222 0 KRAS	mutation	 Outcome	know	-	non-cervical
CRUK-CYT21 9223 6 no	mutation CIN3	and	high	grade	CGIN
CRUK-CYT22 9224 6 no	mutation CIN3	and	high	grade	CGIN
CRUK-CYT23 9225 6 no	mutation CIN1	and	CGIN
CRUK-CYT24 9226 0 no	mutation Outcome	know	-	non-cervical
CRUK-CYT25 9227 6 no	mutation CIN1	and	CGIN
CRUK-CYT26 9228 6 no	mutation high	grade	CGIN
CRUK-CYT27 9229 6 no	mutation CIN2		
CRUK-CYT28 9230 6 EGFR	and	TP53	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT29 9231 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT30 9232 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT31 9233 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT32 9234 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT33 9235 0 no	mutation normal	endometrium	(pipelle)
CRUK-CYT34 9236 6 no	mutation normal	endoemtrium	(pipelle)
CRUK-CYT35 9237 6 KRAS	mutation	 Stage	1B	endometrial	cancer
CRUK-CYT36 9238 6 no	mutation normal	endometrium	(pipelle)
CRUK-CYT37 9239 6 EGFR	mutation normal	endoemtrium	(pipelle)
CRUK-CYT38 9240 0 no	mutation normal	endoemtrium	(pipelle)
CRUK-CYT39 9244 0 KRAS	mutation	 Stage	1B	endometrial	cancer
CRUK-CYT40 9242 6 no	mutation normal	endometrium	(pipelle)
CRUK-CYT41 9241 0 no	mutation normal	endoemtrium	(pipelle)
CRUK-CYT42 9245 6 TP53	and	PIK3CA	mutation Non-cervical	cancer	detected
CRUK-CYT43 9243 6 no	mutation Outcome	known	-	none	of	the	above
CRUK-CYT44 9246 6 no	mutation Endometroid	carcinoma	FIGO	grade	1
CRUK-CYT45 9247 6 TP53	mutation	 Outcome	known	-	none	of	the	above
CRUK-CYT46 9248 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT47 9249 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT48 9250 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT49 9251 0 PTEN	mutation normal	endoemtrium	(pipelle)
CRUK-CYT50 9252 6 TP53	mutation	 Non-cervical	cancer	detected
CRUK-CYT51 9253 0 TP53	and	PIK3CA	mutation	 Non-cervical	cancer	detected
CRUK-CYT52 9254 6 TP53	and	PIK3CA	mutation Endometroid	carcinoma	FIGO	grade	1
CRUK-CYT53 9255 6 no	mutation Outcome	known	-	none	of	the	above
CRUK-CYT64 9256 0 TP53	mutation	 Outcome	known	-	none	of	the	above
CRUK-CYT65 9257 6 no	mutation CIN2		
CRUK-CYT56 9258 6 no	mutation CIN3
CRUK-CYT58 9259 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT55 9260 6 TP53	mutation	 cervical	adenocarcinoma	and	CGIN
CRUK-CYT93 9261 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT67 9262 6 TP53	and	PIK3CA	mutation	 cervical	adenocarcinoma	and	CGIN
CRUK-CYT68 9263 6 TP53	mutation	 cervical	adenocarcinoma	and	CGIN
CRUK-CYT61 9264 0 no	mutation Endometroid	carcinoma	FIGO	grade	1
CRUK-CYT66 9265 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT62 9266 6 PTEN	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT54 9267 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT59 9268 6 no	mutation cervical	adenocarcinoma	and	CGIN
CRUK-CYT60 9269 6 TP53	mutation	 cervical	adenocarcinoma	and	CGIN
CRUK-CYT57 9270 6 no	mutation CIN3
CRUK-CYT69 9271 0 no	mutation Outcome	known	-	none	of	the	above
. Speci ic variant calls for cervical samplesusingTAm-
Seq
Patient Sample type Position Reference Mutation MAF Background error Detected
612 cytology 7578375 DEL4 0.00000 NA FALSE
612 CMA 7578375 DEL4 0.00000 NA FALSE
622 cytology 7578433 G C 0.00003 0.00011 FALSE
622 CMA 7578433 G C 0.00007 0.00006 TRUE
791 cytology 7574003 G A 0.00332 0.00265 TRUE
791 CMA 7574003 G A 0.00255 0.00228 TRUE
617 cytology 7579378 G T 0.00006 0.00007 FALSE
617 CMA 7579378 G T 0.00000 0.00007 FALSE
810 cytology 7578407 G C 0.00168 0.00070 TRUE
810 CMA 7578407 G C 0.02669 0.00046 TRUE
822 cytology 7578259 A C 0.00007 0.00033 FALSE
822 CMA 7578259 A C 0.00000 0.00033 FALSE
831 cytology 7578265 A G 0.00000 0.00307 FALSE
847 cytology 7577094 G A 0.00681 0.00382 TRUE
853 cytology 7577529 A T 0.00019 0.00016 TRUE
870 cytology 7578455 DEL9 0.00000 NA FALSE
870 CMA 7578455 DEL9 0.00000 NA FALSE
890 cytology 7578269 G A 0.00122 0.00111 TRUE
897 cytology 7578394 T C 0.00430 0.00376 TRUE
897 CMA 7578394 T C 0.00338 0.00364 FALSE
cxviii
Patient Sample Type Histology Chromosome Position Reference Mutant Wells Matched	FFPE	Mutation	
OV04	617 9605 smear hgsoc chr17 7574029 C T 2 N
OV04	617 9605 smear hgsoc chr17 7577539 G A 2 N
OV04	617 9605 smear hgsoc chr17 7578245 G A 4 N
OV04	617 9605 smear hgsoc chr17 7578263 G A 3 N
OV04	617 9605 smear hgsoc chr17 7578420 C T 3 N
OV04	617 9605 smear hgsoc chr17 7578471 G A 2 N
OV04	617 9605 smear hgsoc chr17 7578475 G A 3 N
OV04	617 9605 smear hgsoc chr17 7579473 G A 2 N
OV04	617 9605 smear hgsoc chr17 7579547 G A 2 N
OV04	622 9613 smear hgsoc chr17 7574002 C T 2 N
OV04	622 9613 smear hgsoc chr17 7574013 G A 2 N
OV04	622 9613 smear hgsoc chr17 7574018 G A 2 N
OV04	622 9613 smear hgsoc chr17 7577121 G A 2 N
OV04	622 9613 smear hgsoc chr17 7578375 G A 2 N
OV04	622 9613 smear hgsoc chr17 7578388 C T 2 N
OV04	622 9613 smear hgsoc chr17 7578420 C T 2 N
OV04	622 9613 smear hgsoc chr17 7579312 C T 2 N
OV04	622 9613 smear hgsoc chr17 7579365 C T 2 N
OV04	622 9613 smear hgsoc chr17 7579543 G A 2 N
OV04	622 9613 smear hgsoc chr17 7579901 C T 2 N
OV04	791 9623 smear hgsoc chr17 7572978 G T 2 N
OV04	791 9623 smear hgsoc chr17 7574017 C T 3 N
OV04	791 9623 smear hgsoc chr17 7578406 C T 2 N
OV04	791 9623 smear hgsoc chr17 7579312 C T 4 N
OV04	791 9623 smear hgsoc chr17 7579901 C T 3 N
OV04	791 9623 smear hgsoc chr17 7579924 G A 2 N
OV04	810 9635 smear hgsoc chr17 7577070 G A 2 N
OV04	810 9635 smear hgsoc chr17 7577094 G A 2 N
OV04	810 9635 smear hgsoc chr17 7577548 C T 2 N
OV04	810 9635 smear hgsoc chr17 7578244 C T 2 N
OV04	810 9635 smear hgsoc chr17 7578262 C T 2 N
OV04	810 9635 smear hgsoc chr17 7578375 G A 2 N
OV04	810 9635 smear hgsoc chr17 7578407 G C 2 Y
OV04	810 9635 smear hgsoc chr17 7579885 C T 2 N
OV04	810 9651 smear hgsoc chr17 7574002 C T 2 N
OV04	810 9651 smear hgsoc chr17 7574018 G A 3 N
OV04	810 9651 smear hgsoc chr17 7574023 C T 3 N
OV04	810 9651 smear hgsoc chr17 7574023 C T 2 N
OV04	810 9651 smear hgsoc chr17 7577094 G A 4 Y
OV04	810 9651 smear hgsoc chr17 7577481 T C 2 N
OV04	810 9651 smear hgsoc chr17 7577539 G A 3 N
OV04	810 9651 smear hgsoc chr17 7577549 G A 2 N
OV04	810 9651 smear hgsoc chr17 7578212 G A 4 N
OV04	810 9651 smear hgsoc chr17 7578262 C T 2 N
OV04	810 9651 smear hgsoc chr17 7578461 C T 2 N
OV04	810 9651 smear hgsoc chr17 7578475 G A 2 N
OV04	810 9651 smear hgsoc chr17 7579312 C T 2 N
OV04	853 9652 smear hgsoc chr17 7576908 C A 2 N
OV04	853 9652 smear hgsoc chr17 7577539 G A 2 N
OV04	853 9652 smear hgsoc chr17 7577645 G A 2 N
OV04	853 9652 smear hgsoc chr17 7578388 C T 2 N
OV04	853 9652 smear hgsoc chr17 7578420 C T 3 N
OV04	853 9652 smear hgsoc chr17 7578463 C T 3 N
OV04	853 9652 smear hgsoc chr17 7578474 C T 2 N
OV04	853 9652 smear hgsoc chr17 7579437 C T 2 N
OV04	853 9652 smear hgsoc chr17 7579883 G A 2 N
OV05	96 9685 smear benign	 chr17 7572974 G A 2 N
. MutationcallsusingTAm-SeqV incervical samples
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OV05	96 9685 smear benign	 chr17 7574002 C T 4 N
OV05	96 9685 smear benign	 chr17 7574002 C T 3 N
OV05	96 9685 smear benign	 chr17 7574003 G A 3 N
OV05	96 9685 smear benign	 chr17 7574012 C T 4 N
OV05	96 9685 smear benign	 chr17 7574013 G A 4 N
OV05	96 9685 smear benign	 chr17 7574017 C T 2 N
OV05	96 9685 smear benign	 chr17 7574023 C T 6 N
OV05	96 9685 smear benign	 chr17 7574024 G A 4 N
OV05	96 9685 smear benign	 chr17 7574024 G A 3 N
OV05	96 9685 smear benign	 chr17 7574029 C T 5 N
OV05	96 9685 smear benign	 chr17 7574030 G A 2 N
OV05	96 9685 smear benign	 chr17 7577094 G A 2 N
OV05	96 9685 smear benign	 chr17 7577094 G A 3 N
OV05	96 9685 smear benign	 chr17 7577121 G A 2 N
OV05	96 9685 smear benign	 chr17 7577139 G A 2 N
OV05	96 9685 smear benign	 chr17 7577538 C T 3 N
OV05	96 9685 smear benign	 chr17 7577539 G A 2 N
OV05	96 9685 smear benign	 chr17 7577548 C T 4 N
OV05	96 9685 smear benign	 chr17 7577549 G A 2 N
OV05	96 9685 smear benign	 chr17 7577645 G A 4 N
OV05	96 9685 smear benign	 chr17 7578184 G A 3 N
OV05	96 9685 smear benign	 chr17 7578211 C T 2 N
OV05	96 9685 smear benign	 chr17 7578212 G A 5 N
OV05	96 9685 smear benign	 chr17 7578244 C T 3 N
OV05	96 9685 smear benign	 chr17 7578245 G A 3 N
OV05	96 9685 smear benign	 chr17 7578263 G A 2 N
OV05	96 9685 smear benign	 chr17 7578374 C T 2 N
OV05	96 9685 smear benign	 chr17 7578388 C T 3 N
OV05	96 9685 smear benign	 chr17 7578389 G A 3 N
OV05	96 9685 smear benign	 chr17 7578406 C T 3 N
OV05	96 9685 smear benign	 chr17 7578421 G A 2 N
OV05	96 9685 smear benign	 chr17 7578457 C T 4 N
OV05	96 9685 smear benign	 chr17 7578458 G A 8 N
OV05	96 9685 smear benign	 chr17 7578461 C T 3 N
OV05	96 9685 smear benign	 chr17 7578462 G A 3 N
OV05	96 9685 smear benign	 chr17 7578463 C T 4 N
OV05	96 9685 smear benign	 chr17 7578464 G A 2 N
OV05	96 9685 smear benign	 chr17 7578470 C T 2 N
OV05	96 9685 smear benign	 chr17 7578471 G A 10 N
OV05	96 9685 smear benign	 chr17 7578474 C T 5 N
OV05	96 9685 smear benign	 chr17 7578475 G A 6 N
OV05	96 9685 smear benign	 chr17 7579312 C T 2 N
OV05	96 9685 smear benign	 chr17 7579313 G A 2 N
OV05	96 9685 smear benign	 chr17 7579358 C T 8 N
OV05	96 9685 smear benign	 chr17 7579359 G A 2 N
OV05	96 9685 smear benign	 chr17 7579366 G A 3 N
OV05	96 9685 smear benign	 chr17 7579470 C T 2 N
OV05	96 9685 smear benign	 chr17 7579542 C T 2 N
OV05	96 9685 smear benign	 chr17 7579547 G A 4 N
OV05	96 9685 smear benign	 chr17 7579552 C T 2 N
OV05	96 9685 smear benign	 chr17 7579580 G A 2 N
OV05	96 9685 smear benign	 chr17 7579706 G A 3 N
OV05	96 9685 smear benign	 chr17 7579883 G A 7 N
OV05	96 9685 smear benign	 chr17 7579885 C T 2 N
OV05	96 9685 smear benign	 chr17 7579886 G A 2 N
OV05	96 9685 smear benign	 chr17 7579901 C T 4 N
OV05	96 9685 smear benign	 chr17 7579902 G A 3 N
cxx
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OV05	96 9685 smear benign	 chr17 7579924 G A 4 N
OV05	102 9688 smear benign	 chr17 7572973 C T 3 N
OV05	102 9688 smear benign	 chr17 7574002 C T 7 N
OV05	102 9688 smear benign	 chr17 7574003 G A 4 N
OV05	102 9688 smear benign	 chr17 7574012 C T 6 N
OV05	102 9688 smear benign	 chr17 7574013 G A 6 N
OV05	102 9688 smear benign	 chr17 7574018 G A 2 N
OV05	102 9688 smear benign	 chr17 7574024 G A 7 N
OV05	102 9688 smear benign	 chr17 7574029 C T 3 N
OV05	102 9688 smear benign	 chr17 7574030 G A 8 N
OV05	102 9688 smear benign	 chr17 7577022 G A 2 N
OV05	102 9688 smear benign	 chr17 7577070 G A 2 N
OV05	102 9688 smear benign	 chr17 7577090 C T 2 N
OV05	102 9688 smear benign	 chr17 7577139 G A 4 N
OV05	102 9688 smear benign	 chr17 7577144 A G 2 N
OV05	102 9688 smear benign	 chr17 7577484 C A 2 N
OV05	102 9688 smear benign	 chr17 7577538 C T 5 N
OV05	102 9688 smear benign	 chr17 7577539 G A 4 N
OV05	102 9688 smear benign	 chr17 7577548 C T 8 N
OV05	102 9688 smear benign	 chr17 7577549 G A 2 N
OV05	102 9688 smear benign	 chr17 7577645 G A 2 N
OV05	102 9688 smear benign	 chr17 7578184 G A 5 N
OV05	102 9688 smear benign	 chr17 7578211 C T 5 N
OV05	102 9688 smear benign	 chr17 7578212 G A 5 N
OV05	102 9688 smear benign	 chr17 7578239 C A 2 N
OV05	102 9688 smear benign	 chr17 7578244 C T 6 N
OV05	102 9688 smear benign	 chr17 7578245 G A 3 N
OV05	102 9688 smear benign	 chr17 7578262 C T 3 N
OV05	102 9688 smear benign	 chr17 7578263 G A 5 N
OV05	102 9688 smear benign	 chr17 7578374 C T 6 N
OV05	102 9688 smear benign	 chr17 7578388 C T 2 N
OV05	102 9688 smear benign	 chr17 7578389 G A 2 N
OV05	102 9688 smear benign	 chr17 7578406 C T 2 N
OV05	102 9688 smear benign	 chr17 7578420 C T 3 N
OV05	102 9688 smear benign	 chr17 7578421 G A 4 N
OV05	102 9688 smear benign	 chr17 7578455 C T 2 N
OV05	102 9688 smear benign	 chr17 7578461 C T 6 N
OV05	102 9688 smear benign	 chr17 7578462 G A 4 N
OV05	102 9688 smear benign	 chr17 7578463 C T 2 N
OV05	102 9688 smear benign	 chr17 7578464 G A 3 N
OV05	102 9688 smear benign	 chr17 7578470 C T 3 N
OV05	102 9688 smear benign	 chr17 7578471 G A 4 N
OV05	102 9688 smear benign	 chr17 7578474 C T 3 N
OV05	102 9688 smear benign	 chr17 7578475 G A 4 N
OV05	102 9688 smear benign	 chr17 7579312 C T 4 N
OV05	102 9688 smear benign	 chr17 7579313 G A 3 N
OV05	102 9688 smear benign	 chr17 7579358 C T 4 N
OV05	102 9688 smear benign	 chr17 7579365 C T 2 N
OV05	102 9688 smear benign	 chr17 7579366 G A 2 N
OV05	102 9688 smear benign	 chr17 7579423 G A 2 N
OV05	102 9688 smear benign	 chr17 7579438 C T 3 N
OV05	102 9688 smear benign	 chr17 7579438 C T 4 N
OV05	102 9688 smear benign	 chr17 7579441 C T 4 N
OV05	102 9688 smear benign	 chr17 7579441 C T 3 N
OV05	102 9688 smear benign	 chr17 7579442 G A 5 N
OV05	102 9688 smear benign	 chr17 7579543 G A 2 N
OV05	102 9688 smear benign	 chr17 7579547 G A 3 N
cxxi
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OV05	102 9688 smear benign	 chr17 7579883 G A 7 N
OV05	102 9688 smear benign	 chr17 7579885 C T 4 N
OV05	102 9688 smear benign	 chr17 7579886 G A 5 N
OV05	102 9688 smear benign	 chr17 7579902 G A 3 N
OV05	102 9688 smear benign	 chr17 7579923 C T 4 N
OV04	897 9691 smear hgsoc chr17 7572973 C T 3 N
OV04	897 9691 smear hgsoc chr17 7572973 C T 2 N
OV04	897 9691 smear hgsoc chr17 7572974 G A 5 N
OV04	897 9691 smear hgsoc chr17 7574002 C T 9 N
OV04	897 9691 smear hgsoc chr17 7574003 G A 6 N
OV04	897 9691 smear hgsoc chr17 7574012 C T 3 N
OV04	897 9691 smear hgsoc chr17 7574013 G A 7 N
OV04	897 9691 smear hgsoc chr17 7574017 C T 3 N
OV04	897 9691 smear hgsoc chr17 7574023 C T 6 N
OV04	897 9691 smear hgsoc chr17 7574023 C T 5 N
OV04	897 9691 smear hgsoc chr17 7574029 C T 6 N
OV04	897 9691 smear hgsoc chr17 7574030 G A 4 N
OV04	897 9691 smear hgsoc chr17 7574030 G A 5 N
OV04	897 9691 smear hgsoc chr17 7577047 G A 2 N
OV04	897 9691 smear hgsoc chr17 7577070 G A 2 N
OV04	897 9691 smear hgsoc chr17 7577091 G A 3 N
OV04	897 9691 smear hgsoc chr17 7577093 C T 5 N
OV04	897 9691 smear hgsoc chr17 7577093 C T 4 N
OV04	897 9691 smear hgsoc chr17 7577094 G A 4 N
OV04	897 9691 smear hgsoc chr17 7577094 G A 5 N
OV04	897 9691 smear hgsoc chr17 7577121 G A 3 N
OV04	897 9691 smear hgsoc chr17 7577138 C T 2 N
OV04	897 9691 smear hgsoc chr17 7577139 G A 8 N
OV04	897 9691 smear hgsoc chr17 7577538 C T 3 N
OV04	897 9691 smear hgsoc chr17 7577539 G A 2 N
OV04	897 9691 smear hgsoc chr17 7577548 C T 3 N
OV04	897 9691 smear hgsoc chr17 7577645 G A 4 N
OV04	897 9691 smear hgsoc chr17 7578184 G A 2 N
OV04	897 9691 smear hgsoc chr17 7578211 C T 3 N
OV04	897 9691 smear hgsoc chr17 7578212 G A 6 N
OV04	897 9691 smear hgsoc chr17 7578244 C T 4 N
OV04	897 9691 smear hgsoc chr17 7578245 G A 5 N
OV04	897 9691 smear hgsoc chr17 7578245 G A 4 N
OV04	897 9691 smear hgsoc chr17 7578263 G A 6 N
OV04	897 9691 smear hgsoc chr17 7578374 C T 4 N
OV04	897 9691 smear hgsoc chr17 7578375 G A 4 N
OV04	897 9691 smear hgsoc chr17 7578389 G A 5 N
OV04	897 9691 smear hgsoc chr17 7578406 C T 2 N
OV04	897 9691 smear hgsoc chr17 7578407 G A 7 N
OV04	897 9691 smear hgsoc chr17 7578420 C T 3 N
OV04	897 9691 smear hgsoc chr17 7578421 G A 2 N
OV04	897 9691 smear hgsoc chr17 7578455 C T 3 N
OV04	897 9691 smear hgsoc chr17 7578458 G A 3 N
OV04	897 9691 smear hgsoc chr17 7578461 C T 2 N
OV04	897 9691 smear hgsoc chr17 7578462 G A 4 N
OV04	897 9691 smear hgsoc chr17 7578463 C T 2 N
OV04	897 9691 smear hgsoc chr17 7578470 C T 4 N
OV04	897 9691 smear hgsoc chr17 7578474 C T 3 N
OV04	897 9691 smear hgsoc chr17 7578475 G A 6 N
OV04	897 9691 smear hgsoc chr17 7578516 G A 2 N
OV04	897 9691 smear hgsoc chr17 7579312 C T 4 N
OV04	897 9691 smear hgsoc chr17 7579313 G A 6 N
cxxii
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OV04	897 9691 smear hgsoc chr17 7579358 C T 2 N
OV04	897 9691 smear hgsoc chr17 7579358 C T 3 N
OV04	897 9691 smear hgsoc chr17 7579359 G A 3 N
OV04	897 9691 smear hgsoc chr17 7579365 C T 2 N
OV04	897 9691 smear hgsoc chr17 7579366 G A 3 N
OV04	897 9691 smear hgsoc chr17 7579438 C T 5 N
OV04	897 9691 smear hgsoc chr17 7579441 C T 5 N
OV04	897 9691 smear hgsoc chr17 7579441 C T 6 N
OV04	897 9691 smear hgsoc chr17 7579442 G A 2 N
OV04	897 9691 smear hgsoc chr17 7579470 C T 5 N
OV04	897 9691 smear hgsoc chr17 7579470 C T 3 N
OV04	897 9691 smear hgsoc chr17 7579473 G A 3 N
OV04	897 9691 smear hgsoc chr17 7579473 G A 4 N
OV04	897 9691 smear hgsoc chr17 7579542 C T 5 N
OV04	897 9691 smear hgsoc chr17 7579543 G A 4 N
OV04	897 9691 smear hgsoc chr17 7579547 G A 2 N
OV04	897 9691 smear hgsoc chr17 7579580 G A 3 N
OV04	897 9691 smear hgsoc chr17 7579706 G A 4 N
OV04	897 9691 smear hgsoc chr17 7579885 C T 5 N
OV04	897 9691 smear hgsoc chr17 7579886 G A 3 N
OV04	897 9691 smear hgsoc chr17 7579901 C T 5 N
OV04	897 9691 smear hgsoc chr17 7579902 G A 3 N
OV04	897 9691 smear hgsoc chr17 7579923 C T 4 N
OV04	897 9691 smear hgsoc chr17 7579924 G A 5 N
OV05	108 9692 smear benign	 chr17 7572973 C T 3 N
OV05	108 9692 smear benign	 chr17 7574002 C T 9 N
OV05	108 9692 smear benign	 chr17 7574003 G A 3 N
OV05	108 9692 smear benign	 chr17 7574012 C T 6 N
OV05	108 9692 smear benign	 chr17 7574013 G A 7 N
OV05	108 9692 smear benign	 chr17 7574017 C T 6 N
OV05	108 9692 smear benign	 chr17 7574018 G A 4 N
OV05	108 9692 smear benign	 chr17 7574023 C T 4 N
OV05	108 9692 smear benign	 chr17 7574024 G A 2 N
OV05	108 9692 smear benign	 chr17 7574029 C T 3 N
OV05	108 9692 smear benign	 chr17 7574030 G A 3 N
OV05	108 9692 smear benign	 chr17 7577070 G A 3 N
OV05	108 9692 smear benign	 chr17 7577094 G A 2 N
OV05	108 9692 smear benign	 chr17 7577139 G A 3 N
OV05	108 9692 smear benign	 chr17 7577538 C T 3 N
OV05	108 9692 smear benign	 chr17 7577539 G A 5 N
OV05	108 9692 smear benign	 chr17 7577548 C T 6 N
OV05	108 9692 smear benign	 chr17 7578184 G A 4 N
OV05	108 9692 smear benign	 chr17 7578211 C T 2 N
OV05	108 9692 smear benign	 chr17 7578244 C T 5 N
OV05	108 9692 smear benign	 chr17 7578262 C T 4 N
OV05	108 9692 smear benign	 chr17 7578263 G A 2 N
OV05	108 9692 smear benign	 chr17 7578374 C T 2 N
OV05	108 9692 smear benign	 chr17 7578388 C T 3 N
OV05	108 9692 smear benign	 chr17 7578389 G A 2 N
OV05	108 9692 smear benign	 chr17 7578406 C T 2 N
OV05	108 9692 smear benign	 chr17 7578420 C T 3 N
OV05	108 9692 smear benign	 chr17 7578421 G A 2 N
OV05	108 9692 smear benign	 chr17 7578455 C T 4 N
OV05	108 9692 smear benign	 chr17 7578455 C T 3 N
OV05	108 9692 smear benign	 chr17 7578457 C T 3 N
OV05	108 9692 smear benign	 chr17 7578458 G A 3 N
OV05	108 9692 smear benign	 chr17 7578461 C T 8 N
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OV05	108 9692 smear benign	 chr17 7578462 G A 4 N
OV05	108 9692 smear benign	 chr17 7578463 C T 5 N
OV05	108 9692 smear benign	 chr17 7578464 G A 6 N
OV05	108 9692 smear benign	 chr17 7578470 C T 5 N
OV05	108 9692 smear benign	 chr17 7578471 G A 3 N
OV05	108 9692 smear benign	 chr17 7578474 C T 4 N
OV05	108 9692 smear benign	 chr17 7578475 G A 3 N
OV05	108 9692 smear benign	 chr17 7579312 C T 4 N
OV05	108 9692 smear benign	 chr17 7579312 C T 5 N
OV05	108 9692 smear benign	 chr17 7579358 C T 5 N
OV05	108 9692 smear benign	 chr17 7579359 G A 4 N
OV05	108 9692 smear benign	 chr17 7579365 C T 2 N
OV05	108 9692 smear benign	 chr17 7579366 G A 4 N
OV05	108 9692 smear benign	 chr17 7579423 G A 2 N
OV05	108 9692 smear benign	 chr17 7579431 C A 2 N
OV05	108 9692 smear benign	 chr17 7579441 C T 6 N
OV05	108 9692 smear benign	 chr17 7579442 G A 2 N
OV05	108 9692 smear benign	 chr17 7579470 C T 2 N
OV05	108 9692 smear benign	 chr17 7579473 G A 3 N
OV05	108 9692 smear benign	 chr17 7579542 C T 2 N
OV05	108 9692 smear benign	 chr17 7579547 G A 5 N
OV05	108 9692 smear benign	 chr17 7579883 G A 5 N
OV05	108 9692 smear benign	 chr17 7579886 G A 4 N
OV05	108 9692 smear benign	 chr17 7579901 C T 5 N
OV05	108 9692 smear benign	 chr17 7579902 G A 3 N
OV05	108 9692 smear benign	 chr17 7579923 C T 6 N
OV05	108 9692 smear benign	 chr17 7579923 C T 4 N
OV05	108 9692 smear benign	 chr17 7579924 G A 4 N
OV05	12 9903 CMA benign	 chr17 7579423 G A 2 N
OV05	26 9904 CMA benign	 chr17 7578184 G A 2 N
OV05	26 9904 CMA benign	 chr17 7578262 C T 2 N
OV05	26 9904 CMA benign	 chr17 7579423 G A 3 N
OV05	26 9904 CMA benign	 chr17 7579470 C T 2 N
OV05	26 9904 CMA benign	 chr17 7579924 G A 2 N
OV04	612 9906 CMA hgsoc chr17 7578389 G A 3 N
OV04	612 9906 CMA hgsoc chr17 7578475 G A 2 N
OV04	791 9907 CMA hgsoc chr17 7578263 G A 2 N
OV04	897 9923 CMA hgsoc chr17 7574012 C T 2 N
OV04	897 9923 CMA hgsoc chr17 7576899 G T 2 N
OV04	897 9923 CMA hgsoc chr17 7578211 C T 2 N
OV04	897 9923 CMA hgsoc chr17 7578386 A G 2 N
OV04	897 9923 CMA hgsoc chr17 7578420 C T 2 N
OV04	897 9923 CMA hgsoc chr17 7578421 G A 2 N
OV04	897 9923 CMA hgsoc chr17 7578463 C T 2 N
OV04	897 9923 CMA hgsoc chr17 7579312 C T 10 N
OV04	897 9923 CMA hgsoc chr17 7579313 G A 2 N
OV04	897 9923 CMA hgsoc chr17 7579365 C T 2 N
OV04	897 9923 CMA hgsoc chr17 7579366 G A 2 N
OV04	897 9923 CMA hgsoc chr17 7579423 G A 2 N
OV04	897 9923 CMA hgsoc chr17 7579543 G A 2 N
OV04	897 9923 CMA hgsoc chr17 7579706 G A 2 N
OV04	897 9923 CMA hgsoc chr17 7579883 G A 2 N
OV04	897 9923 CMA hgsoc chr17 7579923 C T 2 N
OV04	897 9923 CMA hgsoc chr17 7579924 G A 2 N
cxxiv
. p autoantibodies and ctDNA
OV04 Mutation Protein effect Mutation type MAF p53 autoantibody status
20 c.G646T p.V216L nonsynonymous 0.0333 Strong Positive 
22 c.G824A p.C275Y nonsynonymous 0.0196 Negative
37 c.C298T p.Q100X stopgain ND Negative
47 c.T428A p.V143E nonsynonymous ND Negative
66 c.C742T p.R248W nonsynonymous ND Strong Positive 
68 c.G396C p.K132N nonsynonymous 0.2373 Negative
81 c.T584A p.I195N nonsynonymous 0.0094 Strong Positive 
83 c.C833T p.P278L nonsynonymous 0.2700 Negative
88 c.A774T p.E258D nonsynonymous ND Negative
98 c.681dupT p.D228_C229delinsX indel 0.3506 Negative
127 c.G818A p.R273H nonsynonymous 0.0081 Negative
135 c.583dupA p.I195fs indel 0.0635 Negative
139 c.C742T p.R248W nonsynonymous ND Positive
141 c.C722T p.S241F nonsynonymous 0.0300 Negative
168 c.T526A p.C176S nonsynonymous ND Negative
170 c.G524A p.R175H nonsynonymous ND Negative
174 c.C380T p.S127F nonsynonymous 0.0023 Negative
176 c.A745G p.R249G nonsynonymous ND Negative
189 c.G422A p.C141Y nonsynonymous 0.0313 Negative
190 c.139_148del p.47_50del indel 0.1073 Negative
191 c.G743A p.R248Q nonsynonymous 0.0028 Negative
193 c.G733A p.G245S nonsynonymous ND Negative
194 c.C843G p.D281E nonsynonymous 0.0001 Negative
197 c.C206G p.A69G nonsynonymous 0.0001 Negative
203 c.G469T p.V157F nonsynonymous ND Strong Positive 
211 c.611delA p.E204fs indel ND Negative
212 c.T815G p.V272G nonsynonymous 0.0134 Negative
219 c.1013dupT p.F338fs indel ND Positive
220 c.G743A p.R248Q nonsynonymous ND Negative
223 c.T470G p.V157G nonsynonymous 0.0001 Negative
224 c.G743A p.R248Q nonsynonymous 0.0026 Negative
225 c.G427A p.V143M nonsynonymous 0.0180 Strong Positive 
227 c.C215T p.P72L nonsynonymous 0.0600 Negative
229 c.G524A p.R175H nonsynonymous ND Strong Positive 
235 c.del626-627GA p.209del indel ND Negative
238 c.G1044T p.L348F nonsynonymous ND Negative
242 c.G859T p.E287X stopgain ND Negative
244 c.A838T p.R280X stopgain ND Negative
247 c.G713A p.C238Y nonsynonymous 0.0016 Strong Positive 
254 c.C376T p.Y126T splicing ND Negative
256 c.A659G p.Y220C nonsynonymous 0.1805 Strong Positive 
259 c.A122G p.D41G nonsynonymous ND Negative
260 c.C832T p.P278S nonsynonymous 0.1600 Negative
261 c.T584C p.I195T nonsynonymous 0.0044 Positive
262 c.T584C p.I195T nonsynonymous ND Strong Positive 
263 c.del723C p.241del indel 0.0076 Negative
267 c.G1015T p.E339X stopgain 0.0790 Negative
ND - Not detected
cxxv
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270 c.del308-309AC p.103del indel ND Positive
271 c.G527T p.C176F nonsynonymous 0.0001 Positive
274 c.G673A p.V225I splicing 0.0025 Positive
275 c.A701G p.Y234C nonsynonymous 0.0032 Negative
276 c.C577T p.H193Y nonsynonymous 0.0018 Strong Positive 
277 c.T581G p.L194R nonsynonymous 0.0408 Strong Positive 
279 c.C380T p.S127F nonsynonymous 0.0048 Strong Positive 
280 c.702-703insG p.235del indel 0.0290 Negative
281 C.189delT p.64del indel ND Negative
283 c.G818T p.R273L nonsynonymous ND Negative
284 c.383delC p.128del indel 0.2198 Negative
293 c.275-281delCCCTGT p.86del indel 0.0047 Negative
295 c.T613C p.Y205H nonsynonymous 0.0034 Negative
297 c.G661T p.E221X stopgain 0.0360 Positive
301 c.G713T p.C238F nonsynonymous ND Negative
303 c.G841C p.D281H nonsynonymous ND Positive
304 c.G892T p.E298X stopgain ND Negative
305 c.C376T p.Y126T splicing ND Strong Positive 
307 c.G824T p.C275F nonsynonymous ND Strong Positive 
309 c.C310T p.Q104X stopgain 0.0084 Positive
311 c.G524A p.R175H nonsynonymous ND Strong Positive 
312 c.C742T p.R248W nonsynonymous ND Negative
314 c.A659G p.Y220C nonsynonymous 0.0207 Strong Positive 
315 c.C1024T p.R342X stopgain 0.0029 Negative
316 c.A488G p.Y163C nonsynonymous ND Negative
323 c.585-590delCCGAGT p.197del indel ND Negative
326 c.G524A p.R175H nonsynonymous ND Negative
330 c.403delT p.135del indel 0.0026 Negative
331 c.T809G p.F270C nonsynonymous ND Negative
334 c.G711A p.M237I nonsynonymous ND Positive
337 c.C742T p.R248W nonsynonymous ND Positive
341 c.C430T p.Q144X stopgain 0.0017 Negative
346 c.G524A p.R175H nonsynonymous 0.0039 Negative
348 c.C637T p.R213X stopgain 0.0311 Negative
354 c.761delT p.I254fs indel ND Negative
356 c.G713T p.C238F nonsynonymous 0.0006 Strong Positive 
358 c.1014delC p.F338fs indel 0.0284 Negative
359 c.565delG p.189del indel 0.1872 Negative
362 c.G517T p.V173L nonsynonymous 0.0065 Negative
363 c.A394G p.K132E nonsynonymous 0.0298 Strong Positive 
367 c.C376T p.Y126T splicing ND Negative
373 c.G824A p.C275Y nonsynonymous 0.0013 Strong Positive 
378 c.G1036T p.E346X stopgain ND Positive
379 c.T363G p.S121S synonymous 0.0012 Positive
381 c.G151T p.E51X stopgain 0.0001 Negative
382 c.569-570insG p.190ins indel 0.1700 Negative
383 c.G747T p.R249S nonsynonymous ND Negative
385 c.A659G p.Y220C nonsynonymous 0.0032 Strong Positive 
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Circulating tumour DNA (ctDNA) offers new opportunities for non-invasive cancer 
management. Detecting ctDNA in plasma is challenging since it constitutes only a minor 
fraction of the total cell-free DNA (cfDNA). Pre-analytical factors affect cfDNA levels 
contributed from leukocyte lysis, hence the ability to detect low-frequency mutant alleles. This 
study investigates the effects of (i) delay in processing (ii) storage temperatures, (iii) different 
blood collection tubes, (iv) centrifugation protocols and (v) sample shipment on cfDNA levels. 
Peripheral blood (n=231) from cancer patients (n=62) were collected into K3EDTA or Cell-free 
DNA BCT® (BCT) tubes and analysed by digital PCR (dPCR), targeted amplicon or shallow 
whole-genome (sWGS) sequencing. To assess pre-analytic effects, plasma was processed 
under different conditions after 0h, 6h, 24h, 48h, 96h and 1 week at room temperature (RT) or 
4°C, or using different centrifugation protocols. dPCR showed that cfDNA levels increased 
gradually with time in K3EDTA tubes, but were stable in BCT tubes. K3EDTA samples stored 
at 4°C showed less variation than RT storage, but levels were elevated compared to BCT. A 
second centrifugation at 3000g gave similar cfDNA yields compared to higher speed 
centrifugation. Next-generation sequencing showed negligible differences in background error 
or copy number changes between K3EDTA and BCT, or following shipment in BCT. This study 














Circulating tumour DNA (ctDNA) in plasma offers new opportunities for non-invasive cancer 
management. Recent studies have demonstrated its potential for molecular stratification, 
monitoring tumour response, identifying resistance mutations and patients at risk of relapse [1, 
2] . Detecting ctDNA in plasma is challenging since it constitutes only a minor fraction of the 
total cell-free DNA (cfDNA), particularly in early stage cancers and in the minimal residual 
disease setting [3, 4]. A proportion of background wild-type DNA is believed to originate from 
lysis of white blood cells [5]. Previous studies have highlighted the pre-analytic effects of 
different processing and collection protocols on plasma ctDNA levels from cancer patients and 
pregnant women [6-9]. Based on these results, it is recommended to process whole blood 
samples for retrieval of plasma as soon as possible after collection, prior to in vitro cell lysis. 
At the same time, a double-centrifugation protocol has been recommended to obtain cell-free 
plasma, using an initial slow centrifugation speed to separate plasma, then fast centrifugation 
to clear cellular material [7]. However, some of these procedures may be difficult to carry out 
in a clinical setting due to lack of appropriate personnel or equipment. To circumvent this, cell-
stabilising blood collection tubes have become available to stabilise cell-free DNA, enabling a 
delay in processing which may be carried out under more controlled conditions and within 
centralised laboratories. This study aimed to perform a systematic comparison of the effects 
of different processing protocols and collection tubes on the levels of cfDNA and ctDNA from 
cancer patients using digital PCR (dPCR). With the growing use of next-generation sequencing 
(NGS) for the analysis of ctDNA, we also aimed to investigate the effect of different protocols 
and collection tubes on the performance of targeted amplicon and shallow whole genome 











The study was designed to include 5 different Modules: Module 1 investigated the effects of 
delayed processing on the levels of circulating DNA (cfDNA and ctDNA) in plasma collected in 
K3EDTA tubes (9mL S-Monovette®, Sarstedt, Germany). The separation of plasma was 
delayed for different durations: 0h, 6h, 24h, 48h, 96h, and 1 week at room temperature (19-
25°C, RT). Module 2 investigated the effects of storage temperature on the levels of circulating 
DNA in plasma collected in K3EDTA tubes. Samples were stored at RT or at 4°C prior to 
processing at the following hours post-collection: 0h, 24h, 48h and 96h. Module 3 investigated 
the effects of collection devices on the levels of circulating DNA. Blood samples from each 
patient were collected at the same time point into K3EDTA tubes and cell-stabilization blood 
collection tubes (10mL Cell-Free DNA BCT®, Streck, US) respectively. BCT’s contain a 
proprietary formaldehyde-free preservative that stabilises nucleated blood cells preventing the 
release of genomic DNA [10, 11]. The processing was performed at the following times post-
collection: 0h, 96h and 1 week. Module 4 investigated the effects of different centrifugation 
protocols on the levels of circulating DNA. Module 5 investigated the effects of shipment on 
samples collected in BCT tubes at ambient temperature. For Modules 1, 2, 3 and 5, plasma 
was separated from blood using a double-centrifugation protocol (Protocol A): a first 
centrifugation at 820g for 10min in a mega-centrifuge (Thermo Sorvall Legend RT, Fisher 
Scientific, US), then subjected to a second centrifugation step of the plasma supernatant at 
14,000g for 10min in a bench top micro-centrifuge (Heraeus Fresco 21, Thermo Scientific, US).  
For Module 4, blood aliquots from the same patients were processed with three different 
protocols: Protocol A as above, Protocol B with the first centrifugation performed at 1600g and 
the second centrifugation at 14000g for 10 min in a bench top micro-centrifuge, and Protocol 
C with both first and second centrifugations performed in the same mega-centrifuge, initially at 
1600g for 10min, then at 3000g for 10min.  
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Patient samples and DNA extractions 
 
Peripheral whole blood was collected from 62 patients in total: 47 patients with high-grade 
serous ovarian cancer and 15 patients with metastatic breast cancer. Informed consent was 
obtained from each patient with protocols approved by an institutional ethics committee. 15-
30mL blood from each patient was processed according to each analysis Module. DNA from 
all samples, except Module 5, was extracted from average 1.4 mL (range: 0.3 mL - 2.76 mL) 
plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Germany) according to 
manufacturer’s protocol, except that 6.2 µg carrier RNA was added per sample. DNA was 
eluted twice through the column to maximise yield. A non-human spike-in PCR product was 
added to each sample as an internal quality control to assess extraction efficiency [12]. In 
Module 5, DNA was extracted from plasma on a QIAsymphony robot (Qiagen, Germany) using 
a 2mL extraction protocol. Eluted DNA was stored at -20 °C until analysis.  
 
A total of 231 blood samples aliquots were analysed in this study. Table 1 summarises the 
number of plasma samples collected for each Module. Note that the collection was designed 
in such a way that each sample from every processing condition (temperature; collection tube; 
delayed processing duration) had a matched sample that was collected in K3EDTA and 
processed immediately (denoted E.RT.0h) using centrifugation Protocol A, and was assigned 
as the reference sample for each condition. The levels of circulating DNA (either cfDNA or 
ctDNA), were expressed as a ratio of the respective data with the reference sample (E.RT.0h). 
Therefore, data collected under the same processing conditions could be grouped together to 
evaluate the effect of the processing even though they were collected from different patients. 
A more detailed summary of the distribution of samples involved in each Module is given in 
Supplemental Table S1.  
 




Plasma samples from ovarian and breast cancer patients were first quantified by dPCR (using 
the Biomark microfluidic system (Fluidigm, US) as previously described [13], using an assay 
which targets a 65-bp amplicon in RPP30, a non-amplified region in the genome, to estimate 
cfDNA levels [12, 14]. ctDNA levels were then determined by dPCR using dual-labelled patient-
specific TaqMan assays designed to mutant and wild-type sequences in TP53 or PIK3CA, or 
deletions in chromosome 8, 11 or 17.  A summary of the samples analysed is provided in 
Supplemental Table S1, and sequences of primers and fluorescent probes, amplicon sizes 
and amplification conditions used in dPCR are detailed in Supplemental Table S2.  
 
The levels of cfDNA and ctDNA were calculated from the number of observed amplifications 
above a set threshold, and Poisson statistics were used to convert the number of observed 
amplifications to estimated targets, assuming independent segregation of DNA molecules into 
the microfluidic reaction chambers. The total number of amplifiable copies of DNA molecules 
per mL of plasma (copies/mL) were calculated, taking into account the relative fraction of the 
extracted DNA loaded and the proportion of sample lost during the loading process through 
the microfluidic channels. The levels of ctDNA were calculated as mutant allele fraction (i.e. 
the fraction of mutant DNA copies divided by the total cfDNA copies) expressed as a 
percentage or as mutant copies/mL plasma. For the purpose of comparing different protocols 
in the Modules, we expressed the data at each processing condition as a ratio from the 
E.RT.0h reference sample that was collected in K3EDTA and immediately processed according 
to Protocol A, unless otherwise specified. 
 
To investigate the effects of different collection devices and processing protocols on the 
performance of NGS, plasma samples from all Modules were analysed by TAm-Seq (Tagged 
Amplicon deep sequencing), as previously described [13]. TAm-Seq is a targeted amplicon 
sequencing method that allows identification and quantification of low frequency mutant alleles 
in plasma across sizable genomic regions.  Sequencing was performed using an Illumina 
HiSeq 2500 to an average of greater than 1000x sequencing depth. Mutations were identified 
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and quantified as previously described [13]. To assess the effect of collection and processing 
procedures on the background error rates during NGS, we generated the allelic read ratio 
(reference/alternative) at each position within R (v3.1.2) from the BAM files, using the 
Bioconductor packages Rsamtools and Biostrings. All positions flagged as polymorphic by the 
1000 Genomes Project or the COSMIC database, were filtered out.  
 
To investigate the effects of shipping on global somatic copy number alterations (sCNAs), 
samples in Module 5 were also subjected to sWGS [15]. Briefly, a DNA library was prepared 
from 2-10ng of cfDNA from each sample using the ThruPLEX DNA-seq Kit (Rubicon Genomics, 
US) and sequenced on an Illumina HiSeq 4000 to 0.1x average depth using single-end 
sequencing. Sequence data was analysed using a pipeline that involved the following: single-
end sequence reads were aligned to the human reference genome (GRCh37) using BWA-
mem v0.7.17 [16] after removing any contaminant adapter sequences. SAMtools v1.7 was 
used to convert files to BAM format. PCR and optical duplicates were marked using Picard-
Tools’ ‘MarkDuplicates’ feature v2.17.6 and these were excluded from downstream analysis 
along with reads of low mapping quality and supplementary alignments. Reads in each sample 
were down-sampled to approximately 3 million reads in order to have similar coverage between 
patients and conditions. Subsequently, copy number analysis was performed in R [17] using 
the R package CNAclinic v1.0 (https://github.com/sdchandra/CNAclinic; manuscript under 
review), a software suite which allows for robust copy number analysis of sWGS data. Briefly, 
sequence reads were allocated into equally sized (100Mb) non-overlapping bins throughout 
the length of the genome. Read counts in each bin were corrected to account for sequence 
GC content and mappability, and regions corresponding to artefacts and probable germline 
changes were excluded from downstream analysis utilising a cohort of 45 healthy controls. 
After median normalization, binned counts were segmented using both the ‘Circular Binary 
Segmentation’ and Hidden-Markov Model based algorithms and an averaged log2R value per 






The difference in circulating DNA levels between different sub-groups in each Module was 
analysed using non-parametric Mann Whitney Rank Sum Test unless specified and a p-value 
of <0.05 was considered statistically significant. To assess the noise of sWGS data we 
calculated values corresponding to the `Median of the Absolute values of all Pairwise 
Differences' (MAPD) between log2R copy numbers. This metric provides a measure of the 
noise of the sample that is less dependent on true biological copy number variation and more 
on technical variation[18]. To compare the 3 collection methods in all patients, we calculated 
pairwise Spearman correlations between the binned copy number segments of the 3 collection 
methods. Furthermore, we applied a non-parametric Wilcoxon signed rank test on these values 




Module 1: The effects of delayed processing on the levels of circulating DNA in plasma 
collected in EDTA tubes 
 
In this Module, all samples (n=26) were collected in K3EDTA tubes. One tube from each 
collection was processed immediately. The other tubes were stored at RT and processed at 
different prolonged time points: 6h, 24h, 48h, 96h and 1 week. Analysis by dPCR showed that 
the levels of cfDNA in the plasma samples increased gradually with increasing delay in the 
processing (Figure 1A), whereas the fraction of ctDNA decreased (Figure 1B). In particular, 
the levels of cfDNA increased significantly after 48h, 96h and 1 week of delay, whereas the 
mutant allele fraction of ctDNA decreased significantly after 96h and 1 week of delay (Mann 
Whitney Rank Sum Test, p-value<0.05). Previous reports have indicated that in analysis of 
circulating cell-free DNA from maternal plasma, despite changes in total cfDNA, the levels of 
fetal DNA are relatively stable in different storage and processing conditions [8, 19]. Indeed, 
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our results confirm that the numbers of mutant molecules, expressed as copies/mL of plasma, 
were relatively stable across the different processing time points with no statistically significant 
difference observed compared to samples that were processed immediately (Figure 1C, 
Supplemental Figure S1A and S1B) 
 
Module 2: The effects of storage temperature on the levels of circulating DNA in plasma 
collected in K3EDTA tubes 
 
In this Module, all samples (n=26) were collected in K3EDTA tubes, and either processed to 
plasma immediately or after 24h, 48h and 96h. The individual tubes were stored in two 
conditions: at RT (19-25°C), or at 4°C. If kept at RT, dPCR showed that the levels of cfDNA 
significantly increased after 48h. If kept at 4°C, the levels increased after 48h but were 
significantly lower than those observed at RT (Figure 2A).  If delayed for 96h, samples kept at 
RT and 4°C all increased significantly. The changes in mutant allele fraction showed an 
inverted similar trend, although the amount of available data was too low for statistical analysis 
(Figure 2B).  
 
Module 3: The effects of collection devices (K3EDTA versus Cell-free DNA BCT) on the levels 
of circulating DNA 
 
In this Module, one K3EDTA tube for each collection was processed immediately (E.RT.0h) 
and served as a reference sample (n=20). The other K3EDTA tubes were stored for 96h (n=5) 
and one week (n=5) at RT. Cell-free DNA BCT’s were stored at RT and processed immediately 
(n=5) or delayed for 96h (n=10) and 1 week (n=15). The cfDNA levels increased significantly 
after 1 week if kept in K3EDTA tubes, but remained at similar levels if kept in BCT (Figure 3A). 
The changes in the mutant allele fraction showed an inverted similar trend, but the amount of 
data available was too low for statistical analysis (Figure 3B). We compared the mutant allele 
fraction from 6 patients that were collected in K3EDTA and processed immediately, versus the 
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matched samples that were collected in BCT and processed after 1 week’s delay. The levels 
of ctDNA were similar for 4 patients but decreased two-fold for 2 patient samples 
(Supplemental Figure S2). There was no statistically significant difference in the numbers of 
mutant copies/mL plasma between storage in the two tube types (Supplemental Figure S1A 
and S1B). 
 
We next assessed the effects of collection and processing procedures on the background error 
rates during NGS analysis using targeted amplicon sequencing. As previously described, 
different A/C/G/T base substitutions are associated with different error rates [13]. We plotted 
the distribution of the ratio of non-reference:reference alleles as box plots, shown according to 
mutation types. We did not observe a difference using different collection devices and 
processing conditions (Figure 3C). 
 
Module 4: The effects of different centrifugation speed on the levels of circulating DNA 
 
In this Module, all samples (n=13) were collected in K3EDTA tubes and processed immediately. 
Aliquots from the same patients were processed using three different centrifugation protocols 
(A to C) as defined in Methods. There were no statistically significant differences across the 
three protocols on the total circulating DNA levels as measured by dPCR (Figure 4A and B), 
or in mutant allele fraction as measured by targeted amplicon sequencing (Figure 4C and D). 
 
Module 5: The effects of shipment of Cell-free DNA BCT on mutant allele fraction and global 
copy number changes.  
 
In this Module, three tubes of blood were drawn from each patient (n=13). K3EDTA tubes were 
processed immediately (E.RT.0h), one Cell-free DNA BCT collected and stored at RT within 
the same centralised processing lab while the other BCT was packaged and shipped back to 
the same lab. All shipped samples, apart from three, were received and processed within 48h 
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from the time of collection. Of these, two BCT’s were processed after 96h and one was 
processed after 5 days. The stored BCT’s were processed at the same time as the matched 
shipped sample. There was no statistically significant difference in cfDNA levels between the 
three collection methods (Figure 5A and B). TP53 mutations were identified by amplicon 
sequencing in 4 patients, and there were no statistically significant differences in mutant allele 
fraction using the different collection methods (Figure 5C and D). 
 
To further investigate the effects of collection methods on global copy number changes, we 
performed sWGS analysis on 4 patients that had TP53 mutations detected (P161, P227, P479, 
P488) and 4 without (P615, P489, P464, P450). Data from 1 patient (P464) was excluded from 
further analysis as the total read counts generated for one of the collection methods was below 
1 million. This is below the threshold recommended for inference when analysing shallow 
coverage [20]. The segmental copy number profiles among the 3 collection methods were 
highly similar showing an average Spearman correlation of 0.76, range = 0.44 - 0.98 
(Supplemental Figure S3, Supplemental Table S3). The paired Wilcoxon test p-values 
indicated no significant differences in all 21 copy number distributions comparisons (p-values 
> 0.001). Supplemental Figure S4 shows an example of the copy number alterations in plasma 
samples processed with and without shipping. The same gains and losses in chromosomal 
arms were identified in all three protocols. Supplemental Figure S5 depicts the estimation of 
noise in the sWGS data using MAPD values. All patients showed very similar noise levels 




Multiple research studies have demonstrated the potential of using plasma as a tool for non-
invasive cancer management. There is increasing interest in incorporating ctDNA as a ‘liquid 
biopsy’ in both clinical and research settings. As the frequency of mutant alleles in plasma may 
be low, particularly in early stage disease, it is crucial to optimise and standardise pre-analytic 
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sample processing procedures to maintain the quality of samples for accurate quantification of 
rare mutant molecules. In this study, we examined the pre-analytic effects of blood sample 
processing procedures, including the use of different blood collection tubes, storage conditions 
and centrifugation speeds, on downstream analysis of cfDNA using different molecular 
technologies including dPCR, targeted amplicon and genome-wide sequencing. Our results 
show that levels of cfDNA are stable in K3EDTA tubes at room temperature for up to 24 hours. 
If delayed beyond 24 hours, storage of K3EDTA blood at 4°C appeared to delay the increase 
in background cfDNA. It is worth noting that a recent study demonstrated that storing the 
samples in K2EDTA tubes at 4°C kept the cfDNA levels stable for a course of 3 days [21]. This 
agrees with our observations that storing K3EDTA tubes at 4°C improved the stability of cfDNA 
compared to room temperature storage. Alternatively, collection into Cell-free DNA BCT tubes 
at room temperature maintained stable cfDNA levels for at least a week. These tubes can 
facilitate delayed and centralised blood processing, circumventing issues arising with delayed 
plasma processing. Other researchers have evaluated alternative cell-stabilisation tubes such 
as CellSave (CellSearch) and PAXgene Blood ccfDNA tubes (Qiagen) and demonstrated 
similar stability when sample processing was delayed[9, 22]. New cell-free stabilization tubes 
have recently become available (eg. Cell-free DNA Collection tube, Roche; cf-DNA 
Preservation tube, Norgen; Blood STASIS 21-ccfDNA, Magbio and LBgard Blood tubes, 
Biomatrica) and it will be important to test these thoroughly to assess their performance for 
optimal sample processing procedures prior to next-generation sequencing and dPCR analysis 
of ctDNA.  
 
Our findings have addressed a few of the practical challenges in the ‘blood to plasma’ 
sample processing workflow in a hospital setting. For example, in the clinic, processing may 
be delayed due to shortage of staff to enable immediate processing, or outside office-hours 
collection. In some scenarios, when conducting multi-centre clinical trials, many individual 
centres do not have access to the full spectrum of centrifuges with the higher second 
centrifugation speeds required to carry out the recommended double-centrifugation 
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procedures. The ability to delay processing by collecting into cell-stabilisation tubes, or the 
flexibility to perform the centrifugation in a range of different type of centrifuges or storing at 
4°C after collection for a short period, will greatly improve the feasibility of collecting high-
quality specimens. For samples collected across a wide geographical area, shipment may be 
necessary prior to central processing to standardise pre-analytic factors and maximize cost-
effectiveness. Our study showed no statistically significant difference in NGS background 
noise with or without shipment. However, other studies have shown that the shipping 
temperature of Cell-free DNA BCT was deemed to be a critical factor to ensure delivery of 
high quality specimens for downstream ctDNA analysis[23]. In these studies, variable results 
were observed at extreme temperatures, at ≤10°C and 40°C, which affected the cellular 
interface, resulted in an elevated ratio of long:short genomic DNA fragments, and a decrease 
in plasma volume. These studies indicate that shipment temperature should be carefully 
controlled by use of insulated packages, gel blocks or temperature logging devices to 
maintain stability. 
 
Previous studies have mainly focused on locus-specific analysis using quantitative PCR or 
dPCR which examined one locus at a time. With technology advances, an increasing number 
of molecular profiling strategies have been developed using NGS [24], which provides a higher 
resolution and larger genomic coverage than a locus-specific approach. It is therefore 
important to also understand the effects of cfDNA sample processing on the analytical 
performance of NGS-based analysis. It is particularly important to test whether using a 
collection tube containing a preservative has the potential to introduce DNA sequence 
modifications, which may be misinterpreted as true patient-specific genomic alterations. A 
recent study examined the influence of sample collection in CellSave tubes on the analysis of 
global copy number variations using NGS technology, and did not find differences in allele 
frequencies compared to EDTA blood [9]. In this study with BCT and K3EDTA tubes, we 
evaluated the effects of processing on the background error rates during targeted amplicon 
sequencing and sWGS. As expected, we observed different error rates in different base 
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substitutions, but there was no difference in background error rate regardless of the type of 
collection device and sample processing schedule. Our sWGS analysis results agreed with 
previous findings in that copy number data was consistent across conditions. 
 
All of these findings provide important insights for the potential incorporation of routine NGS 
technology in plasma-based molecular diagnostics. Beyond the analysis of ctDNA, it is crucial 
to also understand the impact of pre-analytical factors on other nucleic acids or genomic 
variants, such as tumour-specific RNA (ctRNA), microRNA or DNA methylation, some of which 
have been studied [25] but more evidence is required. Their quantification would likely be 
affected by the levels of total RNA or methylated DNA that is derived from the blood cells. It is 
important to understand whether the effects of sample processing procedures could be 
addressed in a similar manner to the effects on circulating DNA.  
 
With the increasing understanding of genomic alterations and matched targeted treatment 
options, the demand for a non-invasive molecular profiling tool is growing. Analysing cell-free 
nucleic acids presents a unique opportunity for longitudinal follow-up during treatment of 
cancer patients. Initiatives have begun to pursue the standardization of methods for cell-free 
DNA analysis. Understanding the impact of different pre-analytic factors will help accelerate 
the process and drive large-scale cross-centre validation studies to provide robust evidence 
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Table 1. Summary of number of samples analysed in each Module.  
 
Summary of collection devices, temperatures, number of samples and delay in processing 
for each analysis Module: 
Module 1 Effects of delayed processing 
Module 2 Effects of storage temperature 
Module 3 Effects of collection devices (EDTA versus BCT) 
Module 4 Effects of different centrifugation speed 
Module 5 Effects of shipment in BCT 
21 
 
For Module 2, samples were stored both in room temperature (RT) and at 4°C.  20/11 
indicates that 20 tubes were stored at room temperature and 11 at 4°C, etc.  
 
Figure 1.  The effects of delayed processing on the levels of circulating DNA in plasma 
collected in K3EDTA tubes 
 
Blood samples were collected into K3EDTA tubes and stored at room temperature (RT) for 0h, 
6h, 24h, 48h, 96h and 1week before plasma separation.  
 (A) cfDNA copies/mL plasma and (B) mutant allele fraction and (C) ctDNA copies/mL plasma 
in samples processed at different time of delay. All data were expressed as ratio from E.RT.0h 
(each patient’s immediately processed K3EDTA sample). Asterisk indicates statistical 
significant difference compared with E.RT.0h (Mann Whitney Rank Sum Test, p-value<0.05). 
The bottom and top of the box represent the first and third quartiles, and the band inside the 
box represents the median. 
 
Figure 2. The effects of storage temperature on the levels of circulating DNA in plasma 
collected in K3EDTA tubes 
 
Blood samples collected into K3EDTA tubes were stored at room temperature and at  
4°C for 24h, 48h, 96h and 1 week before plasma was separated. 
 (A) cfDNA copies/mL plasma and (B) mutant allele fraction. All data were expressed as ratio 
from E.RT.0h (each patient’s immediately processed K3EDTA sample). Asterisk indicates 
statistical significant difference compared with E.RT.0h (Mann Whitney Rank Sum Test, p-
value<0.05). The bottom and top of the box represent the first and third quartiles, and the band 
inside the box represents the median. 
 





Blood samples collected into K3EDTA tubes were processed immediately, after 96h or one 
week at room temperature. Blood samples in BCT were stored at room temperature for 96h 
and 1 week before plasma separation.  
 (A) cfDNA copies/mL plasma and (B) mutant allele fraction. All data were expressed as ratio 
from E.RT.0h (each patient’s immediately processed K3EDTA sample). Asterisk indicates 
statistical significant difference compared with E.RT.0h (Mann Whitney Rank Sum Test, p-
value<0.05) (C) The distributions of the ratio of non-reference:reference alleles as generated 
by targeted amplicon sequencing shown in boxplots. The bottom and top of the box represent 
the first and third quartiles, and the band inside the box represents the median. The data are 
represented in log (10) scale. 
 
Figure 4.  The effects of different centrifugation speed on the levels of circulating DNA 
 
Blood samples were collected into K3EDTA tubes and processed to plasma with three different 
protocols. All protocols included two 10 min centrifugation steps, the first on whole blood, and 
the second on plasma aliquots. Protocol A (820g and 14 000g), Protocol B (1600g and 14000g), 
Protocol C (1600g and 3000g). (A and B) cfDNA copies/mL plasma and (C and D) mutant 
allele fractions (%) in samples processed by different protocols. The bottom and top of the box 
represent the first and third quartiles, and the band inside the box represents the median. 
 
Figure 5. The effects of shipping using Cell-free DNA BCT on the levels of circulating DNA 
 
Blood samples were collected in K3EDTA tubes and Cell-free DNA BCT and processed 
immediately except for one Cell-free DNA BCT from each collection that was shipped by mail 
back to the same collection centre. (A and B) cfDNA levels (AC/µl) and (C and D) mutant allele 
fractions. The bottom and top of the box represent the first and third quartiles and the band 




Supplemental Figure S1 
 
The numbers of ctDNA copies, expressed as copies/mL plasma, in (A) different storage and 
processing conditions and (B) the ratio from the sample collected in K3EDTA tubes and 
processed immediately (E.RT.0h). 
 
Supplemental Figure S2 
 
Mutant allele fractions of matched samples from 6 patients, those collected in K3EDTA tubes 
and processed immediately versus those collected in BCT and processed after 1 week of 
delay.  
 
Supplemental Figure S3 Pairwise comparison between copy number profiles of plasma 
samples processed with different protocols. 
 
“EDTA” indicates the sample was collected in K3EDTA tube and processed 
immediately; “BCT post” indicates the sample was collected in BCT and 
delivered in the post and processed upon arrival; “BCT” indicates the sample 
was collected in BCT and stored at room temperature until processing with the 
posted samples. The copy number data were expressed as log2ratio of the 
segmented bin counts. The pairwise comparisons were assessed by Spearman correlation, 
and the correlation coefficients were indicated on top of each panel. 
 
Supplemental Figure S4. The effects of shipping using Cell-free DNA BCT on global copy 




Shallow whole genome sequencing data of an ovarian cancer patient’s (P227) plasma sample 
processed with three different protocols: (A) collection in K3EDTA tube and processed 
immediately; (B) collection in BCT, stored at room temperature, not processed until the posted 
sample arrived; (C) collection in BCT, delivered in the post and processed upon arrival.  The 
data were expressed as log2ratio of segmented bin counts across the 23 chromosomes. Blue 
indicates a statistically significant gain, and orange indicates a significant loss.  
 
Supplemental Figure S5. Estimating noise from the copy number profiles generated by 
sWGS data 
 
Median of all absolute pairwise differences (MAPD) between coordinate-sorted copy number 
values for the different protocols. The data points are coloured by patient ID.  
 
Supplemental Table S1.    Summary of samples analysed in each Module 
 
Table details the number of ovarian and breast cancer samples analysed in each Module, at 
different timepoints, temperatures or using different methods of analysis (dPCR or TAm-
Seq). ND = Not detected; + = Sample analysed; RT = Room temperature 
 
Supplemental Table S2. dPCR Assays 
 
Table details the sequences of the primer and probes sequences of the dPCR assays 
targeting specific mutant and wild-type sequences, the annealing temperature and number of 
PCR cycles used to amplify sequences in the dPCR assay, and the amplicon sizes of each 
of the dPCR assays. 
 
Supplemental Table S3. Comparison of the segmental copy number profiles among 




Table details the values for the Wilcoxon Rank Sum Test, adjusted p-value and Spearman 
correlation for the different comparison of segmental copy number profiles using EDTA, BCT 











. Mutation calling using TAm-Seq for serum samples
OV04 Chemotheraphy	cycle Mutation MAF	pre	size	selection MAF	post	size	selection
77 1 c.C916T,	p.306X ND 0.24
77 2 c.C916T,	p.306X ND 0.01
83 1 c.C833T,	p.P278L ND 0.05
83 2 c.C833T,	p.P278L 0.33 0.04
122 1 c.C817T,	p.R273C 0.58 0.22
122 2 c.C817T,	p.R273C ND ND
141 1 c.T584C,	p.I95T ND-low	coverage 0.41
141 2 c.T584C,	p.I95T ND-low	coverage 0.04
180 1 c.574_578del,	p.192_193del ND 0.1
180 1 c.574_578del,	p.192_193del ND 0.01
211 1 c.611delA,	p.E204fs 0.04 0.05
211 2 c.611delA,	p.E204fs ND ND
226 1 c.225delT,	p.P75fs ND-low	coverage 0.03
226 2 c.225delT,	p.P75fs ND-low	coverage ND-low	coverage
292 1 c.A578G,	p.H193R ND 0.08
292 2 c.A578G,	p.H193R ND ND
295 1 c.T613C,	p.Y205H 0.63 0.13
295 2 c.T613C,	p.Y205H ND ND
297 1 c.G661T,	p.E221X ND 0.07
297 2 c.G661T,	p.E221X ND-low	coverage 0.09
300 1 c.G560T,	p.G187V 0.41 0.04
300 2 c.G560T,	p.G187V ND 0.02
ND	-	Not	detected
clix
